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Introduction:   Houghton   and   colleagues   (2004)   demonstrated   bone   marrow  
derived   cells   (BMDCs)   to   be   the   origin   of   epithelial   cells   in   pre-­‐‑invasive   and  
malignant  gastric  tumours  in  Helicobacter  felis  infected  mice.    However,  this  has  
yet  to  be  replicated  in  any  other  experimental  scenario.      
Methods:     To  clarify   the  significance  of  Houghton’s  observation  we  examined  
four  mouse  models  of  gastrointestinal   tumourigenesis:   the  Tff1-­‐‑/-­‐‑  mouse  model  
of  inflammatory  gastric  adenocarcinoma,  the  ApcMin/+  and  Apc1322T  mouse  models  
of   familial   adenomatous   polyposis,   and   the   Il10-­‐‑/-­‐‑   mouse   model   of   colitis-­‐‑
associated   colorectal   adenocarcinoma,   employing   sex-­‐‑mismatched   bone  
marrow   (BM)   transplantation   (male  BM   to   female   recipients)   followed  by   the  
identification   of   BMDCs   in   tissues   using   Y-­‐‑chromosome   in   situ   hybridisation  
(ISH)  detection  and  immunohistochemical  phenotyping  of  cells.  To  investigate  
the  mechanism   for   BMDC   recruitment   into   tissues,   osteopontin   (Opn)  mRNA  
isotopic  ISH  was  employed.  
Results:      In   four   mouse   models   there   was   not   a   single   instance   of   a   gastric  
gland   or   intestinal   crypt   with   a   patch   of   clonal   Y-­‐‑chromosome   positive   (Y+)  
cells.      Y+   cells   in   the   epithelium  were   very   rare   and  were  mostly   positive   for  
several  markers  of  immune  cells.    In  contrast,  Y+  cells  were  frequently  observed  
in   the  stroma.     Quantification  of  BMD-­‐‑myofibroblasts  demonstrated   increased  
recruitment  into  larger  Apc1322T  mouse  tumours  and  desmoplastic  reaction  sites  
in  Tff1-­‐‑/-­‐‑  mouse   tumours,  but  not   into   inflamed  non-­‐‑fibrotic   tissues.     Similarly,  
 3 
Opn   mRNA   expression   was   unaffected   by   inflammation   but   increased   with  
tumour  burden  and  in  desmoplastic  reaction  sites.    In  the  desmoplastic  reaction  
sites   of   Tff1-­‐‑/-­‐‑   mouse   tumours,   increased   osteopontin   mRNA   expression  
correlated   with   increased   BMD-­‐‑myofibroblasts,   therefore   suggesting   some  
chemoattraction  was  occurring.  
Conclusions:  In  four  mouse  models  of  gastrointestinal  tumourigenesis  BMDCs  
were   not   a   source   of   reparative,   pre-­‐‑cancerous,   or   malignant   epithelial   cells.    
Analysis   of   BM   contribution   in   the   stroma   demonstrated   that   BMD-­‐‑
myofibroblast  engraftment  is  driven  by  increased  tumour  burden  and  fibrosis.    
In   addition,   the   increased   presence   of   BMD-­‐‑myofibroblasts   at   desmoplastic  
reaction   sites   of   Tff1-­‐‑/-­‐‑   mouse   tumours   correlated   with   increased  Opn   mRNA  
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1.1   The  development  of  gastrointestinal  cancers  and  the  role  of  stem  cells    
Cancer   is   the   culmination   of   a   series   of   genetic   changes   that   confer   growth  
advantages  to  cells  allowing  tumour  growth  (such  as  self-­‐‑sufficiency  in  growth  
signals   and   resistance   to   apoptosis)   and   eventually   the   ability   to   invade   the  
submucosa   and  spread   into  other   tissues   (known  as   invasive   carcinoma).     This  
process   can   be   initiated   through   inherited   mutations   (hereditary   cancer)   or  
somatic   mutations   (sporadic   cancer)   of   genes   that   regulate   cell-­‐‑signalling  
pathways   involved   in   cell   proliferation   and/or   apoptosis.      Initial   tumours  
progress   to   invasive  carcinomas   through   the  acquisition  of  additional   somatic  
mutations   or   gene   silencing   from   promoter   hypermethylation   (epigenetic  
changes).      
In   addition   to  mutations,   the  presence   of   chronic   inflammation  plays   a  major  
role  in  carcinogenesis  and  has  been  attributed  to  a  fifth  of  all  cancers  [1].    This  is  
because   increased   cellular   proliferation   resulting   from   continuous   tissue  
damage   and   repair   seen   in   chronic   inflammation   creates   an   environment  
advantageous   to   cancer   development   and   maintenance   [1].      In   addition,  
mutations  can  arise  from  DNA  becoming  damaged  by  free  radicals  released  by  
macrophages,  neutrophils  and  dendritic  cells  during  inflammation  [2].  
Another   histological   hallmark   frequently   observed   in   tumours   is   a  
heterogeneous  cell  population.    This  is  often  referred  to  as  the  cancer  stem  cell  
theory,  in  that  a  population  of  cells  exhibiting  stem-­‐‑cell  like  properties  (known  
as  cancer  stem  cells)  reside  within  tumours  driving  growth  in  a  manner  similar  
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to   the   stem   cells   tissue   stem   cell   niches,   of   which   in   vivo   experiments   have  
shown  this  to  occur  in  GI  tumours.    
As  tumours  progress  to  invasive  carcinoma,  some  GI  cancers  display  step-­‐‑wise  
patterns   of   development.   Outside   of   the   epithelium,   the   stroma   (or  
mesenchyme)   often   also   exhibits   changes   during   carcinogenesis.      Frequently  
observed   is   desmoplasia,   which   is   characterised   by   an   increased   presence   of  
myofibroblasts  that  synthesise  abundant  collagenous  material  [3]  causing  dense  
fibrosis   around   the   tumour.      Experimental   studies   suggest   that   tumour-­‐‑
associated  myofibroblasts  (TAMs)  play  a  role  in  early  tumourigenesis  through  
altered  NF-­‐‑κB  [4]  and  Wnt  signalling  [5]  and  in  promoting  later  tumour  growth  
and/or  invasion  due  to  their  additional  secretion  of  growth  factors,  MMPs,  and  
chemokines   [6-­‐‑8].      In   addition   to   TAMs,   inflammatory   infiltrate   and   tumour  
vasculature  also  make  up  the  tumour  microenvironment.  These  cells  have  been  
shown  to  be  derived  from  bone  marrow  progenitor  cells  in  human  and  mouse  
bone   marrow   transplantation   (BMTx)   studies.      However,   the   contribution   of  
bone  marrow  progenitor  cells  to  tumour  epithelial  cells  remains  controversial.  
This   section   focuses   on   the   development   of   cancers   in   GI   tract,   the   role   of  
altered   stem   cell   dynamics,   and   contribution   of   bone   marrow   derived   cells  
(BMDCs).    For  brevity,  adenocarcinomas  will  only  be  discussed  as  they  account  




1.1.1 Gastric  cancer    
The  stomach  is  divided  into   two  functionally  distinct  parts:   the  corpus,  which  
secretes   hydrochloric   acid   and   the   zymogen   pepsinogen,   and   the   pyloric  
antrum  that  mainly  secretes  mucus  and  gastric  hormones.    Gastric  cancer  is  the  
fourth  most  common  cause  of  cancer  worldwide  with  an  estimated  990,000  new  
cases  diagnosed   in  2008  and   is   the  second  most  common  cause  of  death   from  
cancer  with  740,000  deaths  in  2008  [9].    Gastric  cancer  falls  into  two  histological  
classifications:   diffuse   and   intestinal-­‐‑type.   Intestinal-­‐‑type   gastric   cancer  
accounts   for   the   majority   of   gastric   cancer   cases   and   is   characterised   by  
glandular   structures   surrounded   by   desmoplasia  with   inflammatory   infiltrate  
present.      The   development   of   intestinal-­‐‑type   gastric   cancer   follows   a  
progressive  sequence  of  precancerous  lesions:   involving  an  initial  transition  to  
chronic   gastritis,   followed   by   the   development   of  mucosal   atrophy,   intestinal  
metaplasia,  dysplasia,  and  culminating  in  invasive  adenocarcinoma  in  a  lengthy  
process  often  referred  to  as  the  Correa  pathway  (Figure  1.1).    Additionally,  the  
development   of   antral-­‐‑type   glands   within   the   corpus,   known   as   spasmolytic  
polypeptide-­‐‑expressing   metaplasia   (SPEM),   has   also   been   identified   as   a  
precursor  lesion  [10]  (Figure  1.1).        
Diffuse  gastric   cancer   is   less  common  and   is   composed  of   individual  or   small  
groups   of   neoplastic   cells   that   do   not   form   glandular   structures.      It   is   not  
associated   with   intestinal   metaplasia   and   no   intermediate   steps   have   been  




Risk  factors    
A   major   risk   factor   for   both   intestinal   and   diffuse   type   gastric   cancers   is  
Helicobacter   pylori   (H.   pylori)   infection,   which   accounts   for   two-­‐‑thirds   of   all  
gastric  cancer  cases.     In  contrast,  hereditary  gastric  cancer  only  accounts  for  1-­‐‑
3%  of  gastric  cancer  cases  where  germline  mutations  in  mismatch  repair  genes  
[12],   serine/threonine   kinase   11   (STK11)   tumour   suppressor   gene   [13],   E-­‐‑
cadherin  gene  (CDH1)  [14],  and  the  adenomatous  polyposis  coli  (APC)  gene  [15]  
have  all  been  identified.    Other  risk  factors  for  gastric  cancer  include;  a  high  salt  
diet,   a   low   intake   of   fruits   and   vegetables,   smoking,   and   a   family   history   of  
gastric  cancer  [16,  17].      
  
Helicobacter-­‐‑associated  gastric  cancer  
Numerous  studies  have  linked  H.  pylori  infection  to  gastric  cancer  (reviewed  in  
[18])   and   in   1994   the   International   Agency   for   Research   on   Cancer   (IARC)  
classed   H.   pylori   as   a   Group   1   carcinogen.   This   gram-­‐‑negative   bacterium  
colonizes  the  stomach  by  attaching  to  the  mucosal  epithelia.    Once  attached,  its  
virulence  factors  (such  as  CagA)  induce  inflammation  in  host  cells  and  immune  
cells   are   recruited   to   the   site   of   infection   because   of   the   activation   of   the  
transcription  of  genes  responsible  for  pro-­‐‑inﬂammatory  cytokines,  chemokines,  
inﬂammatory  modulators,  and  growth  factors  [18].    One  of  transcription  factors  
activated  by  H.  pylori  virulence  factors  is  NF-­‐‑κB.    NF-­‐‑ κB  plays  a  pivotal  role  in  
the  inflammatory  and  immune  response  by  regulating  the  expression  of  a  wide  
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range   of   genes   including   those   encoding   pro-­‐‑inflammatory   cytokines,  
numerous  chemokines,  growth  factors,  and  pro-­‐‑survival  factors.    Therefore,  it  is  
hardly   surprising   that   aberrant   NF-­‐‑ κB   activity   is   observed   in   a   number   of  
human  cancers,   including  gastric  cancer  [19].     Studies  have  also  attributed  the  
pathogenicity  of  H.  pylori   to  disruption  of  host   cell  adhesion  and  architecture,  
and  decreased  gastric  acid  secretion  (reviewed  in  [18]).  
  
Altered  stem  cell  dynamics      
Generation  of  cell  lineages  in  the  pylorus  and  corpus  is  maintained  by  the  Wnt  
and  Notch  signalling  pathways,   respectively,  as  demonstrated   in  vivo   [20,  21].    
Unsurprisingly   these   pathways,   which   are   responsible   for   stem   cell  
differentiation  and  proliferation,  are  also  implicated  in  gastric  cancer.    Patients  
harbouring  APC   mutations,   which   affect   Wnt   signalling   (reviewed   in   Figure  
1.2),   are   10   times   more   likely   to   develop   gastric   cancer.      Indeed,   analysis   of  
gastric  cancer  biopsies  frequently  observe  accumulation  of  nuclear  β-­‐‑catenin  as  
well  as  hypermethylation  of  key  components  [22]  of  the  Wnt  pathway  such  as  
DKK  Wnt   inhibitors   [23].         Similarly,   the   expression   of   Notch   receptors   (e.g.  
Notch1,   Notch2   and   Notch3)   and   the   Notch   ligands   such   as   Jagged1   and  
Jagged2  is  observed  human  gastric  cancer  biopsies  (see  Figure  1.3  for  a  review  
of  the  Notch  pathway).    In  particular,  the  expression  of  Notch  1  is  observed  in  




Figure 1.3:  Review of the Notch signalling pathway 
  
Precursor Notch receptor protein is synthesized in the Golgi apparatus, where it is 
cleaved by furin-like convertase to generate two subunits: one subunit containing most 
of the extracellular domain and a second subunit consisting of the remainder of the 
extracellular domain and a transmembrane domain. Binding of Notch ligand (e.g. 
Jagged1/2 or Delta-like 1/3/4) onto the EGF-like repeats present on the extracellular 
domain of a Notch receptor (e.g. Notch 1,2,3, or 4) results in the unfolding of the 
negative regulatory region (NRR) allowing for cleavage by metalloproteases of the 
ADAM family [24].  Afterwards, an intramembrane cleavage mediated by γ-secretase 
complex occurs releasing the Notch intracellular domain (NotchIC).  The Notch 
intracellular domain then translocates to the nucleus where the Mastermind-like family 
of proteins (MAML1/2/3) have been reported to be required for activation of Notch 
signalling [25].  MAML, along with C-promoter binding factor-1 (CBF-1), forms a ternary 
complex with the NotchIC and acts as a transcriptional activator, resulting in the 
transcription of Notch target genes such as LKB1-interacting protein 1 (LIP-1) and 
numerous genes involved in the basic helix-loop-helix (bHLH) family.  Following Notch 
activation, transcriptional repressors Hairy/Enhancer-of-Split (HES) and Hairy-Related 
Transcription factor (HRT), which belong to the bHLH family of proteins, are induced.  
Image taken from [26]. 
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Research   suggests   that   a   stem   cell   population   resides  within   gastric   tumours  
[27].     Karam  and  colleagues  (2008)  observed  an  expansion  of  a  cell  population  
that  expresses  all  antral  cell   lineage  markers  in  the  antral  pyloric  adenomas  of  
trefoil  factor  family  peptide  1  (TFF1)  null  mice  [28].     In  normal  pyloric  glands,  
stem  cells  at   the  base   that  express  Wnt   target  gene  and  stem  cell  marker  Lgr5  
give  rise  to  all  pyloric  cell  lineages.    Barker  and  colleagues  (2010)  demonstrated  
that   the   deletion   of   Apc   in   Lgr5+   pyloric   stem   cells   causes   the   formation   of  
adenomas  in  the  pylorus,  suggesting  that  Lgr5+  stem  cells  are  the  cell  of  origin  
of  APC-­‐‑derived  tumours  [20,  27].      
  
TFF1  
In  two-­‐‑thirds  of  gastric  carcinomas  cases,  the  loss  of  TFF1  protein  expression  is  
observed  resulting  from  either  silencing  of  the  TFF1  gene  due  to  methylation  of  
the  TFF1  promoter  region  or  loss  of  heterozygosity  (LOH)  [29]  [30].    However,  
only  around  5%  of  gastric  carcinomas  harbour  mutations  in  the  TFF1  gene.    
The  TFF1  protein  is  secreted  by  gastric  mucosal  cells  and  plays  important  roles  
in  epithelial  restitution  and  cytoprotection  (reviewed  in  [31]).     Studies  on  Tff1-­‐‑
null   mice   (Tff1-­‐‑/-­‐‑)   suggest   that   this   protein   plays   a   further   role   in   tumour  
suppression.      Tff1-­‐‑/-­‐‑   mice   develop   severe   hyperplasia   and   dysplasia   in   the  
antralpyloric   gastric   mucosa   leading   to   the   development   of   antralpyloric  
adenomas  in  all  mice  [32,  33].     However,  only  30%  of  mice  develop  multifocal  
intraepithelial   or   intramucosal   carcinomas   by   5   months   of   age   [32].      This  
 25 
indicates   that   the   loss   of   TFF1   alone   is   insufficient   for   malignancy   and   that  
further  genetic  alterations  are  required  [32].    A  possibility  is  the  loss  gastrokine  
2   (GKN2)   expression,  which   is   present   as   a   heterodimer  with  TFF1   in   gastric  
mucosa  secretions.     A   tumour-­‐‑suppressing  role   for  GKN2  has  been  suggested  
following  observations  of  expression  loss  in  human  gastric  cancer  and  H.  pylori  
infection  [34,  35].  
Areas   of   downregulated  TFF1   expression   in   human   gastric   tumours   correlate  
with   activated   NF-­‐‑κB   [33].      Soutto   and   colleagues   (2011)   demonstrated   that  
TFF1   attenuates   the   binding   of   tumour   necrosis   factor   receptor   (TNFR)1   to  
TRAF2   (TNF   receptor-­‐‑associated   factor   2)   following   TNF-­‐‑α   stimulation,  
therefore   suppressing  TNF-­‐‑α-­‐‑mediated      activation  of   the  NF-­‐‑κB  pathway   [33]  
(Figure  1.4).    However  in  Tff1-­‐‑/-­‐‑  mice,  this  inhibition  does  not  occur  resulting  in  
uncontrolled  NF-­‐‑κB-­‐‑mediated  transcription  of  pro-­‐‑inflammatory  cytokines  and  
chemokines,   and   pro-­‐‑survival   genes   causing   chronic   inflammation.      These  
findings  suggest  that,  in  addition  to  a  possible  tumour  supressing  role,  the  loss  
of  TFF1   is   important   in  modulating   the   inflammatory   response  during  gastric  
tumourigenesis.      
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Figure 1.4: The role of TFF1 in mediating inflammation in gastric epithelial cells  
 
Under normal circumstances TFF1, a transcriptional target of NF-κB, negatively 
regulates inflammation in gastric epithelial cells by attenuating TNF-α–mediated 
stimulation of NF-κB (right image).  However in Tff1-/- mice or in gastric tumours 
with silenced TFF1 (either by loss of heterozygosity or hypermethylation) NF-κB 
transcription of pro-inflammatory cytokines and chemokines, and pro-survival 
genes goes unregulated (left image). Image:  [33]. 
 
 
1.1.1.1  Contribution  of  BMDCs  in  gastric  cancer  
BMDCs   have   been   shown   to   contribute   TAMs   and   epithelial   cells   in   gastric  
cancer.      Occasional   BMD-­‐‑TAMs   have   been   observed   in   a   gastric  
adenocarcinoma   of   a   female   patient   who   developed   gastric   adenocarcinoma  
after   receiving   a   BMTx  using  BM   from   a  male   donor   [36].      Similarly,  Quante  
and  colleagues  (2011)  demonstrated  a  20%  contribution  of  BMD-­‐‑myofibroblasts  
in  H.  felis-­‐‑induced  gastric  dysplasia  in  BMTx’d  mice.    In  the  same  study,  Quante  
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and   colleagues   performed   FACS   analysis   of   the   BM   of   these   mice   and  
demonstrated   an   expansion   of  α-­‐‑   smooth  muscle   actin   (SMA)+   mesenchymal  
stem  cells   (MSCs)  when  compared  to  the  BM  of  uninfected  mice  or  mice  with  
early   stage   dysplasia.      This   finding   suggests   that   dysplasia   modulates   the  
differentiation  of  BMDCs  within  BM  [37].    Quante  and  colleagues  findings  also  
complement   an   in   vitro   observation   of   the   chemotactic   recruitment   of   BMD-­‐‑
MSCs  via  chemokines  released  from  H.  pylori  infected  GI  epithelial  cells  [38].      
Another  deleterious  consequence  of  Helicobacter  infection  has  been  suggested  by  
in  vivo  studies  carried  out  by  Houghton  et  al.,  (2004)  and  Varon  et  al.,  (2011).    In  
2004,   Houghton   and   colleagues   [39]   carried   out   BMTx   experiments   in   which  
lethally   irradiated  mice  were   transplanted  with  ROSA26   (that   expressed   non-­‐‑
mammalian   beta-­‐‑galactosidase)   or   GFP   transgenic   BM   in   order   to   track   the  
engraftment   of   BMDCs   via   X-­‐‑gal   staining   and   fluorescent   microscopy,  
respectively.      The   transplanted  mice  would   later   be   infected  with  Helicobacter  
felis  (H.  felis).    Houghton  and  colleagues  observed  that  the  transplanted  BMDCs  
repopulated   the   stomachs   of   these  mice   to   the   extent   that   90%   of   the   gastric  
mucosa   at   the   squamocolumnar   junction   was   replaced   by   BMDCs   52   weeks  
after   infection.      With   time,   these   cells   progressed   through   metaplasia   and  
dysplasia  to  intraepithelial  cancer.    Analysis  of  neoplastic  glands  in  both  groups  




Figure 1.5:  BMD-neoplastic gastric glands, from Houghton et al., 2004 
 
After 20 weeks of H. felis infection, few BMD gastric glands are observed (blue; 
arrow) (a).  After 12-16 months of chronic H. felis infection entire gastric glands 
were BMD (blue) (b). A lower power view demonstrating numerous BMD gastric 
glands (c).  BMD-epithelial cells (yellow) in neoplastic gastric glands were 
detected by co-localisation of pan-cytokeratin (green) and beta-galactosidase 
expression (red) (d; scale bar 40µm).  Male GFP+ cells in the nuclei (black) of 
cytokeratin+ cells (red) (e; no magnification provided).  a-c no magnifications 
provided, images taken from [40];  d,e images taken from [39].  
  
A  possible  explanation  for  this  phenomenon  came  a  year  later,  when  Houghton  
and   colleagues   demonstrated   increased   apoptosis   occurring   at   the   isthmus   of  
the  gastric  glands,  the  proposed  stem  cell  region  of  pyloric  glands,  during  early  
H.  felis  and  H.  pylori  infection  [40].  A  proposed  explanation  for  the  observations  
in  both  studies  is  that  Helicobacter  infection  resulted  in  stem  cell  ablation  at  the  
pyloric   gland   niche   (Figure   1.6).      Consequently,   BMDCs   were   recruited   and  
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engrafted   in   the   gastric   stem   cell   niche   where   they   functioned   as   stem   cells.    
However,   in   an   abnormal   chronically   inflamed   environment   these   cells  
progressed   eventually   to   cancer   as   opposed   to   differentiating   into   the   gastric  
cell   lineages.      Therefore,   it   has   been  proposed   that   this   process  may   occur   in  
other  cancers  arising  from  chronic  inflammation  [40].    
  
Figure 1.6:  A proposed paradigm of gastric epithelial cancer resulting from 
BMDC engraftment 
 
Chronic inflammation and tissue damage in the gastric glands resulting from 
Helicobacter infection results in ablation of the stem cell niche resulting in 
replacement with BMDCs. These cells subsequently divide to repopulate the 
entire gastric gland.  A mutation in the BMDCs whether genetic or somatically 
induced by, for example, DNA damage by reactive oxidative species (ROS) by-
products of chronic inflammation results in the development of dysplastic gastric 
glands and subsequent gastric cancer.  Figure courtesy of Malcolm Alison.   
  
1.1.2 Intestinal  cancer  
Colorectal   cancer   (CRC)   is   the   third  most   common  cancer  worldwide  with  an  
estimated  1.2  million  new  cases   in  2008  and  608,700  deaths  estimated   to  have  
occurred   in   2008   [41].      In   contrast,   small   intestinal   cancer   is   relatively  
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uncommon  with  a  global  incidence  of  less  than  1.0  per  100,000  people  [42].    The  
reason  for  the  discrepancy  in  small  intestinal  and  CRC  incidences  is  unknown.    
However,   several   mechanisms   have   been   hypothesised   including:   a   shorter  
exposure  of  mucosa  to  carcinogens  due  to  a  quicker  transit  time  of  food  in  the  
small  intestine  (SI),  a  decreased  concentration  of  potential  carcinogens  from  bile  
acid  breakdown  due   to  a   lower  bacterial   load   in   the  SI,  and   the  generation  of  
less   endogenous   reactive   oxidative   species   (ROS)   in   the   SI   than   the   colon  
resulting  in  less  oxidative  damage  (reviewed  in  [43]).  
Risk   factors   for   intestinal   cancer   include   a   high   fat   diet,   inflammatory   bowel  
disease   (IBD),   and   a   family   history   of   intestinal   cancer   (reviewed   in   [44]   and  
[45]).      The   development   of   intestinal   cancer   can   be   split   into   two   categories:    
non-­‐‑inflammatory  and  inflammatory  mediated.    
  
1.1.2.1  Non-­‐‑inflammation  associated  intestinal  cancer  
The  development  of  adenocarcinoma  in  the  SI  and  colorectum  both  follow  the  
Vogelstein   adenoma-­‐‑carcinoma   sequence   resulting   from   aberrant   Wnt  
signalling   (Figure   1.7).     APC   mutations   are   causally   implicated,   observed   in  
around   80%   of   sporadic   colorectal   cancers   and   responsible   for   the   hereditary  
cancer  syndrome,  familial  adenomatous  polyposis  (FAP).    FAP  patients  harbour  
a   germline   mutation   in   one   APC   allele,   resulting   in   the   development   of  
hundreds   to   thousands  of  neoplastic  colorectal  adenomas  (and  occasionally   in  
the  SI)  driven  by  chronic  Wnt  signalling  [46].    In  both  FAP  and  sporadic  cases,  
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benign  adenomatous  polyps  resulting  from  an  initial  APC  mutation  progress  to  
carcinoma   following  additional   somatic  mutations   [27].     This  progression  was  
suggested   to  occur   in  a  strict   sequence  where  APC  mutations  are   followed  by  
mutations  in  KRAS,  SMAD4  and  lastly  P53  [47],  but  this  may  not  always  be  the  
case.  Collectively,  these  observations  have  not  only  identified  APC  as  a  potent  
tumour  suppressor  gene  but  also  as  the  primary  regulator  of  cell  proliferation  
and  survival.    
  
Figure 1.7: The adenoma-carcinoma sequence of sporadic CRC 
 
In the adenoma-carcinoma sequence, the development of carcinomas from normal 
colonic mucosa is the result of key molecular events that result in characteristic 
histopathological and morphological features (as viewed by colonoscopy).  H&E 




Observations  from  Apc  mutant  mouse  studies  
Over  the  years,  several  Apc  mutant  mice  have  been  developed  to  model  human  
polyposis   and   carcinogenesis.      The   ApcMin/+  mouse   was   the   first   FAP   model  
produced  bearing  a  mutation  in  the  Apc  gene  at  codon  850  [49].      Homozygous  
ApcMin/Min  mice  are  non-­‐‑viable  but  heterozygous  mice  develop  multiple  intestinal  
neoplasms  (Min)  within  weeks  after  birth.    It  is  important  to  note  that  unlike  in  
human   FAP,   most   tumours   in   the   ApcMin/+   mouse   are   benign   small   bowel  
adenomas  and  do  not  progress   to   invasion  or  metastasis   [50].     More   recently,  
the   Apc1322T   mouse   has   been   generated   following   the   observation   that   the  
majority  of  truncated  APC  proteins  found  in  human  colorectal  tumours  retain  a  
total  of  1-­‐‑2,  20  amino  acid  (aa)  repeats  [51-­‐‑53].      These  repeats  play  an  important  
role   in  the  Wnt  pathway  by  binding  β-­‐‑catenin  and  assisting  in  its  degradation  
[54].      Unlike   the   ApcMin/+   mouse,   the   Apc1322T  mouse   retains   one   of   the   20-­‐‑aa  


















Figure 1.8:  Diagram of the APC protein and location of germline mutations in 
Apc mouse models  
 
 
A number of Apc mouse models, including the Min (850) model, harbour mutations 
upstream from the 20-aa repeats in the APC protein. Whereas the 1322T model retains 
one 20-aa repeat.  A mutation at the 1322T codon also means that the 1322T model 
does not carry any of the Ser-Ala-Met-Pro (SAMP) repeats or binding sites found 
further downstream of the APC protein as other Apc mouse models.  Image 
reproduced from [55]. 
  
Compared  to  ApcMin/+  mice,  Apc1322T  mice  have  a  more  severe  disease  phenotype  
with   an   earlier   onset,   greater   percentage   of   tumours   and   higher   grade   of  
dysplasia   [55].      In   addition,   polyps   occur   predominately   in   the   proximal   SI  
contrast  to  the  distal  SI  and  colon  in  the  ApcMin/+  mice  [49,  55].    Moreover,  Apc1322T  
mice  develop  gastric   adenomas.     To  date,   this  has  only  been  observed   in  one  
other  Apc  mutant,  a  strain  of  long-­‐‑lived  Min  mice  [56].    Apc1322T  mouse  tumours,  
as  in  Min  mouse  tumours,  do  not  become  invasive  or  metastasize.      
Although  Apc1322T  mice   develop   a  more   severe   phenotype  when   compared   to  
ApcMin/+   mice,   analysis   of   nuclear   β-­‐‑catenin   and   active   β-­‐‑catenin   levels   are  
consistently  lower  in  Apc1322T  mouse  adenomas  [57].    This  is  believed  due  to  the  
20-­‐‑aa  repeats  retained  in  1322T  mutation  allowing  for  the  capture  of  β-­‐‑catenin  
[55].    Using  microarray  analysis,  Lewis  and  colleagues  (2011)  demonstrated  that  
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this   translates   to   lower   levels  of  Wnt   target  gene  expression   in  Apc1322T  mouse  
adenomas   compared   to   ApcMin/+   mouse   adenomas.         However,   mRNA  
expression   of   Wnt   target   gene   and   stem   cell   marker   Lgr5   increased   nearly  
threefold   in   Apc1322T   adenomas   compared   to   ApcMin/+   mouse   adenomas   and  
mRNA  expression  Wnt  regulators  such  as  Wnt  inhibitory  factor  1  (Wif1),  bone  
morphogenetic  protein  (Bmp)  2,  and  Bmp4  were  significantly  lower  compared  to  
expression  in  ApcMin/+  mouse  adenomas  [57].    Furthermore,  Lgr5  mRNA  isotopic  
in   situ   hybridisation   (ISH)   and   protein   analysis   of   BMI1   and  MSI1   stem   cell  
markers   via   immunohistochemistry   (IHC)   revealed   increased   expression   in  
normal  crypts  and  adenomas  of  Apc1322T  mice  compared  to  ApcMin/+  mice.  These  
findings  lead  to  the  conclusion  that  the  severe  phenotype  seen  in  Apc1322T  mice  
was  due  to  an  increased  number  of  stem  cells  [57].      
  
1.1.2.2  Inflammation-­‐‑associated  intestinal  cancers  
Chronic  inflammation  is  strongly  associated  with  cancer  development  at  sites  of  
inflammation   in   various   organs,   particularly   in   the   intestine.   For   example,  
inflammation  restricted  to  the  SI  in  coeliac  or  Crohn’s  disease  is  associated  with  
up  to  an  80-­‐‑fold  increased  risk  of  small  intestinal  adenocarcinoma  compared  to  
the   general   population   (reviewed   in   [1]).      Similarly,   patients   with   IBD-­‐‑
associated  colitis  (either  Crohn’s  disease  or  ulcerative  colitis)  are  six  times  more  
likely  to  develop  colorectal  cancer  (CRC)  than  the  general  population  [58].        A  
key   difference   however   is   that   small   bowel   adenocarcinoma   is   rare,   whereas  
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CRC  accounts  for  10-­‐‑15%  of  deaths  in  IBD  patients.      Therefore  this  section  will  
focus  on  IBD-­‐‑associated  CRC.  
IBD-­‐‑associated  CRC  does  not  follow  the  adenoma-­‐‑carcinoma  sequence  seen  in  
sporadic   CRC.      Instead,   dysplastic   lesions   arise   from   inflamed   epithelium,  
which  progress  in  severity  and  culminate  in  carcinoma  (Figure  1.9).    Moreover,  
the   timing   and   frequency   of   mutations   in   IBD-­‐‑associated   CRC   differs   from  
sporadic  CRC   [59].         For   example,  APC  mutations   are  often   an   early   event   in  
sporadic  CRC  but  occur  later  in  the  development  of  dysplasia  and  carcinomas  
in   IBD-­‐‑associated   CRC.      Similarly,   p53   LOH   is   often   seen   in   early   dysplastic  
lesions  in  IBD,  whereas  p53  LOH  is  observed  as  a  later  event  in  sporadic  CRC  
(reviewed  in  [59]).    
Risk   factors   for   IBD-­‐‑associated   CRC   include   colitis   duration,   severity   of  











Figure 1.9:  The inflammation-dysplasia-carcinoma sequence of IBD-
associated CRC 
  
(a) Molecular pathogenesis of IBD-associated CRC.  (b) The histopathological 
(top left and centre images; 200x, top right image; 100x) and morphological (as 
viewed by colonoscopy) features of the inflammation-dysplasia-carcinoma 
sequence in IBD-associated CRC.  (a) Figure adapted from [59].  (b) H&E 
images taken from [60], colonoscopy images courtesy of Gerald Dryden. 
  
  
IBD  genetic  factors    
Familial   studies   have   suggested   a   genetic   predisposition   to   IBD   [61].      In  
addition,   race   and   ethnicity   studies   have   indicated   a   difference   in   the  
occurrence  of  IBD  subtypes  and  disease  severity  [62].    An  early  onset  of  colitis  is  
correlated  with   homozygous  mutations   in   the   interleukin   10   receptor   IL10RA  
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and   IL10RB   genes,   that   encode   the   IL10R1   and   IL10R2   subunit   proteins,  
resulting  in  restricted  IL-­‐‑10  induced  signalling  [63].    
  
The  role  of  IL-­‐‑10  
Interleukin   10   (IL-­‐‑10)   is   a   potent   cytokine   essential   to   mucosal  
immunoregulation,   particularly   in   the   intestine.   Secreted   by   almost   all  
leukocytes   [64]   as   well   as   keratinocytes   [65]   and   epithelial   cells   [66],   IL-­‐‑10’s  
primary   role   is   to   restrict   excessive   immune   responses,   thus   limiting   their  
damage   (see   Table   1.1   for   a   selection).   This   is   particularly   important   for   the  
intestine,   where   antigens   from   bacterial   flora   and   ingested   food   can   elicit   an  
immune  response  and  inflammation  and  therefore  must  be  constantly  checked.    
  
Table 1. 1: Immune responses regulated by IL-10 
 




Down regulates the expression of pro-inflammatory 
cytokines such as TNF-α and IL-12.  Increases 





T cell activation 
Down regulates the expression of MHC antigens, 
intercellular adhesion molecule-1 (ICAM-1), and co-
stimulatory molecules CD80 and CD86 present on APCs 
[68]. 
Release of MMPs Inhibits the production of MMP2 and MMP9. 




Emerging   evidence   suggests   that   immunosuppressive   and   anti-­‐‑inflammatory  
effects  of  IL-­‐‑10  is  the  result  of  the  activation  of  signal  transducer  and  activator  
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of  transcription  3  (STAT3)  by  IL-­‐‑10  binding  to  its  receptor  (Figure  1.10).  A  large  
scale   sequencing   study   demonstrated   STAT3-­‐‑induced   transcription   of   most  
genes  involved  in  Th17  cell  differentiation  and  regulation  of  genes  involved  in  
CD4+  T  cell  survival  and  proliferation  [70]  confirming  earlier  in  vivo  [71]  and  in  
vitro  [72,  73]  observations.  
 
Figure 1.10:  Interaction of IL-10 with its receptor 
 
IL-10 first binds to IL-10 receptor 1 (IL-10R1) causing a conformational change 
in IL-10 thus creating a binding site for IL-10R2.  Once bound to IL-10R2, 
receptor-associated Janus kinases Jak1 (IL-10R1) and Tyk2 (IL-10R2) activate 
each other. Following tyrosine phosphorylation of IL-10R1, STAT3 molecules 
bind to and become phosphorylated by the Janus kinases.  In certain cells 
STAT1 and STAT5 molecules are activated. STAT homo- or heterodimers enter 
the nucleus where they bind to promoters and induce gene transcription.  Image 
reproduced from [74]. 
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Observations  from  the  Il10-­‐‑/-­‐‑  model  of  IBD  
IL-­‐‑10   as   an   essential   intestinal   immunoregulator   was   first   noted   in   Il-­‐‑10   null  
(Il10-­‐‑/-­‐‑)  mice.      These  mice  develop  Th-­‐‑1  type  chronic  enterocolitis  characterized  
by  discontinuous  transmural   lesions  and  infiltration  of   lymphocytes,  activated  
macrophages  and  neutrophils  [75].    By  six  months  of  age,  29−60%  of  Il10-­‐‑/-­‐‑  mice  
develop  colorectal  adenocarcinoma.     However,   this   incidence   is  dependent  on  
which   genetic   background   Il10-­‐‑/-­‐‑  mice   are   generated   on.      For   example,  whilst  
60%   of   Il10-­‐‑/-­‐‑   mice   on   a   129/SvEv   background   develop   colorectal  
adenocarcinoma,   Il10-­‐‑/-­‐‑   mice   on   a   C57BL/6   background   do   not   develop  
colorectal   adenocarcinomas.      Underscoring   the   relationship   between  
inflammation  and  carcinogenesis,  Il10-­‐‑/-­‐‑  mice  on  a  129/SvEv  background  exhibit  
the  most  severe  enterocolitis  compared  to  other  Il10-­‐‑/-­‐‑  mice  on  different  genetic  
backgrounds,  [76].    This  difference  in  enterocolitis  severity  according  to  genetic  
background   echoes   differences   in   IBD   disease   severity   from   aforementioned  
racial  and  ethnicity  studies.    
Interestingly,   restoration   of   Il10   through   adenoviral   vectors   [77]   or  
transplantation   of   wild-­‐‑type   (WT)   bone   marrow   has   been   shown   to   reverse  
colitis  Il10-­‐‑/-­‐‑  mice  [78].    The  potential  therapeutic  effect  of  IL10  gene  transfer  has  
yet   to   be   carried   out   in   patients,   however,   restoration   of   IL-­‐‑10   through  
haematopoietic   stem  cell   transplantation  has  been   shown   to   induce   long-­‐‑term  
remission  in  a  majority  of  patients  with  active  severe  Crohn’s  disease  [79].    
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1.1.2.3  Contribution  of  BMDCs  in  colitis  and  intestinal  cancer  
In  2006  Bamba  and  colleagues  demonstrated  that  an  influx  of  IL-­‐‑10  expressing  
myeloid   cells   from   transplanted  WT   bone  marrow   could   ameliorate   colitis   in  
Il10-­‐‑/-­‐‑  mice.    The  amelioration  of  colitis  also  involved  the  repair  and  regeneration  
of  the  damaged  mucosa,  possibly  mediated  by  BMD-­‐‑myofibroblasts.     Analysis  
of   the   colonic   crypts   of   these   mice   demonsrated   up   to   30%   of   subepithelial  
myofibroblasts   (SEMFs)   being   of   BM   origin.   In   comparison,   the   inflamed  
mucosa  of  Il10-­‐‑/-­‐‑  mice  that  received  Il10-­‐‑/-­‐‑  BM  in  the  same  study  had  up  to  45%  
colonic  SEMFs  being  of  BM  origin,  emphasizing  the  important  role  of  these  cells  
in  tissue  regeneration  in  inflammation  [78].  
How   BMD-­‐‑myofibroblasts   would   have   contributed   to   the   tumour   stroma   of  
colitis-­‐‑associated  tumours   in   Il10-­‐‑/-­‐‑  mice  is  unknown  as   the   Il10-­‐‑/-­‐‑  mice  used  by  
Bamba   and   colleagues   were   on   a   C57/BL10   genetic   background   that   do   not  
develop   colorectal   adenocarcinoma.      However,   observations   in   non-­‐‑
inflammatory  colonic  tumours  indicate  a  BM  contribution  to  tumour  stroma  is  
highly   likely.      BMD-­‐‑TAMs   have   been   observed   in   a   rectal   adenoma   that  
developed  in  a  female  patient  after  she  had  received  a  BMTx  using  BM  from  a  
male  donor  [36].     Observations  by  Davies  and  colleagues  (2011)   in   the  ApcMin/+  
mouse   also   suggest   that   BMDCs   may   preferentially   engraft   in   the   tumour  
stroma  of  colonic  tumours  compared  normal  nearby  tissue  [80].    However  that  
study   did   not   identify   the   cell   lineages   of   engrafted   cells   or   quantify  
engraftment.      
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1.1.3   Overview  of  BMTx  experiments,  controversies,  and  theories  of  the  
mechanisms  behind  BMDC  mobilisation  and  engraftment  
Over  the  last  decade,  several  research  groups  have  investigated  the  role  of  stem  
cells  from  the  bone  marrow  (bone  marrow  derived  cells)  in  GI  tumourigenesis.  
From  human  and  mouse  BMTx  studies,  it  is  understood  that  BM  can  contribute  
differentiated   epithelial,   endothelial   and   stromal   cell   lineages   to   numerous  
tissues  that  are  capable  of  replication;  and  that  this  contribution  increases  when  
there   is   increased  regenerative  demand   in   tissues   [81-­‐‑83].     However,  how  this  
translates  in  the  setting  of  carcinogenesis  remains  controversial.      
This  section  focuses  on  methodology  used  in  BMTx  experiments,  the  issues  that  
arise  from  such  experiments,  and  the  mechanisms  for  BMDC  mobilisation  and  
engraftment.  
  
Identification  of  BMDCs  
BM  houses  three  stem  cell  types;  haematopoietic  stem  cells  (HSCs)  which  give  
rise  to  all  blood  cells,  mesenchymal  stem  cells  (MSCs)  which  can  possibly  give  
rise   to   adipocytes,   chondrocytes,   osteocytes,   myocytes   and   neurons,   and  
endothelial  progenitor  cells  (EPCs)  which  give  rise  to  endothelial  cells.  
HSCs  are  readily  identified  by  their  expression  of  the  cluster  of  differentiation  
(CD)  34  antigen.    In  humans,  these  cells  occur  at  an  estimated  frequency  of  1  in  
10,000  BM  cells  and  1  in  100,000  peripheral  blood  cells  [84].    In  contrast,  there  is  
no   single  marker   for  MSCs.      Instead   these   cells   are  defined  by   their   ability   to  
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adhere   to   plastic,   expression   of   CD73,   CD90   and   CD105,   and   the   absence   of  
haematopoietic   markers   CD34,   CD45,   CD14,   and   human   leukocyte   antigen  
(HLA)-­‐‑DR  and  by  differentiation  into  adipocytes,  chondrocytes,  and  osteocytes  
in   vitro   [85].      MSCs   occur   more   rarely   with   an   estimated   frequency   of   1   in  
100,000  BM  cells  [86].    The  presence  of  a  significant  number  MSCs  in  peripheral  
blood  has  been  controversial  [87,  88].    However,  MSCs  isolated  from  peripheral  
blood  that  could  be  expanded   in  vitro  has  been  recently  reported  by  Chong  et  
al.,   (2012),   albeit   limited   in   number  when   compared   to  BM   [89].      There   are   a  
number   of   markers   for   EPCs   including   fetal   liver   kinase   1   (Flk-­‐‑1),   Von  
Willebrand   factor   (vWF),   vascular   endothelial   (VE)-­‐‑cadherin,   CD31,   tyrosine  
kinase   with   immunoglobulin-­‐‑like   and   EGF-­‐‑like   domains   (Tie)1,   Tie2,   c-­‐‑Kit,  
CD34,  CD133,  stem  cell  antigen  (Sca)-­‐‑1  and  fms-­‐‑related  tyrosine  kinase  1  (Flt)-­‐‑1  
[90].  EPCs  have  been   identified   in  peripheral  blood,  however   establishing   the  
number  of  EPCs  in  peripheral  blood  has  been  difficult  as  these  cells,  along  with  
mature  endothelial  cells  (e.g.  endothelial  cells  that  do  not  express  CD133)  make  
up  between  0.01%  and  0.0001%  of  mononuclear  cells  in  healthy  individuals  [91].  
Analysis   of   BMDC   engraftment   in   tissues   in   vivo   has   mostly   been   via  
experimental  mouse   studies,  while   analysis   in   human   tissue   comes   from   rare  
clinical  cases  of  BMTx  patients  that  received  a  sex  mismatched  BM  graft.     Sex-­‐‑
mismatched  BMTx  has  been  used  extensively  in  mouse  studies  where  BMDCs  
can   be   traced  using  X   and/or  Y-­‐‑chromosome   ISH.     Other   approaches  used   to  
trace  BMDCs  in  mouse  studies  include  the  transplantation  of  green  fluorescent  
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protein   (GFP)   or   ROSA26-­‐‑expressing   BM.      Other   mouse   studies   have   been  
carried   out   by   injecting   purified   MSCs   or   HSCs   directly   into   an   affected  
tissue/organ,  however  this  section  focuses  on  BMTx  studies  as  they  are  the  most  
relevant  to  this  study.  
In   BMTx   studies   BMDCs   are   identified   in   tissues   or   biopsies   through   a   two-­‐‑
pronged  approach:  identification  of  donor  markers  and  phenotyping  of  cells.  To  
phenotype   cells,   cell   marker   immunohistochemistry   (IHC)   is   carried   out.    
Figure  1.11  demonstrates  the  identification  of  BMD-­‐‑myofibroblasts  through  Y-­‐‑





























Figure 1.11:  BMD-myofibroblasts in the tumour stroma of a pancreatic 
insulinoma, from Direkze et al., 2004 
 
 
BMD-myofibroblasts at the junction between the tumour and surrounding 
pancreas are demonstrated through α-SMA positivity (red staining) and Y 
chromosome positivity (brown dot; x20). A donor-derived myofibroblast is 
shown enlarged (x60; white arrow, inset).  Image taken from [92]. 
  
Issues  surrounding  BMTx  experimentation    
When   assessing   the   contribution   of   BMDCs   to   tissues   in   BMTx   studies,  
particularly   in   the  GI   tract,   it   is   important   to   remember   that   BMTx   itself   can  
contribute  to  tissue  damage  and  potentially  instigate  or  advance  carcinogenesis.      
A  complication  of  allogeneic  BMTx  (e.g.  BMTx  where   the  donor  and  recipient  
are  genetically  different)  is  graft-­‐‑versus-­‐‑host  disease  (GvHD),  in  which  donor  T  
cells   attack   host   tissues   of   which   the   skin,   liver,   and   GI   tract   are   the   major  
targets.   Indeed,   BMDCs   were   identified   in   biopsies   from   patients   suspected  
having  GvHD  where   intestinal   epithelial   damage   resulting   from   acute  GvHD  
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increases   the   contribution   of   BMD   stromal   and   epithelial   cells   [83,   93].  
Moreover,  the  engraftment  of  BMD-­‐‑epithelial  cells  increased  5-­‐‑50  fold  in  GvHD  
damaged  epithelium  compared  to  unaffected  epithelium  [83].    
In   addition   to   GvHD,   ionising   radiation   can   damage   tissues.   Prior   to  
transplantation,  ionizing  radiation  is  administered,  causing  double-­‐‑strand  DNA  
breaks   leading   to   the   apoptosis   of   haematopoietic   cells   (known   as  
myeloablation).   Moreover,   mitotically   active   intestinal   epithelial   cells   are  
susceptible  to  damage  as  well.  Clinically  and  experimentally  this  is  avoided  by  
using   a   radiation   dose   that   allows   for   myeloablation   but   prevents   tissue  
damage.    Additionally,  DNA  damage  incurred  may  cause  DNA  mutations  that  
can   lead   to   the   development   of   tumours.      Indeed,   the   development   of  
secondary   tumours   has   been   observed   years   after   patients   had   undergone  
BMTx  to  treat  haematopoietic  malignancies  (reviewed  in  [94]).  
Using   BMTx   experimentally   to   assess   the   contribution   of   BMDCs   to   GI  
tumourigenesis   presents   numerous   potential   challenges   as   touched   upon  
previously.     Any   intestinal   epithelium  damage   creates   an   additional   stimulus  
for  BMDC  recruitment.  Moreover,  DNA  damage  caused  by   ionising   radiation  
can  accelerate  the  development  of  tumours.    Therefore,  histological  comparison  
of   tumours   and   pathology   with   untransplanted   mice   is   necessary   to  




Evidence  and  controversy  surrounding  the  BM  contribution    
Whilst  there  is  consensus  that  BMDCs  contribute  fully  functional  immune  cells  
and   TAMS   to   the   tumour   microenvironment   (reviewed   in   [95]),   there   is  
controversy   regarding   the   contribution   of   BMDCs   to   the   tumour   vasculature  
and  epithelium.    Several  in  vivo  studies  suggest  that  BMDCs  play  an  important  
role   in   tumour   angiogenesis   [96,   97].      These   studies   have   demonstrated   a  
contribution  of  endothelial  progenitor  cells   (EPCs)   [98,  99]   [100]  and  pericytes  
[101]   [102]   to   tumour   endothelium.   However,   the   magnitude   of   this   BMDC-­‐‑
contribution  to  endothelial  cells  varies  greatly  from  undetectable  [103-­‐‑107]  [108-­‐‑
110]  or  low  [111],  to  half  [112],  to  nearly  all  [100]  endothelial  cells  lining  tumour  
vessels.  
More  controversial  is  the  contribution  of  BMDCs  to  tumour  epithelial  cells.    As  
with   BMD-­‐‑endothelial   cells,   estimates   of   the   contribution   of   BMDCs   to   the  
tumour  epithelial  cell  population  vary  greatly.     For  example,   in  human  BMTx  
studies   this   can   vary   from   occurring   at   low   frequencies   (<10%)   [113, 114] to  
nearly   all  malignant   cells   in   one   patient   that   developed   a   gingival   squamous  
carcinoma   [115].      However,   whether   these   cells   are   playing   an   active   role   in  
tumourigenesis  remains  unknown.  
  
Mechanisms  of  BMDC  mobilisation   
The   recruitment   of   BMDCs   into   the   tumour   microenvironment   and   the  
demonstration   of   BMD   neoplastic   cells,   raises   an   interesting   conundrum:   do  
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circulating   BMDCs   engraft   as   a   result   of   the   inflammation/increased  
regenerative  demand  present  in  these  areas,  or  are  tumours  actively  siphoning  
stem  cells  from  host  cell  reservoirs  such  as  BM?      
Under  normal  circumstances,  BMDCs  are  recruited  into  tissues  via  chemotaxis  
in   which   cells   move   towards   areas   of   an   increased   extracellular   signal.    
Chemokines   and   growth   factors   (such   as   vascular   endothelial   growth   factor  
[VEGF])   released  by  epithelial   and   stromal   cells   are  active  participants   in   this  
process.    Recently,  CXC12  and  osteopontin  have  emerged  as  two  key  players  in  
BMDC   recruitment,   particularly   during   tumourigenesis.      CXCL12   (formally  
known   as   stromal   derived   factor   1   [SDF-­‐‑1])   is   a   α-­‐‑chemokine   secreted   by  
osteoblasts,   BM  endothelium,   endothelial   and   smooth  muscle  progenitor   cells  
and  stromal  fibroblasts.     There  are  two  known  receptors  for  CXCL12:     CXCR4  
and,   recently  discovered,  CXCR7.     Binding  of  CXCL12   to   the  CXCR4  receptor  
(known   as   the   CXC12/CXCR4   axis)   present   on   HSCs   and   circulating   white  
blood   cells   activates   numerous   cell   signalling   pathways   responsible   for  
chemotaxis,  cell  proliferation,  and  survival  of  CXCR4+  cells  [116]  (Figure  1.12).    
The  role  of  CXCR7  in  immune  processes  remains  unknown.    
CXCL12   expression   by   osteoblasts   and   BM   endothelium   is   crucial   to   the  
homing   and   retention   of   CXCR4+   HSCs   in   the   BM;   and   has   been   exploited  
therapeutically,   where   inhibition   of   CXCL12   binding   with   Plerixafor   (AMD-­‐‑
3100)   has   been   shown   to   significantly   increase   the   mobilisation   of   HSCs   for  
autologous  stem  cell  transplantation  [117-­‐‑119].      
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Figure 1.12:  CXCL12/CXCR4 intracellular cell signalling pathways 
 
Binding of CXCL12 to G protein coupled receptor CXCR4 initiates numerous 
cell signalling pathways. This figure illustrates some of the key signalling 
pathways thought to be involved in CXCR4 signal transduction including P13 
Kinase-mediated chemotaxis, gene transcription and cell proliferation. Figure 
taken from [120] 
 
In  the  GI  tract,  CXCL12  is  expressed  by  intestinal  epithelial  cells  (IECs)  stromal  
T  cells  and  peripheral  blood  T  cells.    In  IBD  patients,  an  increase  in  CXCR4+  cells  
is   observed   in   the   intestinal   stroma   and   peripheral   blood   [121].      In   addition,  
CXCL12  expression  is  upregulated  on  IBD-­‐‑IECs  compared  to  normal  IECs  [121].    
Indeed,   blocking   the   CXCL12/CXCR4   axis   ameliorates   DSS-­‐‑induced   colitis   in  
mice   [122].      In   these   experiments,   CXCR4   expression   on   CD4-­‐‑positive   cells  
significantly   increased   after   the   start   of   DSS   administration   compared   with  
normal  mice,   and   CXCL12   expression  was   significantly   higher   in   the   colonic  
tissue  of  DSS  colitic  mice  than  in  normal  mice.        
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The  functional  role  of  CXC12  and  CXCR4  expression  in  the  GI  tract  depends  on  
whether   inflammation   is   present.      For   instance,   expression   in   normal   IECs  
mediates   cell   migration,   barrier   maturation   and   restitution   through   cAMP-­‐‑
mediated   cellular   functions   [121].      Whilst   in   vitro   studies   suggest   that   the  
upregulation   CXCL12   in   IBD   serves   to   attract   peripheral   blood   T   cells   and  
stromal  T  cells  to  inflammation  sites-­‐‑  thus  increasing  inflammation  [123].  
In  cancer,  increased  CXCR4  expression  is  observed  on  malignant  epithelial  cells  
and  is  correlated  with  increased  metastasis  that  is  believed  to  occur  through  the  
migration   of   CXCR4+   malignant   cells   to   tissues   that   express   CXCL12   [124].    
Furthermore,   expression   of   CXCR4+   on   endothelial   cells   may   contribute   to  
tumour   vascularisation   [120].      The   recruitment   of   BMDCs   through   the  
CXCL12/CXCR4   axis   may   be   important   for   the   role   of   BMDCs   in   GI  
tumourigenesis.    Takemoto  and  colleagues  (2011)  demonstrated  that  an  increase  
of  circulating  CD34+  BMDCs  following  gastrectomy  led  to  the  increased  growth  
of   implanted   tumours   and   tumour   microvessel   density   compared   to  
unoperated   mice   [96].      Blocking   of   CXCL12   with   AMD-­‐‑3100   negated   these  
changes.     Quante   and   colleagues   (2011)   also  blocked  CXCL12  and  observed  a  
decrease  in  gastric  α-­‐‑SMA+  myofibroblasts  and  inhibition  of  gastric  dysplasia  in  
mice  infected  with  H.  felis   [37].        Observation  of  CXCL12  expression  in  ApcMin/+  
mice   revealed   that   expression   occurred   solely   in   intestinal   tumours   and   not  
normal  tissues;  this  correlated  with  increased  BMDC  engraftment  (Figure  1.15)  
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[80].    Collectively  these  findings  indicate  that  the  CXCL12/CXCR4  axis  plays  an  
important  role  in  the  BM-­‐‑  contribution  to  tumour  vasculature  and  desmoplasia.  
  
Like  CXCL12,  osteopontin  (OPN)  has  also  been  implicated  in  the  recruitment  of  
BMDCs.   OPN   is   an   acidic   glycoprotein   that   through   its   interaction   with  
integrins  present  on  other  cells  or  with  its  receptor  CD44,  activates  various  cell  
signalling   pathways   involved   in   cell-­‐‑cell   interactions,   angiogenesis,   cell  
migration,   proliferation,   and   survival   (Figure   1.13).   OPN   can   exist   both  
extracellularly  and  intracellularly,  free  or  bound,  and  secreted  by  numerous  cell  
types   including  bone,  BM  cells,   immune  cells   (such  as  B  and  T   lymphocytes),  
macrophages,  smooth  muscle  cells,  and  epithelial  cells.  
  
Figure 1.13:  OPN induced cell signalling pathways 
 
By interacting with integrins (such as avb1, avb5, or avb3) or its receptor CD44 on the 
surface of cells, osteopontin can act on numerous cell signalling pathways affecting cell 
migration, proliferation and survival, adhesion and angiogenesis. Figure adapted from 
[125]. 
 51 
In  vitro  and  in  vivo  studies  have  shown  that  OPN  is  a  key  maintainer  of  the  BM  
niche.         This   occurs   through   the   homing   of  HSCs   to   the   BM   niche   and   their  
retention  through  the  regulation  of  HSC  proliferation  [126].    Thrombin-­‐‑cleaved  
OPN,  which  is  abundant   in  human  and  mouse  BM,  has  been  demonstrated   in  
vivo  to  be  a  key  regulator  of  human  and  mouse  HSCs  via  interactions  with  α9β1  
and  α4β1  integrins  present  on  HSCs  [127].  
In  the  GI  tract,  IBD  and  tumourigenesis  are  associated  with  an  increase  in  OPN  
[128,   129].      In   various   cancers   (not   just   those   in   the   GI   tract)   OPN   is  
overexpressed   on   tumour   cells   (reviewed   in   [125]).     Moreover,   high   levels   of  
OPN  is  observed  in  the  blood  of  patients  with  metastatic  cancers  [130].    In  vitro  
and   in  vivo  studies   implicate  OPN  in  every  step  of   tumourigenesis  [125],   from  
increased  migration  via  overexpression  of  integrins  on  cancer  cells  [131-­‐‑133]  to  
the  apoptotic  resistance  in  cancer  cells  due  to  the  interaction  of  OPN  with  CD44  
activating  Src-­‐‑mediated  cell  signalling  [134].      One  burgeoning  theory  is  that  the  
increased  OPN  expression  in  tumourigenesis  disrupts  the  regulation  of  the  BM  
(see  Figure  1.14)   [135].     McAllister  and  colleagues   (2008)  demonstrated   in  vivo  
that  OPN  produced  from  aggressive  tumours  increased  BMDC  recruitment  into  
neighbouring   indolent   tumours,   and   that   small   hairpin   RNA   (shRNA)  
suppression   of   Opn   mRNA   resulted   in   a   significant   decrease   in   BMDC  
recruitment   into   indolent   tumours   [136].      In   vivo   studies   by   Davis   and  
colleagues   (2011)   demonstrated   frequent   OPN   expression   on   the   BMD-­‐‑HSCs  
present  in  tumour  stroma  but  not  in  the  BMD-­‐‑HSCs  present  in  normal  intestinal  
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stroma  (Figure  1.15).    Moreover,  they  observed  increased  BMDC  engraftment  in  
tumour  stroma  compared  to  the  normal  intestinal  stroma  [80];    however  which  
cell  lineages  the  BMDCs  contributed  to  was  not  investigated.  
These   findings   suggest   a   role   of   OPN   in   BMDC   recruitment   during  
tumourigenesis.      Whether   aberrant   OPN   expression   in   tumours   is   solely  
associated   with   the   recruitment   of   HSCs   or   whether   MSCs   or   EPCs   become  




Figure 1.14:  Proposed paradigm of OPN instigated BMDC recruitment into 
secondary tumour sites 
 
 
OPN secreted by an instigating primary tumour disrupts normal HSC regulation 
causing the mobilisation of activated BMDCs into the circulation that eventually 









Figure 1.15:  OPN and CXCL12 expression in ApcMin/+ mouse tumours, from 
Davis et al., 2011 
 
Fluorescent in situ hybridisation for OPN protein (red) demonstrates co-
expression in eGFP (green) BMDCs in a small intestinal tumour (a) but similar 
expression is not observed in normal SI (b).  Similarly, CXCL12 protein 
expression (red; c) is observed in an intestinal tumour (c) but not in normal 
intestine.  Blue; DAPI.  Magnifications were not provided in the paper.  Figure 
taken from [80].  
  
Mechanisms  proposed  for  BMD-­‐‑epithelial  cell  engraftment    
The  presence  of  BMD-­‐‑epithelial  cells  and  tumours  cells  has  led  to  a  debate  as  to  
how   these   cells   engraft,  with   two   competing   theories:      BM  plasticity   and   cell  
fusion.      For   example   with   BM   plasticity,   a   fraction   of   cytokeratin   19+   BMD-­‐‑
MSCs   can   differentiate   into   epithelial   cells,   as   demonstrated   to   occur   with  
gastric   epithelial   cells   in   vivo   [137].      A   competing   theory   is   that   BMDCs   fuse  
with   somatic   cells.      Cell   fusion   events   occur   as   part   of   mammalian  
development,  for  example  macrophage  fusion  to  produce  osteoclasts  [138].    Cell  
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fusion  in  BMTx  experiments  is  the  result  of  the  nuclear  fusion  of  donor  and  host  
cells,   identified   by   either   the   combination   of   donor   and   host   cell   markers   or  
chromosomes,   demonstrated   by   fluorescence   in   situ   hybridisation   (FISH).    
Chromosomal  analysis  has  demonstrated   that   fused   cells   are   synkaryons   (e.g.  
containing   a   single   nucleus),   stable,   and   non-­‐‑proliferating   containing  
chromosomes   from   different   cell   types   [139,   140].      However,   loss   of  
chromosomes  has  been  shown  to  occur  following  nuclear  fusion  (cytoreductive  
division),  which  would  then  make  demonstrating  cell  fusion  impossible  due  to  
the  loss  of  chromosomes  and  genetic  markers  [141].  
BMDCs  have  been  reported   to  stably   fuse  with  various  cell   types   in  vivo   [139,  
142-­‐‑149]  including  intestinal  cells  [150]-­‐‑[151]  at  low  frequencies.    Moreover,  cell  
fusion-­‐‑mediated   tissue   repair   has   also   been   reported   in   vivo   [152,   153].    
However,  evidence  from  several  in  vivo  mouse  [39,  154,  155]  and  human  BMTx  
studies  [83]  [82]  have  cast  doubt  on  the  contribution  of  cell  fusion  to  intestinal  
tract   epithelial   cells.     Most   recently,   de   Jong   and   colleagues   (2012)   presented  
what   could   be  defining   research   on  BMDC   cell   fusion.      By   tracking  GFP   and  
inducible   diphtheria   toxin   receptor   (iDTR)   expression   in   BMTx’d   mice,   they  
concluded  that  cell   fusion  events  were  rare,  occurring  at  a  rate  of  around  1   in  
1000  cells  and  that  they  were  isolated  incidences  in  the  crypt.    Moreover,  DSS-­‐‑
induced   intestinal   damage   did   not   increase   cell-­‐‑fusion   events.      In   these  
experiments   a   novel   Cre-­‐‑Lox   BMTx   model   was   created   in   which   inducible  
diphtheria   toxin   receptor   (iDTR)/GFP   BM   harbouring   a   LoxP   site   was  
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transplanted   into   CMV-­‐‑Cre  mice.      Therefore,   fused   cells   would   express   both  
GFP   and   DTR.      Using   semi-­‐‑quantitative   PCR   analysis   of   the   iDTR   locus   to  
analyse   the   biological   contribution   of   cell   fusion   to   tissue   repair,   diphtheria  
toxin  (DT)  was  routinely   injected  into  a  group  of  mice  following  DSS-­‐‑induced  
damage   of   intestinal   epithelium,   while   another   group   remained   untreated.    
DSS-­‐‑induced  damage  and  inflammation  did  not  result  in  a  significant  increase  
in   cell   fusion   events,   while   the   DT   treated   group   displayed   no   difference   in  
histology  compared  to  the  untreated  group,  indicating  that  cell  fusion  was  not  
necessary  for  intestinal  epithelial  repair  [156].    
Therefore,  a  question  that  arises   is   if  cell   fusion  is  a  rare  event  how  could  one  
explain  the  past  studies  demonstrating  a  significant  contribution  of  cell  fusion?  
One   possible   explanation   is   the   horizontal   DNA   transfer   via   phagocytosis   of  
apoptotic   bodies   as   recently   demonstrated   by  Waterhouse   et   al.,   (2011)   [157].    
Nevertheless,   cell   fusion   remains  a   controversial   theory   for   explaining  BMDC  
engraftment  in  the  gastrointestinal  tract.        
  
1.2   Aims  and  hypotheses  of  this  study  
1.2.1   Overview  
Sex-­‐‑mismatched  BMTx  was  utilised  to  investigate  the  contribution  of  BMDCs  to  
GI   tumourigenesis   in   the   following   four   different   mouse   models:   the   Tff1-­‐‑/-­‐‑  
mouse   model   of   inflammation-­‐‑associated   gastric   tumourigenesis,   the   ApcMin/+  
and   Apc1322T   mouse   models   of   adenomatous   polyposis,   and   the   Il10-­‐‑/-­‐‑   mouse  
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model   of   chronic   enterocolitis   with   a   predisposition   to   colorectal  
adenocarcinoma.      The   aim   was   to   conduct   a   comprehensive   study   of   the  
contribution   of   BMDCs   to   tumour   epithelium   and   stroma;   comparing  
engraftment  in  inflammatory  and  non-­‐‑inflammatory  associated  neoplasia,  early  
dysplasia  to  later  adenocarcinoma,  and  the  effect  of  increased  tumour  burden.    
  
1.2.2        Major  aims  and  hypotheses  
The  overall  remit  of   this  study  was  to   investigate  whether  BMDC-­‐‑tumours,  as  
demonstrated   by   Houghton   et   al.,   (2004)   [39],   could   occur   in   absence   of  
Helicobacter   infection.      To   this,   we   utilised   IHC   to   identify   putative   donor-­‐‑
derived  epithelial  cells  with  Y-­‐‑chromosome  ISH.  
As   chronic   inflammation   from  Helicobacter   infection  was   a   key   feature   of   the  
Houghton   et   al.,   (2004)   study,   we   aimed   to   determine  whether   inflammation  
alone  could  drive  the  creation  of  BMDC-­‐‑crypts  and  glands.    Therefore,  the  Il10-­‐‑/-­‐‑  
and  Tff1-­‐‑/-­‐‑  mouse  models  were  chosen  as   these  models  develop   tumours   in  an  
inflammation  context.    From  this,  a  hypothesis  developed  was  that  engraftment  
of   BMD-­‐‑epithelial   cells   would   be   significantly   higher   in   the   Il10-­‐‑/-­‐‑   and   Tff1-­‐‑/-­‐‑  
mouse  models   compared   to  ApcMin/+  and  Apc1322T  mouse  models,  which   do   not  
develop  chronic  inflammation  as  part  of  their  pathology.    
As  BMD  recruitment  appears  to  correlate  with  increased  regenerative  demand  
[78],  another  hypothesis  was  that  engraftment  of  BMD-­‐‑epithelial  cells  would  be  
higher  in  Apc1322T  mice  which  have  a  greater  tumour  burden  than  ApcMin/+  mice.    
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1.2.3      Minor  aims  and  hypotheses    
Several   minor   hypotheses   and   aims   were   developed   to   further   investigate  
BMD-­‐‑myofibroblast   contribution  and   recruitment   to   tumour   stroma,   stem  cell  
dynamics  within  tumours,  cell  fusion  events,  and  whether  BMTx  could  reverse  
the  pathology  observed  in  ApcMin/+  and  Tff1-­‐‑/-­‐‑  mice.  
In  addition,  the  development  of  SPEM  in  WT  mice  of  the  Tff1-­‐‑/-­‐‑    mouse  crossover  
study   let   to   the   formation   of   additional   hypotheses   which   are   discussed   in  
Section  1.2.3.1.  
  
BMD-­‐‑myofibroblast  contribution  and  recruitment  to  tumour  stroma  
In   this   study,  we   aimed   to   understand  whether   increases   in   inflammation   or  
tumour   burden  would   impact   on   BMDC  myofibroblast   recruitment   using  α-­‐‑
SMA   IHC/   Y-­‐‑chromosome   ISH   identification   of   BMD   myofibroblasts.      A  
hypothesis  was   that  BMD-­‐‑myofibroblasts  would  home   into  areas  of   increased  
inflammation  or  increased  tumour  burden.  
Despite  previous   studies   that  have  demonstrated   a   significant   contribution  of  
BMD-­‐‑myofibroblasts   to   inflammation   and   to   tumour   stroma   [78,   92],   little   is  
known  about  the  mechanisms  of  BMD-­‐‑myofibroblast  recruitment.    To  improve  
our  understanding  of  this,  isotopic  ISH  was  carried  out  to  identify  and  compare  
Opn   mRNA   expression   in   tumours,   areas   of   inflammation   and   normal  
surrounding  tissues.    Opn  was  chosen  based  on  the  findings  from  McAllister  et  
al.,   (2008)   and  Davis   et   al.,   (2011)   that   suggested   a   role   in   the   recruitment   of  
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BMDCs   into   the   tumour  stroma   [80,  136].  Therefore  we  propose   that  aberrant  
Opn   mRNA   expression   in   tumours   and/or   inflammation   correlates   with  
increased  BMDC  engraftment.  
  
Stem  cell  dynamics  within  tumours  
Numerous   studies   have   indicated   that   stem   cell   dynamics   are   altered  within  
tumours.     For  example,   strong  mRNA  expression  of   the  Wnt   target  gene  Lgr5  
has  been  described   in  a  number  of  human   tumours   [158]   [159]  and   in  ApcMin/+  
and  Apc1322T  mouse   SI   adenomas   [57].      Therefore,  we   aimed   to   compare   Lgr5  
mRNA  expression  in  the  tumours  and  normal  tissues  of  Tff1-­‐‑/-­‐‑  and  Il10-­‐‑/-­‐‑  mouse  
models  that  do  not  harbour  Apc  mutations.  
In  addition,   a   stem  cell   origin  of  Tff1-­‐‑/-­‐‑  mouse   invasive  gastric   carcinomas  has  
been   suggested   by   Karam   et   al.,   (2008)   [28].      Therefore,   a   hypothesis   in   this  
study  is  that  the  highly  proliferative,  heterogeneous  cell  populations  observed  
in  Tff1-­‐‑/-­‐‑  mouse  adenocarcinomas  are  the  result  of  aberrant  Wnt  signalling.     To  
investigate  this  we  employed  Lgr5  mRNA  isotopic  ISH  to  compare  expression  
in  WT  mouse  pyloric  antrum  with  expression  in  Tff1-­‐‑/-­‐‑  mouse  adenocarcinomas.  
Of  particular  interest  is  a  proposed  paradigm  of  BMDC  engraftment  developed  
by   Houghton   and   colleagues   (2005)   in   which   BMDCs   could   engraft   in   an  
ablated  stem  cell  niche  and  function  as  stem  cells  [40].    We  aimed  to  use  isotopic  
ISH   to   analyse  Lgr5  mRNA  expression   to   investigate  whether  BMD-­‐‑epithelial  
cells  could  adopt  stem-­‐‑like  properties.  A  hypothesis  was  that   if  BMDCs  could  
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adopt   stem-­‐‑like   properties,   these   cells  would   strongly   express   the  Wnt   target  
gene  Lgr5  and  be  capable  of  replication  producing  clones  of  cells  recognisable  in  
tissue  sections  as  donor-­‐‑derived.    However,  we  did  not  observe  engraftment  of  
putative  BMD-­‐‑epithelial  cells  in  the  stem  cell  niche  of  any  tissues  analysed.    
  
Cell  fusion  events  
Fusion  of  BMDCs  with  normal  and  neoplastic  intestinal  cells  has  been  reported  
as   the   means   of   BMDC   engraftment   [150,   151],   eliciting   much   controversy.    
Based  on  these  studies,  if  cell  fusion  events  do  occur  they  would  correlate  with  
tumours   and/or   areas   of   inflammation  with   a   relatively   low   frequency   of   cell  
fusion   events   occurring   in   nearby   normal   tissue   [141].      We   attempted   to  
optimise   X/Y-­‐‑chromosome   FISH      (as   well   as   the   detection   of   other   mouse  
chromosomes  with   the  Y-­‐‑chromosome)  and   the  use  of  pancentromeric  probes  
to   demonstrate   cell   fusion.      We   were   unable   to   find   a   reliable   method   of  
demonstrating  cell  fusion;  discussed  Section  A.1  in  the  Appendix.  
  
BMTx-­‐‑induced  alteration  of  pathology  
Amelioration   of   colitis   in   Il10-­‐‑/-­‐‑  mice   following   transplantation   of   wild-­‐‑type  
(WT)  mouse  BM  has  been  described  previously  and  therefore  was  not  repeated  
with   the   Il10-­‐‑/-­‐‑  mice   of   this   study.      However,   this   (WT   mouse   BMTx)   was  
repeated   for   the  ApcMin/+  and  Tff1-­‐‑/-­‐‑  mice.      In   other  words,   not   only  were   these  
mice  transplanted  with  similar  mutant  BM  (e.g.  Tff1-­‐‑/-­‐‑  BM  transplanted  into  Tff1-­‐‑
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/-­‐‑  mice)  but  also  these  mutant  mice  were  transplanted  with  WT  BM.    We  did  not  
expect  transplantation  of  mutant  or  WT  mouse  BM  into  mutant  mice  to  have  an  
observable   effect   on   pathology.      This   is   because   the   enterocolitis   observed   in  
Il10-­‐‑/-­‐‑  mice  is  due  to  a  mutation  that  affects  immune  cells,  therefore  replacement  
of   these   cells   with   WT   immune   cells   via   BMTx   would   ameliorate   colitis.  
Whereas  the  pathology  observed  in  ApcMin/+  and  Tff1-­‐‑/-­‐‑  mice  is  due  to  mutations  
that  effect  epithelial  cells.    In  addition  to  these  transplantations,  mutant  mouse  
BM  was   transplanted   into  WT  mice   to   investigate  whether   this  BMTx  of   cells  
harbouring   mutations   could   have   a   deleterious   effect.   In   carrying   out   these  
crossover  studies,  our  aim  was  to  understand  what  effects  BMTx  could  have  on  
pathology  and  on  BMDC  recruitment.  
  
1.2.3.1  Aims  and  hypotheses  formed  during  this  study  
SPEM  was  observed   in  WT  mice   transplanted  with  either  WT  or  Tff1-­‐‑/-­‐‑    mouse  
BM  in  the  Tff1-­‐‑/-­‐‑    mouse  crossover  study  from  6  months  post  BMTx.    At  the  time  
that  this  study  was  being  carried  out,  one  hypothesis  as  to  why  SPEM  occurred  
was  that  there  was  an  expansion  of  TFF2  protein  expressing  progenitor  (stem)  
cells.      In  addition,   rare  Lgr5   expressing  cells   in   the  oxyntic  mucosa  have  been  
occasionally  shown  to  give  rise  to  oxyntic  mucosal  cell  lineages  [20].  Therefore,  
we   aimed   to   investigate  whether   Lgr5   expression   is   altered   during   SPEM   by  
utilising  isotopic  ISH  to  analyse  Lgr5  mRNA  expression.    A  hypothesis  formed  
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was  that  there  would  be  an  increase  in  Lgr5  mRNA  in  SPEM  tissues  as  a  result  
of  increased  Wnt  signalling  to  create  SPEM  lineages.    
In   the   histological   examination   of   SPEM   tissues   inflammatory   infiltrate   was  
always   observed.      As   with   an   earlier   hypothesis   that   BMDC   engraftment   in  
epithelium  and  stroma  would  be  driven  by  inflammation,  we  utilised  the  same  
methods  described  in  Sections  1.2.2  and  1.2.3  to  investigate  the  contribution  of  
BMD-­‐‑putative   epithelial   cells   and   myofibroblasts,   respectively,   in   inflamed  
SPEM  tissues.    Similarly,  we  also  investigated  Opn  mRNA  expression  in  SPEM  
tissues  using   isotopic   ISH  based  on  previous  reports  of   increased  Opn  mRNA  
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2.1   Overview  of  experiments  and  rationale  
All  incubations  were  carried  out  at  room  temperature  unless  otherwise  stated.  
Water  refers  to  Milli-­‐‑Q  purified  water  unless  otherwise  stated.  
  
To   investigate   the   contribution  of  BMDCs   to   tumourigenesis,   sex-­‐‑mismatched  
BMTx  (male  BM  into  female  recipient  mice)  was  carried  out  in  the  Tff1-­‐‑/-­‐‑,  ApcMin/+  
Apc1322T  and  Il10-­‐‑/-­‐‑  mouse  studies.        BMTx  involved  the  use  of  ionising  radiation  
which   ablated   the   recipient   mouse’s   BM   to   allow   for   the   reconstitution   with  
haematopoietic  stem  cells  harvested  from  donor  male  BM.      
A   consequence   of   irradiation   is   that   the   recipient   mice   are   immuno-­‐‑
compromised   and   thus   susceptible   to   infectious   pathogens.      Therefore,   it   is  
common  practice  to  administer  antibiotics   to  mice  and  humans  pre-­‐‑  and  post-­‐‑
BMTx,  to  minimise  pathogen  infection  and  reduce  the  risk  of  systemic  infection  
from   gastrointestinal   bacteria.      However,   there   are   several   limitations   to  
administering  antibiotics   such  as   the   risk  of   antibiotic   resistance  development  
[160].   In   this   study   we   did   not   administer   antibiotics   to   BMTx’d   mice   and  
instead   relied   upon   the   following   common   animal   husbandry   practices   to  
reduce  the  risk  of  pathogen  infection:  
• Mice  were  fed  acidified  water  two  weeks  prior  to  BMTx  which  continued  
for   6   weeks   after   BMTx.      This   served   two   purposes.   The   first   was   to  
cleanse   the   GI   tract   of   pathogens   prior   to   BMTx.      The   second  was   to  
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reduce  the  likelihood  of  bacterial  contamination  from  water  bottles  post  
BMTx  [160].  
• Mouse   chow   and   water,   cages   and   water   bottles   were   autoclaved   to  
reduce  the  likelihood  of  bacterial  and  fungal  infection.    
• Mice   were   kept   in   HEPA-­‐‑filtered   individually   ventilated   cages   and  
handled   only   under   a   HEPA-­‐‑filtered   flow   hood   to   remove   aerolised  
bacteria  and  fungal  spores  [160].    
• Screening   for   common  mouse   colony   bacterial   and   parasitic   infections  
(such  as  Streptococcus  spp.  and  Giardia)  was  carried  out  post  BMTx.      
Following   BMTx,   mice   were   monitored   daily   and   then   culled   at   determined  
time  points.     Prior  to  culling,  mice  were  administered  Vincristine  and  BrdU  to  
analyse  for  mitotic  activity  and  DNA  synthesis,  respectively.    Tissues  were  then  
harvested,   fixed   in   formalin,   embedded   into   paraffin   blocks.      Tissue   blocks  
were   cut   into   serial   sections,  with   the   first   section   stained  with   haematoxylin  
and  eosin  (H&E)  to  be  used  as  a  guide  and  the  remaining  sections  to  be  used  for  
special   stains   and   immunohistochemistry.      Sections   to   be   analysed   for  Opn,  
Lgr5,   Tff1,   Tff2,   and   Tff3   mRNA   expression   via   isotopic   ISH   were   cut   under  
RNase  free  conditions  a  day  prior  to  the  experiment  to  provide  optimal  results.      
To   analyse   the   contribution   of   BMDCs   in   tissues,   an   IHC/Y-­‐‑chromosome   ISH  
assay   was   carried   out   on   a   single   section   for   either   α-­‐‑SMA   (to   analyse   for  
myofibroblasts)   or   lymphocytic   cells   and   macrophages,   followed   by   Y-­‐‑
chromosome   ISH.      The   presence   of   BMD-­‐‑myofibroblasts   in   the   processed  
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sections  was  then  quantitated  using  Nikon  microscope/image  analysis  software  
and  quantified  using  PRISM  statistical  software.    
  
Statement  on  experimental  collaborations  
This   study   contained   a   number   of   collaborations.      Paraffin   embedded  ApcMin/+  
mouse   crossover   study   tissues   were   presented   as   a   kind   gift   from   Shigeki  
Bamba.      Apc1322T  mice   were   presented   as   a   kind   gift   from   Annabelle   Lewis  
(University   of   Cambridge).      Genotyping   of  ApcMin/+   crossover   study  mice  was  
carried   out   by   Alison   Martin   (CRUK)   and   genotyping   of   Apc1322T  mice   was  
performed  by  Annabelle  Lewis.    The  author  was  responsible  for  the  genotyping  
of  Il10-­‐‑/-­‐‑  and  Tff1-­‐‑/-­‐‑  mouse  crossover  study  mice.  
The  Biological  Resources  Unit  (Cancer  Research  UK)  was  responsible  for  animal  
husbandry   and   carried   out  whole-­‐‑body   irradiation   of  mice  Apc1322T,   Il10-­‐‑/-­‐‑   and  
Tff1-­‐‑/-­‐‑   mouse   crossover   study   mice.   The   author   carried   out   bone   marrow  
collection,  processing,  and  stem  cell  transplantation.    Microbiological  screening  
for   bacterial   and  parasitic   infections  was   carried   out   by  Minal   Panya   (Cancer  
Research  UK),  whilst  screening  for  Helicobacter  species   in  mice  was  performed  
by  Harlan   Laboratories.     The   author  was   responsible   for  monitoring,   culling,  
and  harvesting  and  processing  of  mouse  tissues.  
The  Experimental  Histopathology  laboratory  (Cancer  Research  UK)  carried  out  
tissue   paraffin   embedding   and   sectioning;   and   H&E   and   Alcian  
blue/diastase/PAS  staining.    Nicholas  Wright  (Pathologist;  QMUL)  performed  a  
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histological   assessment   of   Apc1322T,   ApcMin/+   and   Tff1-­‐‑/-­‐‑   mouse   crossover   study  
mouse   tissues.      Gordon   Stamp   (Pathologist;   ICL)   performed   a   histological  
assessment  of  Il10-­‐‑/-­‐‑  mouse  tissues.  
All   immunohistochemistry,   Y-­‐‑chromosome   ISH   and   detection   and  
quantification  of  BMDCs  was  carried  out  by  the  author.  
Both   the  author   and  Rosemary   Jeffrey   (Cancer  Research  UK)  performed  Lgr5,  
Tff1,  Tff2,  and  Tff3  mRNA  isotopic   ISH  experiments.     Table  2.1  outlines  which  
experiments  were  performed  by  Rosemary   Jeffrey  and  which  were  performed  
by  the  author.     The  author  was  responsible  for  preparation  and  purification  of  
Opn   containing  plasmids   and  Opn  mRNA   isotopic   ISH.      Isotopic   ISH   for  Tff1  
mRNA  was  carried  out  only  on   Il10-­‐‑/-­‐‑  mouse   tissues  before   switching   to  more  
time  and  cost  effective  TFF1  IHC.  
  
Table 2.1:  Delegation of isotopic ISH experiments 
Experimental 
group 
Isotopic ISH experiment 









RJ: Tff1-/-→Tff1-/- mice 
group, WT →Tff1-/- 
mice group at 6 
months post BMTx, 
Tff1-/-→WT mice at 6 
months post BMTx 
ALB remaining groups 
ALB ---- 
RJ: Tff1-/-→Tff1-/- 
mice at 6 months 
post BMTx, Tff1-/- 
→WT mice at 6 and 








ALB ALB ---- ---- ---- 
Apc1322T RJ ALB ---- RJ ---- 
Il10-/- mice RJ ALB RJ ---- RJ 
 
RJ Rosemary Jeffrey; ALB Arielle Le Brenne; → mouse BM transplanted into;  -
--- experiment not performed 
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2.2   Animals  
Il10-­‐‑/-­‐‑  mice  (on  a  BALB/c  background)  from  the  Jackson  Laboratory  were  used  to  
create   an   experimental   colony.      Tff1-­‐‑/-­‐‑   mice   (on   a   C57BL/6   background)  
generated  by  Lefebvre  et  al.  (1996)  were  used  in  this  study.    Apc1322T  mice  (on  a  
C57BL/6  background)  mice  were  a  kind  gift  from  Annabelle  Lewis.  
  
Husbandry  
All   mice   were   maintained   under   barrier   housing   at   the   Biological   Resources  
Unit      (London   Research   Institute,   Cancer   Research   UK)   and   provided   with  
standard  chow  diet  and  water  ad   libitum   in  accordance  with  UK  Home  Office  
guidelines.      
  
Microbiological  screening    
Microbiological  screening  was  carried  out  on  a  mouse  from  each  cage  present  in  
the  Tff1-­‐‑/-­‐‑,  Apc1322T,  and  Il10-­‐‑/-­‐‑  mouse  colonies.  This  was  done  a  week  post  BMTx  
and  prior  to  culling  for  Apc1322T  mice  and  was  carried  out  monthly  for  the  Tff1-­‐‑/-­‐‑  
and  Il10-­‐‑/-­‐‑  mice.     Oral  swabs  and  faecal  samples  were  taken  from  the  mice  and  
analysed  by  Minal  Pandya  (Clare  Hall,  CRUK).    Entamoeba,  Giardia,  Chilomastix,  
and  Tritrichomonas   were   detected   using   a   routine   faecal   smear  method   [161].    
Streptococci   and   Lactobacilli,   which   are   present   in   normal   murine   flora,   were  
tested  for  antibiotic  sensitivity  using  disk-­‐‑diffusion  antibiotic  testing  (the  Kirby-­‐‑
Bauer   antibiotic   testing   method)   [162].      Testing   for   Helicobacter   species   was  
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performed  by  Harlan  Laboratories.     DNA  was   extracted   from   faecal   samples,  
using  methods  described  by  Shen  et  al.,  (1997)  [163].    
  
Genotyping  
Genotyping  of  Apc1322T  mice  was  carried  out  by  Annabelle  Lewis.     Genotyping  
of   ApcMin/+  mice   was   carried   out   by   Alison   Martin.      The   author   carried   out  
genotyping  of  Tff1-­‐‑/-­‐‑  and  Il10-­‐‑/-­‐‑  mice.  
All  mice  were  genotyped  using  PCR  and  agarose  gel   electrophoresis.     Mouse  
DNA   was   extracted   from   mouse   ear   or   tail   snip   tissue   using   manufacturer-­‐‑
supplied  instructions  and  reagents  from  a  DNEasy  blood  &  tissue  kit  (Qiagen)  
for   Tff1-­‐‑/-­‐‑,   ApcMin/+   and   Il10-­‐‑/-­‐‑   mouse   genotyping   or   following   the   HotSHOT  
alkaline  lysis  method  [164]  for  Apc1322T  mouse  genotyping.    Extracted  DNA  and  
amplified  products  were   then   kept   at   4°C   (or   frozen   for   longer   term   storage)  
until  use.  
Genotyping   involved   PCR   of   extracted   DNA   using   a   three-­‐‑primer   mix   that  
allowed   for   the   amplification   of   +/+,   -­‐‑/+,   or   -­‐‑/-­‐‑   alleles   in  mice  which   can   then  
allow   for   the   determination   of  mouse   genotype   by   specific  molecular  weight  
bands   following  1%  agarose  gel  electrophoresis.     For  example,  Tff1-­‐‑/-­‐‑  and   Il10-­‐‑/-­‐‑  
mice   possess   a   neomycin   (Neo)   resistance   gene   that   is   amplified   by   a   Neo  
primer  produced  in  any  mice  possessing  a  mutated  allele(s).    Similarly,  specific  
primers   bind   onto   a   mutated   allele   found   only   in   ApcMin/+   and   Apc1322T   mice,  






Amplified   PCR   products   were   separated   on   a   1%   agarose   gel   containing  
ethidium  bromide.     A  150ml  agarose  gel  was  made  by  adding  1.5g  molecular  
biology  grade  agarose   to   150ml  1x  TBE  and  heating   in   a  microwave  until   the  
agarose  fully  dissolved  (~3  minutes).     The  melted  agarose  was  allowed  to  cool  
for   ~2   minutes   and   1.5µl   of   ethidium   bromide   was   then   added,   mixed   and  
poured  into  a  gel-­‐‑casting  tray  with  a  comb(s)  inserted  in  order  to  create  sample  
wells.    The  gel  was  allowed  to  set  (~30  minutes)  before  the  combs  were  removed  
and   the   gel   tray   was   placed   into   a   gel   tank   filled   with   1x   TBE   buffer.      5µl  
amplified  PCR  product  was  mixed  with  2µl  5x  loading  buffer  and  loaded  into  
respective   wells   in   the   gel.      6µl   of   100bp   DNA   ladder   was   run   alongside   in  
order   to  determine   fragment  size   (see  Table  2.3   for  PCR  product  sizes  of  each  
genotyping   protocol).      The   gel   was   run   at   400V   for   40  minutes,   then   placed  
under  UV  light  to  visualise  DNA  and  a  digital  image  was  taken  (See  Figure  2.1  
and  2.2).    
 
Table 2.3:  PCR product sizes of Tff1-/-, ApcMin/+, Apc1322T and Il10-/- mouse 
genotyping  
 
 PCR product size (base pairs) for each genotype 
Genotyping  
protocol 
+/+ -/+ -/- 
Tff1-/- 200 200 and 500 500 
ApcMin/+ 600 340 and 600 ---- 
Apc1322T 217 217 and 433 ---- 
Il10-/- 200 200 and 450 450 
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A digital photograph of Tff1+/+ (1), Tff1-/+ (2) and Tff1-/- (3) mouse DNA separated 
on a 1% agarose gel.  A 100bp ladder (4) was run alongside to determine the 
molecular weight of the samples. 
 




A digital photograph of Il-10+/+ (1), Il-10-/+ (2) and Il10-/- (3) mouse DNA 
separated on a 1% agarose gel.  A 100bp ladder (4) was run alongside to 
determine the molecular weight of the samples. 
  
Bone  marrow  transplantation  
Female  mice   that  underwent   transplantation  were  housed  under  conventional  
conditions.      A   week   prior   to   transplantation,   these   mice   were   fed   acidified  
water  (pH2.5-­‐‑3.0),  as  previously  described  [160].     ApcMin/+,  Il10-­‐‑/-­‐‑  and  Tff1-­‐‑/-­‐‑  mice  
of  at  least  six  weeks  of  age  to  a  maximum  of  2  months  of  age  were  subjected  to  
a  total  of  12  Gray  whole  body  gamma-­‐‑irradiation  divided  into  two  doses  three  
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hours   apart   to   allow   for   BM   ablation.      Apc1322T   mice   received   a   similar  
transplantation   protocol   except   these  mice   received   a   total   of   10   Gray  whole  
body  gamma-­‐‑irradiation.    A  lower  radiation  dose  was  given  to  these  mice  due  
to   their   severe   phenotype   as   a   12  Gray   dose   resulted   in   their   death  within   a  
week  of  transplantation.  
Within  4  hours  after  the  second  dose  of  irradiation,  female  recipient  mice  were  
injected   with   1   x   106   whole   BM   cells   from   litter   matched   male   donors   (one  
donor  being  sufficient  to  reconstitute  3  recipients).    BM  was  flushed  from  both  
the  femurs  and  tibias  of  donor  mice  using  sterile  PBSA  in  a  5ml  syringe.     The  
cells   were   then   centrifuged   at   400g   for   5   minutes   and   re-­‐‑suspended   in   5ml  
sterile  PBSA.    Re-­‐‑suspended  cells  were  then  needled  (using  19,  23,  and  27  gauge  
needles)  to  disaggregate  the  cells  and  filtered  using  a  40µm  filter.    The  number  
of   nucleated   cells   was   counted   using   a   haemocytometer.      Donor   BM   was  
injected  via  the  tail  vein  (cell  injection  volume  equal  5ml/kg  mouse  weight)  at  2  
x  106  cells  in  100µμl  PBS.    
Post-­‐‑transplantation  mice  were  kept  on  acidified  water  for  6  weeks.    Mice  were  
monitored  daily  and  weighed  weekly.  
  
Experimental  groups  
A   crossover   study  was   carried   out   for   both  Tff1-­‐‑/-­‐‑  and  ApcMin/+  mouse  models.    
Il10-­‐‑/-­‐‑  mice  were  not  studied  in  a  crossover  design,  due  to  the  findings  of  Bamba  
and  colleagues  (2006)  [78].    In  addition,  due  to  a  small  number  of  Apc1322T  mice  
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available  from  Annabelle  Lewis,  a  crossover  study  could  not  be  carried  out  on  
this   mouse   model.   For   the   crossover   study   groups,   WT   mice   on   the   same  
genetic   background   as   mutant   mice   were   used   as   controls.   Table   2.4  
summarises   the   experimental   groups   and   culling   time   points   for   each  mouse  
model.    
  






Experimental groups  
(number of mice) 
 
Time points culled 
 
Tff1-/- 72 
WT mouse BM→WT mice 
(n=18) 
Six mice from each 
experimental group 
were culled at 6, 12, or 
18 months post BMTx 
Tff1-/- mouse BM→WT mice 
(n=18) 
Tff1-/- mouse BM→Tff1-/- mice 
(n=18) 




WT mouse BM→WT mice 
(n=12) 
Six mice from each 
experimental group 
were culled 1 or 2 
months post BMTx 
ApcMin/+ mouse BM →WT mice 
(n=12) 
ApcMin/+ mouse BM→ApcMin/+ mice 
(n=12) 




Apc1322T mouse BM→Apc1322T mice 
(n=4) 
All mice were culled 4 
weeks post BMTx 
 
Il10-/-  12 
Il10-/- mouse BM → Il10-/- mice 
(n=12) 
Six mice were culled 3 
or 5 months post BMTx 
 





Analysis  of  cell  proliferation  prior  to  tissue  harvesting  
BrdU  and  Vincristine  were   injected   into  mice   (except   for  BM  donors)  prior   to  
culling  in  order  to  assess  cell  proliferation.    BrdU  is  a  thymidine  analogue  that  
incorporates   into   DNA   during   DNA   synthesis   [165]   while   Vincristine   arrests  
mitoses  in  metaphase  by  binding  to  microtubules.  
Mice   (with   the   exception   of   BM   donors)   were   administered   Vincristine   and  
bromodeoxyuridine  (BrdU)  prior  to  culling.    BrdU  (50µg/g  BW)  and  vincristine  
(1µg/g   BW)   were   administered   via   intraperitoneal   (IP)   injection   one   and   two  
hours,   respectively,  prior   to   the   culling  of   transplanted  and  control  mice.     All  
mice  were  killed  by  cervical  dislocation.  
  
Tissue  harvesting,  fixation  and  processing  
All   organs   of   the   gastrointestinal   tract   (stomach,   intestines,   liver,   pancreas,  
spleen,   kidneys)   were   fixed   in   10%   neutral   buffered   formalin   (NBF)   for   24  
hours,  transferred  to  70%  ethanol  and  then  embedded  in  paraffin  wax  the  same  
day.    Organs  were  then  sectioned  at  4µm.    Serial  sections  were  used  for  analysis  
and  a  representative  H&E  stained  section  was  used  as  a  guide.  
  
2.3     Special  stains  and  IHC  
2.3.1   All  experiments  
Buffers   and   solutions   are   described   in   Table   2.5.      Formalin-­‐‑fixed,   paraffin  
embedded   sections   were   dewaxed   in   xylene   with   two   5   minute   washes,  
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changing  to  fresh  xylene  for  each  wash.    Sections  were  then  rehydrated  in  100%  
industrial   methylated   spirit   (IMS)   for   5   minutes.      If   IHC   using   an  
avidin/biotin/peroxidase   complex   was   to   be   carried   out,   endogenous  
peroxidases   were   then   blocked   with   a   1.5%   hydrogen   peroxide   in   methanol  
solution  for  15  minutes.    If  IHC  using  a  biotin/streptavidin/alkaline  phosphatase  
was   used,   a   block   for   endogenous   alkaline   phosphatases   (20%   acetic   acid   in  
methanol   at   4°C   for   15   minutes)   was   carried   out.      Sections   were   them   re-­‐‑
immersed  in  100%  IMS  for  5  minutes  then  rehydrated  through  graded  alcohols  
(95%;  70%;  5  minutes  each)  to  PBS.    
Heat-­‐‑induced  epitope   retrieval   (HIER)  or  proteolytic   enzyme   induced  epitope  
retrieval  (PIER)  was  carried  out  if  antigenic  retrieval  was  required.     HIER  was  
performed  by  microwaving  de-­‐‑waxed  sections  in  boiling  0.01M  sodium  citrate  
buffer  at  pH6.0  for  10  minutes  at  full  power  then  quenching  in  cold  running  tap  
water   prior   to   carrying   out   the   standard   IHC   protocol,   unless   otherwise  
specified.      PIER   was   performed   by   immersing   de-­‐‑waxed   sections   in   0.04%  
pepsin  in  0.1M  HCl  for  30  minutes  at  37°C  then  quenching  0.2%  glycine  in  PBS  
prior  to  carrying  out  the  standard  IHC  protocol.    
All   serum/  antibody   incubations  were  carried  out   in  a  humidified  chamber  at  
room  temperature.    A  block  using  normal  serum  from  the  host  of  the  secondary  
antibody   was   applied   onto   sections   for   30   minutes   at   the   start   of   the   IHC  
protocol  to  prevent  non-­‐‑specific  staining.    Primary  antibody  was  replaced  with  
1%   bovine   serum   albumin   (BSA)   in   PBS   for   negative   controls.      Blocking  
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serum  and  all  antibodies  and  were  made  up  in  1%  BSA  in  PBS.    0.1%  Tween®  
20  in  PBS  was  used  to  wash  sections  in  between  antibody  layers.  
Light  microscopy  involved  the  use  of  an  avidin/biotin/peroxidase  complex  or  a  
biotin/streptavidin/alkaline   phosphatase   complex   with   chromogenic  
visualisation.    For  both  complexes  a  biotinylated  secondary  antibody  was  used.    
The   third   and   final   layer   involved   the   use   of   either   an   avidin-­‐‑peroxidase  
conjugated  layer  (VECTASTAIN®  Elite  ABC  kit)  for  an  avidin/biotin/peroxidase  
complex   or   a   streptavidin-­‐‑alkaline   phosphatase   conjugated   layer   for   a  
biotin/streptavidin/alkaline  phosphatase  complex.  
3,3'ʹ-­‐‑Diaminobenzidine (DAB)  was  used  to  develop  an  avidin/biotin/peroxidase  
complex  whilst  Vector  Red  was  used  to  develop  a  biotin/streptavidin/alkaline  
phosphatase  complex.    Both  substrates  were  prepared  following  manufacturer’s  
instructions   and   development   was   monitored   microscopically.      Generally,  
Vector   Red   development   took   10   minutes   while   DAB   development   took   1  
minute.      DAB  was  washed   off   using   dH20.      Vector   Red   was  washed   using  
PBS.      Tissue   sections   were   then   counterstained   using   light   haematoxylin,  
dehydrated   through   graded   alcohols,   cleared   in   xylene   and   mounted   using  
DPX  mounting  medium.    
For   immunofluorescence,   sections   were   placed   into   PBS   during   the   final  
antibody   layer   washes.      Any   excess   was   tipped   off   and   a   small   amount   of  
VECTASHIELD   HardSet   Mounting   Medium   with   DAPI   (Vector   Labs)   was  
applied  and  slides  were  kept  refrigerated  at  4°C.  
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Table 2.5:  Buffers and solutions used in IHC experiments 
Buffer/solution Details/Reference number 
Citrate buffer pH6.0 2.94g tri-sodium citrate (BDH) dissolved in 
1l water and adjusted to pH6.0 with 10x 
HCl 
 
0.04% pepsin in 0.1M HCl 0.08g pepsin (6887; Sigma) dissolved in 
200ml 0.1M HCl at 37°C 
 
VECTASTAIN® Elite ABC kit Prepared according to manufacturer’s 
instructions. 
SK-4100; Vector Labs 
 
Alkaline phosphatase streptavidin Diluted 1:50.  Incubated for 30 minutes. 
SA-5100; Vector Labs 
 
DAB Prepared according to manufacturer’s 
instructions. 
SK-4100; Vector Labs 
 
Vector Red  Prepared according to manufacturer’s 
instructions. 
SK-5100; Vector labs 
 
VECTASHIELD HardSet 
Mounting Medium with DAPI 
H-1200; Vector Labs 
 
  
2.3.2   Combined  Alcian  blue/diastase/PAS  demonstration  of  mucins  
Stomach   sections   from   the  Tff1-­‐‑/-­‐‑   mouse   crossover   study  were   stained   by   the  
Experimental  Histopathology   Laboratory   (CRUK)   using   the   combined  Alcian  
blue/diastase/PAS   method.      This   was   to   demonstrate   changes   in   mucin  
expression   due   to   TFF1   deficiency   and/or   disease   progression.      Combined  
Alcian  blue  and  Periodic  Acid-­‐‑Schiff’s  with  diastase  pre-­‐‑treatment  (ABdPAS)  is  
a  pan-­‐‑mucin  detection  stain.    Alcian  blue  is  a  cationic  dye  that  forms  reversible  
electrostatic  bonds  with  anionic   sites   in  acid  mucins.     Neutral  mucins  and  N-­‐‑
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acetyl   sialomucins   contain  a   reactive  hexose   component   that   is   stained  by   the  
PAS   reaction.      The  PAS   reaction   is   a   two-­‐‑step  process   in  which  periodic   acid  
causes   oxidative   cleavage   of   carbon-­‐‑to-­‐‑carbon   bonds   in   1.2-­‐‑glycols   or   their  
amino   derivatives   forming   dialdehydes.      Then   Schiff’s   reagent   is   applied  
causing   the   aldehydes   to   combine   with   the   fuchsin-­‐‑sulfurous   acid   and  
pararosaniline  present   in   the   reagent   forming   a  magenta   coloured   compound  
[166].     As  the  PAS  reaction  stains  glycogen  as  well,  a  diastase  pre-­‐‑treatment  is  
carried   out   to   digest   glycogen   prior   to   Alcian   blue   staining.   Therefore   only  
neutral  mucins  will   be   stained   by   the   PAS   reaction.      This   combined  method  
results  in  acid  mucins  stained  blue  and  neutral  mucins  stained  magenta  (Figure  
2.3).  
The  ABdPAS   protocol   is   as   follows;   tissue   section   slides  were   dewaxed   then  
rinsed  in  tap  water.    Sections  were  incubated  in  0.5%  α-­‐‑amylase  for  30  minutes  
at  37°C.     Sections  were  stained   in  Alcian  Blue   for  5  minutes  and  then  washed  
under  running  deionised  water  for  5  minutes.    Sections  were  then  treated  with  
1%   periodic   acid   for   5   minutes   and   washed   as   before.      Sections   were   then  
immersed  in  Schiff’s  reagent  for  15  minutes.    Afterwards  sections  were  washed  
as  before.    Sections  were  then  counterstained  in  haematoxylin  for  5  minutes  and  
differentiated   in   1%   acid   alcohol   for   10   seconds.      Sections  were   then  washed  
under  running  tap  water  for  5  minutes.    Afterwards  sections  were  dehydrated  
and  cleared  (in  xylene)  and  then  mounted  using  DPX.  
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Figure 2.3:  ABdPAS staining of mouse stomach and duodenum 
 
Alcian blue/diastase/PAS (ABdPAS) staining of the stomach and duodenum of a WT 
mouse transplanted with WT mouse BM 6 months post BMTx.  The mucosal surface of 
the fundus (a; x10) and pylorus (b; x20) stains positive for PAS while the basal region 
of the pylorus is positive for Alcian blue (rectangle; b). In the duodenum (c; x10), 
Brunner’s glands are PAS positive while goblet cells are identified by their Alcian blue 
positivity and morphology (arrows).   
  
2.3.3   IHC  for  BrdU,  GKN2,  H+/K+  ATPase,  pepsinogen,  and  TFF1  
BrdU   IHC  was   carried   out   on   the   four  mouse  models   to   identify   where   cell  
proliferation   was   occurring.      IHC   for   GKN2,   H+/K+   ATPase,   pepsinogen   and  
TFF1  gastric  markers  was   carried  out  on   stomach   sections  of   the  Tff1-­‐‑/-­‐‑  mouse  
crossover  study  mice,  to  investigate  which  gastric  cell  lineages  were  affected  by  
the  BMTx  and/or   tumourigenesis   and   their   expression  patterns.     Parietal   cells  
were   identified   with   an   antibody   against   H+/K+   ATPase,   chief   cells   were  
identified  with  an  anti-­‐‑pepsinogen  antibody  and  foveolar  cells  were  identified  
with   anti-­‐‑GKN2   and   anti-­‐‑TFF1   antibodies.      We   attempted   TFF3   IHC   (as   an  
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alternative  to  Tff3  isotopic  ISH)  but  at  the  time  of  this  study  were  unable  to  find  
a  suitable  commercially  available  anti-­‐‑TFF3  antibody  for  mouse  tissues.  
Monoclonal  antibodies  to  BrdU  and  H+/K+  ATPase  and  polyclonal  antibodies  to  
pepsinogen,   GKN2   and   TFF1   were   obtained.   Details   of   antibodies   and  
substrates   used   are   shown   in   Table   2.6.      Indirect   immunohistochemistry  was  
carried   out   using   an   avidin/biotin/peroxidase   for   all   antibodies   except   for  
GKN2,   which   was   detected   using   a   streptavidin/biotin/alkaline   phosphatase  
complex.      This   was   performed   to   allow   for   comparison   of   TFF1   and   GKN2,  



























Table 2.6:  Details of BrdU, GKN2, H+/K+ ATPase, pepsinogen and TFF1 
antibodies 
 







BrdU MM Fab fragments 
with POD 
conjugated  
specific to BrdU 
Ref: 11 585 860 
011 
1:5 60 C Roche  
GKN2 RP IgG raised 
against 
synthesised GKN2 
with an additional 
cysteine at the N-
terminus 
Ref: [167] 






MM clone 2G11 
raised against the 
34 kDa core 
peptide of t the β-
subunit of H+/K+ 
ATPase. 
 Ref: A-274 
1:6000 35  C Sigma-
Aldrich 




1:4000 35 P Binding 
Site 
TFF1 RP IgG raised 
against aa 5-87 
mapping at the C-
terminus of mouse 
TFF1 
Ref: SC-28926 
1:250 60 ---- Santa Cruz 
 
Key: MM mouse monoclonal; RP rabbit polyclonal; SP sheep polyclonal; P 
PIER with 0.04% pepsin for 30 minutes; C HIER with sodium citrate  
 
2.4   Combined   IHC/Y-­‐‑chromosome   ISH   detection   of   male   donor-­‐‑derived  
cells 
2.4.1   Overview  
Rationale  
Combined   IHC/Y-­‐‑chromosome   ISH   (the   combined   detection   protocol)   allows  
for  the  detection  and  immunohistochemical  phenotyping  of  donor-­‐‑derived  cells  
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in   formalin-­‐‑fixed   paraffin   embedded   tissue   sections.      This   method   takes  
advantage   of   IHC   using   a   biotin/streptavidin/alkaline   phosphatase   complex  
followed  by  indirect  Y-­‐‑chromosome  ISH  to  detect  whether  any  myofibroblasts,  
lymphocytes,   macrophages   or   epithelial   cells   are   donor-­‐‑derived.      Indirect   Y-­‐‑
chromosome  ISH  utilises  anti-­‐‑fluorescein  antibodies  to  bind  onto  the  hybridised  
fluorescein   isothiocyanate   (FITC)   labelled  Y-­‐‑chromosome   in   cells   (Figure   2.4).    
The  indirect  method  was  chosen  over  the  direct  method  due  to  the  stability  of  
DAB  that  was  required  for  lengthy  quantifications.    
A  criticism  of   the   indirect  Y-­‐‑chromosome  ISH  with  anti-­‐‑fluorescein   is   that   the  
DAB  end-­‐‑product  can  sometimes  stain  nucleoli   resulting   in  small   light  brown  
dots   inside   the   nucleus   upon   DAB   development.   However,   when   this   cell   is  
compared   with   one   containing   a   Y-­‐‑chromosome   signal   there   are   very   clear  
differences.    The  Y-­‐‑chromosome  signal  is  larger,  at  the  edge  of  the  nucleus  and  
very  dark  brown  (Figure  2.5).    
  
The  methods  used   in   IHC  phenotyping  will   be  discussed   in   this   section.        Y-­‐‑
chromosome   ISH   controls   were   male   spleen   hybridised   with   either   the   Y-­‐‑









Post ISH, FITC-labelled chromosome probe is bound onto any Y-chromosome 
present in cells.  An anti-fluorescein antibody is applied and binds onto the 
fluorescein present in the FITC.  As this antibody is peroxidase (POD) 
conjugated, bound antibody can be visualised by the DAB substrate.  The POD 
binds the DAB oxidising it, resulting in a brown coloured insoluble reaction 
product in the nuclei of cells containing a Y-chromosome. 
 
 
Figure 2.5:  Comparison of Y-chromosome signal and DAB-stained nucleoli  
 
Y-chromosome signal appears as a dark brown rice-shaped signal (black 
arrows.  In comparison, DAB-stained nucleoli (red arrows) appear as smaller 
dots which are lighter in colour.  Image magnification: x40. 
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Statement   on   external   validation   of   interpretation   and   scoring   of   donor-­‐‑
derived  myofibroblasts  
External  validation  of  the  author’s  scoring  and  interpretation  of  donor-­‐‑derived  
myofibroblasts   was   carried   out   by   Malcolm   Alison.      The   number   of   donor-­‐‑
derived   myofibroblasts   (e.g.   Y-­‐‑chromosome   positive   cells   which   are   ∝-­‐‑SMA  
positive   [Y+/∝-­‐‑SMA+])   and   the   total   number   of  ∝-­‐‑SMA+   cells   (e.g.   Y+/∝-­‐‑SMA+  
cells  and  Y-­‐‑chromosome  negative  cells  which  are  ∝-­‐‑SMA  positive  [Y-­‐‑/∝-­‐‑SMA+])  
were  counted  in  five  different  x20  images  by  Malcolm  Alison  and  the  author.    A  
Wilcoxon   signed-­‐‑rank   test   was   performed   determine   whether   the   counted  
number  of  donor-­‐‑derived  myofibroblasts  and  the  total  number  of  ∝-­‐‑SMA+  cells  
was  significantly  different  between  Malcolm  Alison  and  the  author    (Table  2.7).    
This   non-­‐‑parametric   test   was   chosen   as   it   is   used   to   compare   two   related  
samples.      
There   was   no   significant   difference   in   the   number   of   donor-­‐‑derived  
myofibroblasts  counted  (P=0.22).    However,  there  was  a  significant  difference  in  
the  counted  total  number  of  ∝-­‐‑SMA+  cells  (P=0.04).     This  finding  suggests  that  
the  author  undercounted  the  total  number  of  ∝-­‐‑SMA+  cells,  or  conversely,  that  
Malcolm  Alison  overcounted   these  cells.     Analysis  of   the  percentage  of  BMD-­‐‑
myofibroblasts,   derived   from  dividing   the   number   of   Y+/∝-­‐‑SMA+   cells   by   the  
total  number  of  ∝-­‐‑SMA+  cells,  which  was  used  to  quantify  BMD-­‐‑myofibroblast  
engraftment   in   this   study   (see   Section   2.4.5),   revealed   that   the   difference   in  
counted  cells  amounted  to  a  percentage  difference  of  less  than  2%.   
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Table 2.7: Statistical analysis of scoring and interpretation of donor-derived 
myofibroblasts 
 










difference  MA ALB MA ALB MA ALB 
Image 1 118 103 4 3 3 3 0 
Image 2 107 97 9 9 8 9 1 
Image 3 193 131 21 13 11 10 1 
Image 4 144 115 9 7 6 6 0 
Image 5 100 95 9 10 9 11 2 
 
P value 0.04 0.22  
MA Malcolm Alison; ALB Arielle Le Brenne 
  
  
Statement  on  method  development  
This   study   utilised   a  ∝-­‐‑SMA   IHC/Y-­‐‑chromosome   ISH  method   for   identifying  
donor-­‐‑derived   myofibroblasts   that   had   been   previously   described   [78,   92].    
Similarly,   a   previously   described   method   of   identifying   BMD-­‐‑epithelial   cells  
using  CD45  and  Dolichos  biflorus  agglutinin  (DBA)  IHC/  Y-­‐‑chromosome  ISH  was  
attempted   [155].     However   the  method  was   unable   to   be   successfully   carried  
out,  most   likely   as   it  was   optimised   for   tissues   fixed   in  methanol   rather   than  
NBF.    Therefore  in  order  to  investigate  the  occurrence  of  BMD-­‐‑epithelial  cells,  a  
dual-­‐‑staining  IHC  method  was  developed  with  the  following  aims:  
• To   identify   gastrointestinal   epithelial   cells   using   an   epithelial   cell  
marker.  
• Use   anti-­‐‑lymphocytic   markers   to   exclude   possible   intraepithelial  
lymphocytes  (IELs).  
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• To   take   into   account   the   possibility   of  macrophages   fusing  with  BMD-­‐‑
epithelial   cells   as   reported   to   occur   in   the   liver   [168],   IBA1,   an   anti-­‐‑
macrophage  antibody  was  included  (the  marker  also  identified  dendritic  
cells)  was  included  in  the  cocktail  of  anti-­‐‑lymphocytic  antibodies.    
I   attempted   to   optimise   a   dual   immunohistochemical   staining   method   for  
cytokeratin   8   (expressed   throughout   the   GI   tract   and   in   GI   cancers)   and   a  
mixture   of   lymphocytic,   macrophage,   dendritic   cell   (immune   cell)   markers.    
However,   the  Y-­‐‑chromosome  signal  could  not  be  visualised   (either  directly  or  
indirectly)   in   dual   stained   sections   (Figure   2.6).      On   the   other   hand,   Y-­‐‑
chromosome   signal  was   easily   detected   in   tissues   that   had   only   been   stained  
with  cytokeratin  8  or  immune  cell  markers.    This  discrepancy  could  have  been  
the  result  of  the  extra  microwaving  steps  required  for  dual  IHC  causing  DNA  
damage.      With  this  in  mind,  immune  cell  marker  IHC  /Y-­‐‑chromosome  ISH  was  
utilised  to  identify  putative  BMD-­‐‑epithelial  cells.    The  rationale  behind  this  was  
that  of  a  process-­‐‑of-­‐‑elimination.    That  is,  if  Y-­‐‑chromosome  positive  cells  present  
in  the  epithelium  were  negative  for  lymphocytic,  macrophage  and  dendritic  cell  







Figure 2.6:  Attempted optimisation of epithelial cell IHC/Y-chromosome ISH 
 
 
(a) Cytokeratin 8 IHC/Y-chromosome ISH on a gastric adenoma of a Tff1-/- 
mouse transplanted with Tff1-/- mouse BM at 12 months post BMTX.  Epithelial 
cells were identified by cytokeratin 8 staining (pink).  Y-chromosome signal 
(dark brown nuclear dots) identified donor-derived stromal cells (green arrows) 
and a putative donor-derived epithelial cell (black arrow). A red arrow points to 
DAB-stained nucleoli. (b) Double IHC for cytokeratin 8 and lymphocytic markers 
was carried out on Si tissue of a 12 month-old male stock Tff1-/- mouse.  
Epithelial cells were identified by cytokeratin 8 staining (brown staining) and 
lymphocytic cells are identified with lymphocytic markers (pink staining).  Blue 
arrows point to IELs.  Magnifications: a; x40, b; x20.  
  
2.4.2   α-­‐‑SMA  IHC  detection  of  myofibroblasts  
A  monoclonal  antibody  to  α-­‐‑SMA  was  used  to  detect  myofibroblasts.  Details  of  
antibodies  and  reagents  used can  be  found  in  Table  2.8.    Positive  controls  for  α-­‐‑
SMA  IHC  were  mouse  intestinal  sections.  
 









α-SMA MM IgG2a specific 
to α-smooth muscle 
actin. Ref: A2547 






Ref: E0354 1:250 35 Dako 
Normal rabbit 
serum 
Ref: 10510 1:10 30  Invitrogen 
MM  mouse monoclonal 
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2.4.3   Immune  cell  marker  IHC  detection  of  putative  BMD-­‐‑epithelial  cells  
Monoclonal   antibodies   to   CD45R/B220   were   used   to   identify   B   cells   and  
polyclonal  antibodies  to  CD3  and  IBA1  were  used  to  identify  donor  derived  T  
cells,   B   cells   and  macrophages   and   dendritic   cells.      Details   of   antibodies   and  
reagents  used can  be  found  in  Table  2.9.  
Positive   controls   for   the   immune   cell   IHC  were  mouse   spleen   and   intestinal  
Peyer’s  patches.    For  negative  controls,  the  antibody  (with  the  exception  of  goat  
anti-­‐‑rabbit)   was   omitted   from   the   primary   and   secondary   antibody   layers.    
Sections  required  HIER  using  boiling  0.01M  sodium  citrate  buffer  at  pH6.0  for  
15  minutes  on  medium  power   followed  quenching   in   cold   running   tap  water  
prior  to  carrying  out  the  protocol.    Following  goat  serum  incubation,  both  CD3  
and   IBA1   antibodies   were   applied   onto   sections   and   incubated.   Following  
standard   washes,   CD45R/B220   and   goat   anti-­‐‑rabbit   biotinylated   antibodies  
were  applied  onto  sections.  The  protocol  then  proceeded  as  described  in  Section  
2.3.1.    The  resultant  staining  patterns  of  immune  cell  IHC  on  GI  tissue  samples  






















CD3 RP IgG raised against a 
synthetic peptide 
corresponding to the 
intracellular part of the ε-
chain of human CD3. 
Ref: A0452 
1:150 60 DAKO 
CD45R/ 
B220 
RM IgG2a, κ. RA3-6b2 
antibody. 
Specific to an epitope of 
mouse CD45 conjugated 
with biotin 
Ref: 553086 
1:200 45 BD 
Pharmin
-gen 
IBA1 RP IgG raised against a 
synthetic peptide 
corresponding to C-
terminus of IBA1. 
Ref: 019-19741 





Ref: B7389 1:250 45 Sigma 
Normal goat 
serum 
G9023 1:10 30  Sigma 
















Figure 2.7:  Immune cell marker IHC 
 
CD45R/B220 /CD3 / IBA1 IHC is shown by red staining.  Magnification: x10. 
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2.4.4   Y-­‐‑chromosome  ISH  identification  of  donor-­‐‑derived  cells  
Immediately   following   IHC   phenotyping,   sections   were   placed   into   0.1M  
sodium  thiocyanate  for  10  minutes  at  80°C.    However,  this  step  was  omitted  for  
sections  that  had  undergone  immune  cell  IHC  to  avoid  loss  of  tissue  integrity.    
Afterwards,   sections   were   washed   in   PBS   for   5   minutes   with   3   changes.    
Sections   were   then   incubated   in   freshly   made   0.4%   pepsin   at   37°C   for   an  
optimised  digestion  time  determined  beforehand.    
Pepsin   digestion   was   quenched   using   0.1%   glycine   for   5   minutes   and   then  
washed  in  PBS.     Sections  were  then  post-­‐‑fixed  in  4%  paraformaldehyde  (PFA)  
for   2   minutes   followed   by   PBS   washes.      Following   this,   sections   were   then  
dehydrated   to   absolute   alcohol   and   allowed   to   air   dry.      FITC  Y-­‐‑chromosome  
probe  paint  was  applied  to  sections  and  the  slides  were  then  coverslipped  and  
sealed  with  vulcanizing  rubber  solution.  Negative  controls  were  incubated  with  
hybridisation   buffer   alone.      Sections   were   then   denatured   at   60°C   for   10  
minutes  and  then  transferred  to  a  humidified  chamber  and  allowed  to  incubate  
overnight  at  37°C.    
The  following  morning,  the  coverslips  were  carefully  removed  and  slides  were  
washed   in   0.5x   SSC   solution   for   5   minutes   at   37°C   and   then   rinsed   in   PBS.  
Fluorescein   labelled  chromosomes  were  detected  using  sheep  anti-­‐‑fluorescein-­‐‑
peroxidase  applied  onto  sections  and  incubating  them  in  a  humidified  chamber  
for  35  minutes  followed  by  PBS  washes.    The  Y-­‐‑chromosome  was  visualised  by  
DAB  staining.    Sections  were  washed  in  distilled  water  for  5  minutes  and  then  
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counterstained   with   light   haematoxylin.      Afterwards,   sections   were   rinsed,  
dehydrated,  cleared  (in  xylene)  and  then  mounted  in  DPX.    
Details  of  reagents  and  buffers  can  be  found  in  Table  210.     
 
 
Table 2.10:  Reagents and buffers used in Y-chromosome ISH 
 
Buffer/solution Details 
Sodium thiocyanate 16g sodium thiocyanate (251410; Sigma) 
dissolved in 200ml water at 80°C  
0.4% pepsin  0.8g pepsin (P-6887; Sigma) dissolved in 0.1M 
HCl for 30 minutes at 37°C 
4% paraformaldehyde 
(PFA) 
8g PFA dissolved in 200 ml boiling PBS until clear 
and immediately cooled on ice. 
0.1% glycine 10 PBS tablets (P-4417; Sigma), 2g glycine 
dissolved in 1l water.  
  
  
2.4.5   Quantification  and  statistical  analysis  
Quantification  of  donor-­‐‑derived  myofibroblasts    
There   have   been   various   methods   of   quantifying   donor-­‐‑derived   cell  
engraftment   described   in   previous   BMTx   studies.      Donor-­‐‑derived   cells   have  
been  counted  in  one  high  power  (e.g.  x40)  objective  field  [92]  [169],  three  high  
power  objective  fields  [78]  or  15-­‐‑25  high  power  objective  fields  [170],  or  within  a  
defined  measured  area  [171].     Some  studies  would  then  divide  the  percentage  
of   donor-­‐‑derived   cells   by   a   correction   factor   taken   from   the   percentage   of   Y-­‐‑
chromosome  positive  cells  in  a  male  spleen  control  to  account  for  loss  of  part  of  
the  nucleus  resulting  from  tissue  sectioning  [78]  [92,  172].    In  this  study,  donor-­‐‑
derived  cells  were  quantified   in  a  150,000µm2  area  of  either   lamina  propria  or  
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epithelium.    This  area  was  used  as  it  was  the  first  area  to  fall  within  5%  of  the  
standard   error   of   the  mean   (SEM)   following   a   quantitation   of   the   number   of  
donor-­‐‑derived  myofibroblasts  in  the  lamina  propria  in  different  areas  of  lamina  
propria   (Figure   2.8).      This   area  was   used   to   quantify   putative   donor-­‐‑derived  
epithelial  cells  as  a  similar  counting  optimisation  could  not  be  carried  out  in  the  
epithelium  as  the  number  of  donor-­‐‑derived  cells  was  so  low.  
 




























Donor-derived myofibroblasts were counted in three measurements of lamina 
propria within the gastric adenomas of Tff1-/- mice transplanted with Tff1-/- 
mouse BM at 12 months post BMTx (n=6).  In each measurement, donor-
derived myofibroblasts were counted in areas of lamina propria ranging from 
10,000 to 150,000µm2.  The standard error of mean (SEM) was calculated for 
each area and it was found that counting within a 150,000µm2 area was closest 
to 5% of SEM.  
  
To   quantify   donor-­‐‑derived  myofibroblasts   or   epithelial   cells,   stained   sections  
were   photographed   and   analysed   using   a   Nikon   microscope   system.      This  
comprised   of   a   digital   camera   used   to   capture   images   from   a   connected  
microscope.    The  captured  images  were  then  viewed  and  calibrated  in  µm  using  
the  Nikon  NIS  Elements   software.      From   the   calibrated   images,   a   150,000µm2  
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area  was  measured   using   the   region   of   interest   (ROI)   option   of   the   software.    
Cells  were  counted  using  the  taxonomy  option.  
A   donor-­‐‑derived   myofibroblast   was   identified   by   dark   pink   α–SMA  
cytoplasmic   staining  encircling  a  nucleus  with  a  dark  brown  dot   representing  
the  Y-­‐‑chromosome  (Y+).    The  degree  of  engraftment  was  quantified  by  counting  
the  number  of  α–SMA+  cells  with  and  without  a  Y-­‐‑chromosome  signal  within  
150,000µm2  of   lamina  propria  beneath  the  epithelium.     Then  the  number  of  Y+/  
α–SMA+  cells  was  divided  by  the  total  number  of  α–SMA+  cells  and  multiplied  
by  100  to  derive  the  percentage  of  donor-­‐‑derived  myofibroblasts.  
  
Quantification  of  putative  donor-­‐‑derived  epithelial  cells  
A   putative   donor-­‐‑derived   epithelial   cell   was   identified   as   being   negative   for  
immune  cell  markers  and  containing  a  Y+  nucleus.     The  degree  of  engraftment  
was  quantified  by  counting  the  number  of  epithelial  cells  with  and  without  a  Y  
chromosome   signal   in   a   150,000µm2   area   of   epithelium.      The   number   of  
Y+/immune   cell   marker   negative   cells   was   then   divided   by   the   total   number  
epithelial   cells   counted   and   multiplied   by   100   to   derive   the   percentage   of  
putative  donor-­‐‑derived  epithelial  cells.  
  
Statistical  analysis  
The   statistical   significance   of   differences   between   measurements   was  
determined   by   a   Student’s   t-­‐‑test   and   differences   between   groups   was  
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determined  by  ANOVA,  both  using  GraphPad  Prisim  software   (Version  5.0c).  
Differences  resulting  in  P  values  of   less  than  0.05  were  considered  statistically  
significant.    
  
2.5   Assessment  of  Lgr5,  Tff2,  Tff3  and  Opn  mRNA  distribution  in  normal  
and  diseased  mouse  tissue  using  isotopic  ISH    
Isotopic   ISH   allows   for   the   specific   localisation   of   mRNA   in   formalin-­‐‑fixed  
paraffin   embedded   (FFPE)   tissues   using   antisense   RNA   probes   labelled  with  
35S-­‐‑UTP.  The  methods  used  were  based  on  those  previously  described  by  Senior  
et  al,  (1988),  with  modifications  [173].       As  a  control  to  assess  mRNA  presence,  
an  RNA  probe  to  rat  β-­‐‑actin  (Actb)  control  was  used  in  each  assay.    
  
Growth  of  plasmid  containing  E.  coli  cultures  
Labelled   RNA  probes  were   produced   through   in   vitro   transcription   of   cDNA  
template   linearised   from   plasmid   vectors.   Opn   IMAGE   clones   arrive   pre-­‐‑
transfected  into  E.  coli  hosts.    Plasmids  were  prepared  by  growing  transfected  E.  
coli  cultures  in  the  presence  of  an  antibiotic  to  allow  for  the  selection  of  plasmid  
vectors  harbouring  a  gene  conferring  resistance  to  that  antibiotic.    
Agar  was  melted   in  a  microwave  at   full  power   for  5-­‐‑8  minutes   in  one-­‐‑minute  
bursts.   2ml   stock  ampicillin   (Table  2.11)  was  added   to  400ml   cooled  agar  and  
gently  mixed.         The   ampicillin-­‐‑containing   agar  was  poured   into   the  base  of   8  
clean  petri  dishes  and  covered  with  their  lids  before  being  allowed  to  set  for  1  
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hour  at  room  temperature.     Agar  plates  were   then  transferred  to  an   incubator  
set   a   37°C   and   incubated   for   1   hour   to   remove   condensation   by   partially  
covering  the  plate  with  its  lid.  
Using   an   aseptic   technique,   50µl  E.   coli   culture  was  pipetted   onto   agar   plates  
and   spread   by   placing   5-­‐‑10   autoclaved   glass   beads   and   gently   shaking   the  
covered   plates.      The   beads   were   then   carefully   transferred   to   a   new   clean  
labelled   plate   and   the   previous   plate   was   covered   with   its   lid   to   prevent  
contamination.      This   process   was   repeated   for   the   remaining   labelled   plates.    
Plates  were  then  inverted  (e.g.  agar  side  up)  and  incubated  overnight  a  37°C.  
The  following  day,  L-­‐‑Broth  was  prepared  to  grow  bacterial  colonies  by  adding  
4ml  stock  ampicillin  to  400ml  L-­‐‑Broth  warmed  to  37°C.      10ml  was  added  to  a  
glass  screw  top  tube.    Using  an  aseptic  technique,  a  single  colony  was  picked  off  
using  a   flame-­‐‑sterilised  wire  hoop  and   transferred   to   the   tube.     The   tube  was  
then   transferred  onto   a  heated   rotor  plate   and   incubated   for   5   hours   at   37°C.  
Unused  L-­‐‑broth  was   transferred   to  a  37°C  incubator   to  maintain   temperature.    
Afterwards,   the  contents  of   the   tube  was   tipped   into  a   flask   filled  with  250ml  
ampicillin   containing   L-­‐‑Broth   at   37°C.      The   flask   was   stopped   with   a   foam  
stopper  and  covered  with  aluminium  before  being  transferred  to  a  heated  rotor  
plate  to  be  incubated  overnight  at  37°C.      The  following  day,  the  entire  contents  
of  the  flask  were  tipped  into  a  centrifugation  container  and  centrifuged  at  6000g  
at  4°C  for  15  minutes.     The  supernatant  was  tipped  out  and  the  pellet  was  re-­‐‑
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suspended   in   10ml   P1   buffer   from   the  QIAGEN  plasmid  maxi   kit.   From   this  
step  plasmid  purification  was  performed.  
  
Table 2.11:  Reagents used for the growth of E. coli culture 
 
Reagent Details  
Agar Prepared in-house; CRUK 
Ampicillin stock 
solution 
0.2g Ampicillin (Sigma) in 20ml 50% ethanol 
Luria Broth (L-Broth) Prepared in-house; CRUK 
  
Plasmid  purification  and  determination  of  plasmid  DNA  concentration  
Plasmids  were  purified  from  E.  coli  bacteria  using  a  QIAGEN  plasmid  maxi  kit  
following   manufacturer-­‐‑supplied   instructions.      Plasmid   DNA   concentration  
was   determined   using   UV   spectroscopy   using   a   NanoDrop   2000  
spectrophometer   connected   to   a   computer   running   the   NanoDrop   2000  
software  programme.    1  µl  of  purified  plasmid  DNA  sample  was  pipetted  onto  
the   pedestal   of   the   NanoDrop   spectrophotometer   and   the   machine   arm   was  
closed  forming  sample  column  in  which  the  sample  was  exposed  to  ultraviolet  
(UV)   light   at   260nm   and   280nm   to   measure   the   concentration   of   DNA   and  
possible   protein   contamination   (detected   at   280nm).      The   A260   and   A280  
measurements,   DNA   concentration   (in   ng/µl)   and   an   A260/A280   ratio   were  
calculated   by   the   NanoDrop   2000   software   programme   and   printed   off   and  
recorded.      Samples   with   a  A260/A280   ratio   less   than   1.8   were   not   used   due   to  
protein  contamination.  
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Template  preparation  from  purified  plasmids  
50µg  of  plasmid  DNA  was  linearised  using  restriction  enzyme  digestion  (Table  
2.12)  for  2  hours  in  a  water  bath  set  at  37°C.    A  5µμl  sample  was  taken  prior  to  
the   addition   of   the   restriction   enzyme.      Following   digestion,   the   sample  was  
mixed   and   a   5µl   sample   was   taken.   340µl   bottom   phase   phenol   chloroform  
(Invitrogen)   was   added   and   the   sample   was   mixed   for   30   seconds   and   then  
centrifuged   for   5  minutes   at   16,000   relative   centrifugal   force   (RCF).      The   top  
phase   was   then   transferred   to   a   new   tube.      330µl   bottom   phase   phenol  
chloroform   was   added   to   the   top   phase   and   then   mixed   and   centrifuged   as  
before.     The  top  phase  was  transferred  to  a  new  tube  and  320µl  bottom  phase  
chloroform  isoamyl  alcohol  (Fluka)  was  added  and  then  mixed  and  centrifuged.  
The   top   phase   was   transferred   to   a   new   tube   where   150µl   7.5M   ammonium  
acetate  and  1.125ml  absolute  ethanol  was  added.     The  sample  was  mixed  and  
allowed   to   precipitate   for   30   minutes.      The   sample   was   then   centrifuged   as  
before.      The   supernatant  was  discarded   into   a   spare   tube   and  kept   in   case   of  
error.     The  pellet  was  washed  with  70%  alcohol  and  then  the  supernatant  was  
removed  taking  care  not  to  disturb  the  pellet.  The  pellet  was  dried  at  37°C  until  
all   residual   ethanol   evaporated.   The   dried   pellet   was   dissolved   in   25µl  
10mMTris/0.1mM  EDTA  and  a  1µl  sample  was  taken.    The  template  (dissolved  
pellet)   was   then   stored   at   -­‐‑20°C.      To   check   the   quality   and   quantity   of   the  
template,   the   pre-­‐‑digest,   post-­‐‑digest,   cleaned   template,   and   a   10kb  molecular  
weight  ladder  were  loaded  onto  a  1%  agarose  gel  and  run  at  100V  for  2  hours  
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Table 2.12:  Regents used for plasmid linearization 
 
Reagent Details  
Rat Actb EcoRI restriction enzyme and 10x buffer 
Mouse Lgr5 HindII restriction enzyme and 10x buffer 
Mouse Opn EcoRI restriction enzyme and 10x buffer 
MouseTff1 and 10x buffer 
Rat Tff2 HindII restriction enzyme and 10x buffer 




1x restriction enzyme buffer  
4-fold restriction enzyme to plasmid DNA concentration 
water to make up to 350µl 
  
Preparation  of  35S  labelled  RNA  probes  
35S  labelled  RNA  probes  to  rat  Tff2,  rat  Actb,  mouse  Opn,  and  mouse  Lgr5  were  
prepared  using  in  vitro  transcription  using  linearised  DNA  templates.  For  each  
probe  required,  DNA  template  was  added  to  a  prepared  mastermix  containing  
an   appropriate   RNA   polymerase   (Table   2.13).      The   reaction  was  mixed  well,  
centrifuged   for   10   seconds   to   ensure   thorough  mixing   and   then   incubated   at  
37°C   for   60   minutes.      The   template   was   then   destroyed   using   1µl   of   1U/µμl  
RNAse-­‐‑free  DNAse  I  (Boehringer  or  Promega  Quality  Grade)  to  each  reaction.  
Again   the   tubes  were  mixed  and  centrifuged   for   10   seconds.     The   tubes  were  
then  incubated  at  37°C  for  15  minutes.     Following  the   incubation,   the  reaction  
was  diluted  with  a  mixture  of  25µl  DTT  and  1.5µl   ribosomal  RNA  (10mg/ml).  
1µl   of   diluted   reaction   was   then   mixed   with   50µl   water   and   4ml   scintillant  
(Ultima  Gold;  Perkin  Elmer)  in  scintillation  vials.  
The   remaining   diluted   reaction   was   purified   using   a   CHROMA   SPIN-­‐‑30  
column  (Biorad)  to  remove  DNA/RNA  fragments  smaller  than  40bp.    First,  the  
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column  was  prepared  by   centrifuging  at   1000g  or   equivalent   for   2  minutes  at  
15°C and  discarding  the  eluate.    A  new  collection  tube  was  prepared  containing  
4µμl  RNAsin  and  6µμl  DTT   (10  mM)  and   the   column  was  placed   into   the   tube.    
The   diluted   reaction   was   added   to   the   column   and   then   centrifuged   for   4  
minutes.    The  resultant  eluate  containing  the  purified  probe  was  stored  at  -­‐‑20°C 
for  no  more  than  48  hours  or  used  immediately.    
1µl  of  probe  was  added  to  50µl  water  and  4ml  scintillant   in  scintillation  vials.  
This  aliquot  and  the  unpurified  aliquot  were  then  assessed  for  the  total  35S-­‐‑UTP  
incorporation   into   the   probe   using   a   Beckman   LS6500   scintillation   counter.  
Successful  incorporation  of  35S-­‐‑UTP  results  in  counts  for  the  purified  sample  of  
between  40-­‐‑80%  of  the  counts  recorded  for  the  unpurified  control  and  sufficient  
to  give  1x106  cpm  per  slide  in  the  subsequent  hybridisation.  
To  assess  probe  quality,  a  sample  of  purified  probe  containing  1x106  cpm  was  
loaded  onto  a  prepared  6%  TBE-­‐‑urea  gel  (Invitrogen)  and  run  for  35  minutes  at  
250V.    To  calculate  the  amount  needed  to  load  1x106cpm  onto  the  gel,  the  total  
cpm   of   the   purified   riboprobe  was   divided   by   1x106.      This   amount  was   then  
made  up  to  10µl  using  5x  loading  buffer.    The  sample  was  loaded  onto  the  gel  
alongside   a   nucleic   acid   standard   ladder   (Novagen   Perfect   RNA   Marker  
Template  Mix,  0.1-­‐‑1Kb).    
Once   the  gel  had  run,   it  was   then  fixed   in  10%  acetic  acid   for  10  minutes  and  
then   rinsed   for   a   further   10   minutes   in   tap   water.   The   gel   was   then   gently  
placed   onto   blotting  paper   and   covered  with   cellulose   film   leaving   the   edges  
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exposed.   The   gel   and   paper   were   dried   at   80°C   in   a   vacuum   slab   gel   dryer  
(Hoefer  GD2000,  Amersham  Biosciences)  for  90  minutes.    The  cellulose  film  was  
removed   and   under   an   X-­‐‑ray   safe   light   in   a   darkroom,   the   dried   gel   and  
adherent   paper   were   taped   to   the   bottom   of   an   X-­‐‑ray   film   cassette  
(Hypercassette  TM,  Amersham  Life  Sciences)  and  an  X-­‐‑ray  film  (Hyperfilm  MP,  
Amersham  Life  Sciences  28906844)  was  placed  on  top.    The  cassette  was  closed  
and  locked  and  left  to  expose  for  15  minutes.    Afterwards,  under  an  X-­‐‑ray  safe  
light   in   a   darkroom   as   before,   the   cassette   was   opened   and   the   film   was  
removed   and   processed   using   an   automatic   X-­‐‑ray   film   processor   (Lungwon  
Precision   Industrial   Co.   Korea   JP-­‐‑33).      A   good   quality   probe   is   defined   as   a  
strong  single  band  of  the  expected  molecular  weight  (Figure  2.9).    On  the  other  
hand,  probes  of  poor  quality  are  often  a  mixture  of  different  molecular  weight  
transcripts   (due   to  either  degradation  or  poor  quality   template  DNA)  or  have  
high  molecular  weight  bands  due  to  incomplete  plasmid  linearization.    
 
 
Figure 2.9:  Purified 35S labelled RNA probes on a 6% TBE-urea gel  
 
1 million counts of 35S labelled RNA probes to rat Actb (1), mouse Opn (2), and 
rat Tff2 (3) are run alongside a nucleic acid standard ladder (4) to give the 





For   each   assay,   one   section  was   cut   for   the   rat  Actb   control.      There  were   two  
sections  cut  for  each  probe  to  be  analysed,  one  for  a  first  (initial)  exposure  the  
other   for   a   second   exposure.      Sectioning   was   carried   out   under   RNAse-­‐‑free  
conditions.      5µm   thick   serial   sections   were   cut   onto   water   treated   with   the  
Table 2.13:  Reagents used for 35S labelled RNA probe production 
 




Rat partial Actb cDNA PCR product inserted 
into the EcoRV site of pBSIIKS 
Ref: [173] 






562bp from 5’ UTR to exon 5 (UCSC chr10: 
114, 915,553-115,024,557, introns excluded). 
Amplified from polyp cDNA from an ApcMin/+ 
mouse, sequenced to exclude mutations. 
Cloned into pGEM3Z. 
Ref: [57] 







IMAGE clone 1382028, anti-sense from 
mouse Opn cloned into pT7T3D-PacI 
Ref: [78] 
Obtained from Shigeki Bamba 
T3 (as above) 
Mouse Tff1 Full length 435nt sequence of the mouse Tff1 
gene. 
Ref:[ 174] 




270 nt sequence of positions 149–419 of the 
rat Tff2 gene. 
Ref: [175] 






Full length coding region of the rat Tff3 gene 
inserted into the EcoRV site of Bluescript II 
KS+. 
Ref: [176] 
Obtained from Richard Poulsom 
T3  
Mastermix 1X Promega Transcription Buffer 
1.5 U/µl Promega 20U/µl RNAsin  
11.2mM DTT (D9779; Sigma) 
1mM each ATP, GTP, CTP 
14µM 35S-UTP (40383; Amersham SJ)+ 
5.6mM DTT  
----- 
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RNAse   inhibitor   diethylpyrocarbonate   (DEPC)   and   collected   onto   clean  
SuperFrost  slides.    Cut  sections  were  stored  for  a  maximum  of  24  hours  prior  to  
labelling.    Reagents  used  are  detailed  in  Table  2.14.    
Sections  were  de-­‐‑waxed  in  xylene,  rehydrated  through  graded  alcohols  (100%,  
80%,   60%   and   30%),   treated   with   0.1%   DEPC,   and   washed   in   DEPC-­‐‑treated  
phosphate-­‐‑buffered   saline   (PBS+).      Sections   were   then   permeabilised   with  
20µμg/ml   proteinase   K   in   PBS   for   10   minutes   at   37°C,   quenched   in   2x   PBS+  
containing   0.2%   (w/v)   glycine   for   5   minutes,   and   then   rinsed   in   PBS+   for   5  
minutes   (with   two   changes).      Post-­‐‑fixation   was   carried   out   using   freshly  
prepared  4%  PFA  for  10  minutes  followed  by  three  rinses  in  PBS+  of  5  minutes  
each.    Sections  were  then  acetylated  with  litre  0.1M  triethanolamine  +  2.5  acetic  
anhydride   added   and   mixed   well   just   before   immersing   the   slides   for   10  
minutes.     Afterwards  sections  were  rinsed   three   times   in  PBS+,  dehydrated   to  
absolute  ethanol/0.1%  DEPC  and  air  dried  overnight.  
The   same   day,   35S-­‐‑labelled   probes   were   diluted   with   enough   hybridisation  
buffer  to  allow  for  1x106  cpm  in  20µl.    Diluted  probe  was  denatured  at  80°C  for  
1  minute  and   immediately  placed  on   ice.     20µl  of  probe  was   then  added  onto  
each   tissue   section   and   covered   with   an   RNAse-­‐‑free   glass   coverslip.      Slides  
were   then   placed   in   slide   racks   in   sealed   humidified   boxes   containing   paper  
towels  saturated  with  1X  salts  mix/50%  formamide  and  incubated  overnight  at  
55°C  to  allow  hybridisation.  
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The  following  day,   the  slides  were  removed  from  boxes   in  a   fume  hood.     The  
coverslips  were  carefully  removed  and  the  slides  were  placed  into  a  clean  rack.    
The  rack  was  then  immersed  in  50%  formamide  buffer  at  55°C  and  incubated  at  
55°C   for   3  hours  on  a   rocking  platform  with  3   evenly   spaced   changes  of   50%  
formamide   buffer.      Formamide   was   then   removed   with   TNE   buffer   with  
changes   every  5  minutes   totalling   to  9  washes  at   37°C  on  a   rocking  platform.    
RNAse  A  stock  solution  was  thawed  at  room  temperature  and  added  to  1l  TNE  
buffer  at  37°C.    The  slides  were  then  incubated  in  RNAse  A/TNE  for  1  hour  at  
37°C  in  order  to  remove  all  unbound  probe.    RNAse  contaminated  gloves  were  
removed   to   avoid   laboratory   contamination.      Probe   fragments  were   removed  
with  washes   in   2X   and   then   0.5X   SSC   for   30  minutes,   each   at   65°C.      Finally,  
slides  were  dehydrated   through  graded   alcohols   containing   0.3M  ammonium  
acetate   (to   ensure   bound   probes   remain   bound   to   mRNA)   and   air   dried  










Table 2.14:  Reagents used for isotopic in situ hybridisation 
 
Reagent Details/ Reference number 
Acetic anhydride Commercially prepared.  A6404; Sigma 
Ammonium acetate 5M 
stock 
96.25g ammonium acetate (A1542; Sigma) in 1l distilled 
H2O. 
Autoclaved prior to use 
Denhardt’s solution in 
10X salts 
Denhardt’s solution (D9905; Sigma) comes prepared in 
50mg vials containing BSA, Ficoll® and 
polyvinylpyrollidine. 5ml  
Denhardt’s solution was dissolved in 20ml 10X salts 
solution to produce a 0.2% solution.  Stored at -20°C in 
300µl aliquots. 
DEPC Commercially prepared (D9779; Sigma). Stored at 4°C.  
Add to make 0.1% in treated solutions. 
Dextran sulphate 50g dextran sulphate (D8906; Sigma) dissolved in 10ml 
autoclaved water at 80°C.  Stored at -20°C. 
0.2M EDTA stock 14.88g EDTA dissolved in 200ml water and adjusted to 




20g AG 501-X8 resin (20–50 mesh size fully 
regenerated; 143-7424;BioRad) dissolved in 400ml 
formamide (BDH). Stirred overnight in fume hood, filtered 
to remove resin using a No 1 filter paper (Whatman) and 
stored at -20°C in 1ml aliquots.  
50% Formamide buffer 250ml 10X salt solution added to 1250ml non de-ionised 
formamide and made to 2.5l with autoclaved DEPC-
treated water. 
0.2% Glycine 2g glycine (G5516; Sigma) dissolved in 2X PBS. 
Autoclaved afterwards.  
Hybridisation buffer 100µl Denhardt’s solution in 10X salts (used to buffer pH 
and osmolarity), 500µl deionised formamide, 30µl 
ribosomal RNA (which acts as a probe carrier, 200µl 
dextran sulphate, 10µl 1M DTT, 160µl DEPC treated 
water (wetting agent with added RNase inhibiton). 
4% PFA 40g PFA dissolved in 1l PBS at 80°C. Cooled on ice 
once completely dissolved.   
10mg/ml Proteinase K 
stock 
200mg Proteinase K (4914; Sigma) added to 20ml TE 
buffer and stored at -20ºC in 1ml aliquots. 
20µg/ml  
Proteinase K solution for 
permeabilisation  
1ml aliquot of 10mg/ml Proteinase K stock to 500ml TE 
buffer. 
RNAse A 500mg RNAse A (Sigma; R5503g in 100mls 10mm NaAc 
pH5.2 
rRNA rRNA (R5502; Sigma) comes in 50units (17.7 units/mg) 
vials. 283µl DEPC-treated water was added directly to 











Principles  of  autoradiography:  this  technique  facilitates  the  hybridised  labelled  
probe  to  be  visualised.    Post-­‐‑hybridisation  tissue  sections  are  immersed  in  Ilford  
K5   scientific   emulsion,   which   contains   silver   halide   crystals   dispersed   in   a  
gelatine  matrix.     When   the   emulsion   comes   into   contact  with   bound   labelled  
probe,   the   ionising   radiation   causes   clusters   of   silver   atoms   to   be   produced  
from  the  silver  halide  crystals  present  in  the  emulsion.    The  same  process  occurs  
if  the  emulsion  is  exposed  to  light,  therefore  autoradiography  and  development  
are  carried  out  under     “safe”  902  (orange)  filtered  light  and  slides  were  left   to  
expose  in  complete  darkness.    When  the  emulsion  is  developed,  the  developer  
reduces   the   clusters   of   silver   atoms   to   metallic   silver   allowing   them   to   be  
visualised.      As   the   development   reaction   is   pH   dependent,   it   is   stopped   by  
Table 2.14:  Reagents used for isotopic in situ hybridisation (Contd.) 
 
Reagent Details/ Reference number 
10X Salts mix 14.2g Na2HPO4 (Fisher) dissolved in 50ml water and adjusted 
to pH6.8.  Then 176.2g NaCl (BDH), followed by 100ml 1M 
Tris/HCl and 250ml 0.2M EDTA. Mixed and made up to 1l. The 
concentrations in the final volume were; 3M NaCl, 100mM 




Prepared in-house; CRUK. 
TNE buffer 146g NaCl added to 50ml 1M Tris/HCl and 25ml 0.2M EDTA 
and made to 5l with water and pH adjusted to 7.2-7.6.  Stored 
overnight at 37ºC prior to use. 
0.1M 
Triethanolamine 
37.5g triethanolamine (T1502; Sigma) made to 2l with DEPC-
treated water. Autoclaved and stored at room temp. 
 
TE buffer for 
proteinase K  
permeabilisation 
200ml 1M Tris/HCl added to 100ml 0.2M EDTA and made up 
to 4l with water, pH7.6. Autoclaved and stored at room 
temperature. 
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immersing  the  sections  in  an  acidic  environment  (here  1%  acetic  acid).    Fixation  
with  10%  sodium  thiocyanate  is  carried  out  to  remove  any  residual  silver  halide  
leaving   only  metallic   silver.      This   is   done   as   any   remaining   silver   halide  will  
eventually   turn   brown   and   degrade   the   image.      The   sections   are   then  
extensively  washed   in  water   to   remove   all   the   silver   thiosulphate   complexes  
present   as   any   remaining   complexes  will   eventually   turn  brown  and  degrade  
the  image.    Reagents  are  detailed  in  Table  2.15.  
Method:  a  glass  measuring  cylinder  containing  25ml  water  was  warmed  to  42°C  
in  a  water  bath.      Ilford  K5  scientific  emulsion  was  added   to  give  a  volume  of  
40ml,   mixed  well   with   a   glass   rod   and   allowed   to  melt   for   15  minutes   with  
gentle   stirring   every   5  minutes.      Emulsion  was   then   transferred   to   a   dipping  
vessel  and  the  consistency  of  the  emulsion  was  determined  by  immersing  a  test  
slide  and  assessing  coverage  and  whether  air  bubbles  are  present.    Slides  were  
dipped   in   emulsion   to   completely   cover   the   tissue   section   and   excess   on   the  
bottom  and  back  of  the  slide  was  wiped  off.    Then  the  slides  were  placed  onto  
pre-­‐‑cooled  metal  plates   emulsion   side  up  and  allowed   to  dry   for  2.5  hours   in  
the   dark   until   the   emulsion   was   set.      After   drying,   slides   were   placed   into  
plastic  slide  racks  and  then  into  black  boxes  that  were  placed  into  black  plastic  
bags,  sealed  with  tape  and  incubated  at  4°C.    
Two  exposures  were  performed  at  7  days  (initial  exposure)  and  up  to  14  days  
depending  on  the  strength  of  the  first  exposure  signals  compared  to  the  rBAC  
control.    To  develop  slides,  plastic  racks  containing  the  slides  were  immersed  in  
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Kodak   D19   developer   for   4   minutes.      The   reaction   was   stopped   by   quickly  
transferring   racks   into   1%   acetic   acid   for   30   seconds   and   then   rinsed   in   tap  
water  for  30  seconds.    Fixation  was  carried  out  in  30%  sodium  thiosulphate  for  
8  minutes  and  then  finally  slides  were  washed  in  running  tap  water  for  1  hour.    
Sections  were  then  counterstained  with  Giemsa  solution,  dehydrated,  air  dried  
at  37°C  and  then  mounted  in  DPX  ready  for  microscopy.  
  
 
Table 2.15:  Reagents used in autoradiography 
 
Reagent Details 
Emulsion Comes in gel form. Stored at 4ºC : Ilford; K5 
Kodak D19 developer Prepared according to manufacturer’s instructions 
(1464593; Kodak) 
1% acetic acid 10ml glacial acetic acid dissolved in 10l water 
30% sodium thiosulphate 1kg sodium thiosulphate dissolved in 3.3l water 
Stock Giemsa 
counterstain 
10ml Giemsa (35086; BDH) added to 20ml acetate 
buffer*, 50ml acetone and 320ml water 
*200mM Acetate buffer 442µl glacial acetic acid, 359mg sodium acetate 




Scoring  and  assessment  of  mRNA  expression  
Sections   were   examined   with   both   transmitted   light   (bright   field)   and   epi-­‐‑
illumination   (dark   field)   using   a   Nikon   Eclipse  ME600   microscope   equipped  
with  a  digital  camera  (Q  Imaging  MicroPublisher  5.0  RTV)  by  Richard  Poulsom  
and   the   author.      Images   were   captured   using   QCapture   Pro   6   software  
(QImaging)   and   using   Photoshop   (Adobe,   CS3),   were   processed   to   remove  
shadows  using  methods  described  by  Marty  et  al.,  (2007)  [177].      
 110 
mRNA  labelling  was  assessed  by  distribution  pattern,    frequency  and  intensity  
in  tissue  sections  compared  to  positive  rat  β-­‐‑actin  controls  and  negative  controls  
using   a   semi-­‐‑quantitative   and   qualitative   scoring   system   based   on   several  
histopathological  scoring  systems.    Each  examined  area  (i.e.  small  adenomas  in  
Apc1322T  mice)  was  given  a   score   for   the   frequency  and  a   score   for   intensity  of  
mRNA  signal.    The  two  scores  were  then  added  together  to  produce  a  derived  
score  value  between  0  and  6  which  were  indicated  by  a  symbol  score  of  either  a  
minus  or  up  to  three  plusses  (see  Table  2.16).    
  














Negative 0 Negative 0 0 - 
Focal 1 Weak 1 1-3 + 
Patchy 2 Moderate 2 4 ++ 
Diffuse 3 Strong 3 5-6 +++ 
     
*Frequency    
Focal < 25% cells showing expression 
Patchy 25-75% cells showing expression 
Diffuse > 75% cells showing expression 
 


























3.1   Summary  of  pathological  findings  
All  representative  Tff1-­‐‑/-­‐‑  mouse  crossover  study,  Apc1322T  or  Il10-­‐‑/-­‐‑  samples  tested  
negative   for  Entamoeba,  Giardia,  Chilomastix,   Tritrichomonas,   antibiotic   resistant  
Streptococci  or  Lactobacilli,  or  any  of  the  Helicobacter  species.      
  
Representative   H&E-­‐‑stained   tissue   sections   from   Apc1322T,   ApcMin/+   and   Tff1-­‐‑/-­‐‑  
mouse   crossover   study  mice  were   histologically   assessed   by  Nicholas  Wright  
and  Gordon  Stamp  performed  a  histological   assessment  of  H&E-­‐‑stained   Il10-­‐‑/-­‐‑  
mouse   tissues.      Analysis   of   ApcMin/+   and   Apc1322T   mouse   tissues   revealed  
pathology  consistent  with  observations  by  Moser  et  al.,  (1990)  and  Pollard  et  al.,  
(2009),  respectively  (see  Figure.  3.1  and  3.2)  [49,  55].    The  same  however  cannot  
be  said  for  analysis  of  the  other  two  mouse  models.    For  example,  Il10-­‐‑/-­‐‑  mice  of  
this  study  exhibited  moderate-­‐‑to-­‐‑severe  colitis  as  Il10-­‐‑/-­‐‑  mice  of  the  same  genetic  
background  (e.g.  BALB/c)  and  age  as  described  by  Berg  et  al.,  (1996)  [76]  (Figure  
3.3).    However,  there  was  not  a  single  instance  of  colitis  progressing  to  colonic  
adenocarcinoma  by  six  months  of  age   in   the   Il10-­‐‑/-­‐‑  mice  of   this  study  (e.g.  at  5  
months  post  BMTx)   as  had  been   reported   to   occur   in   29%  of   Il10-­‐‑/-­‐‑  mice   on   a  
BALB/c     background  by  six  months  of  age  by  Berg  and  colleagues  (1996)   [76].    
An  important  point  to  note  is  that  micrographs  demonstrating  enterocolitis  and  
adenocarcinoma  in  the  Il10-­‐‑/-­‐‑  mouse  on  a  BALB/c  genetic  background  are  absent  
from   the   original   Berg   et   al.,   (1996)   publication   and   in   the   literature   to   date,  
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therefore   it   is   difficult   to   compare   the   pathology   observed   in   this   study  with  
previous  studies.    
Tff1-­‐‑/-­‐‑   mice   of   this   study   developed   antral   pyloric   adenomas   and   occasional  
intramucosal   carcinoma   similar   to   that   described   by   Karam   et   al.,   (2008)   [28]  
and  Soutto  et  al.,  (2011)  [33]  (Figure  3.4).    We  also  observed  similar  histology  to  
what   has   been   previously   described   as   adenocarcinoma   invading   the  
submucosa  by  Karam  et  al.,  (2008)  [28]  (Figure  3.5).    However,  in  both  instances  
it   was   identified   as   herniation   by   Nicholas   Wright   due   to   an   absence   of   a  
stromal   or   inflammatory   reaction.     We   also   observed   a   loss   of  GKN2  protein  
expression  in  Tff1-­‐‑/-­‐‑  mouse  group  adenomas  (further  discussed  in  Section  A.2  in  
the  Appendix).  
There   was   additional   unexpected   pathology   in   the   Tff1-­‐‑/-­‐‑   mouse   crossover  
experimental  groups.     WT  mice  that  had  been  transplanted  with  either  WT  or  
Tff1-­‐‑/-­‐‑   mouse   BM   occasionally   developed   spasmolytic   polypeptide   expressing  
metaplasia  (SPEM),  also  known  as  oxyntic  atrophy.     SPEM  is  characterised  by  
fundic   glands   becoming   populated   with   spasmolytic   polypeptide   (TFF2)  
expressing   cells   and   is   associated  with  Helicobacter   infection   [178].        However  
none   of   these   mice,   or   any   of   the   mice   of   this   study   for   that   matter,   tested  
positive  for  Helicobacter  species.    SPEM  was  initially  identified  through  the  loss  
of   parietal   and   chief   cells   in   fundic   glands   (Figure   3.6a),   both   hallmarks   of  
SPEM.      Isotopic   ISH   for  Tff2   mRNA   confirmed   the   presence   of   SPEM   in   the  
fundic   glands   with   parietal   cell   loss   (Figure   3.6b).      ABdPAS   staining  
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demonstrated   a   loss   of   PAS+   neutral  mucins   on   the  mucosal   surface   and   the  
presence  of  AB+  acid  mucins  in  Tff2  mRNA  expressing  cells  in  regions  of  SPEM,  
consistent  with  previous   observations   by  Goldenring   et   al.,   2000   [179]   (Figure  
3.6b).      In   addition,   SPEM  was   also   associated   with   decreased   GKN2   protein  
expression   (Figure  3.6b),  which  has  been  previously  observed   in  experimental  
models   of   SPEM   [180,   181].     Analysis   of   cell   proliferation   revealed   that   there  
was  no  uptake  of   the  BrdU  label  by  Tff2  mRNA  expressing  cells   in  regions  of  
SPEM,  suggesting  that  these  cells  were  not  actively  proliferating  (Figure  3.6b)  as  
has  been   reported  by  Nam  and  Colleagues   (2010)   [182].     However,  unlike   the  
group’s   observations,   we   did   not   observe   a   modulation   of   cell   proliferation  
with  increased  inflammation.    Comparison  of  Tff2  mRNA  expression  in  the  WT  
groups  suggests  that  WT  mice  transplanted  with  Tff1-­‐‑/-­‐‑  BM  had  an  earlier  onset  
and  more  severe  SPEM  than  their  WT  counterparts  (Table  3.1).    SPEM  was  not  
observed   in   Tff1-­‐‑/-­‐‑   mouse   groups   (e.g.   transplanted   with   either   WT   or   Tff1-­‐‑/-­‐‑  
mouse  BM),  ApcMin/+  mouse  crossover  study  mice,  Apc1322T  or  Il10-­‐‑/-­‐‑  mice.  
The   development   of   SPEM   in   WT   mice   was   the   only   incidence   where   our  
observations   suggested   BMTx   may   have   played   a   role   in   disease   outcome.    
Allogeneic  BMTx  had  no  histologically  observable  effect  on  any  of   the  ApcMin/+  
crossover  experimental  groups.    Similarly  the  transplantation  of  WT  mouse  BM  




Figure 3.1:  Comparison of ApcMin/+ mouse intestinal tumour pathology 
reviewed by Yamada and Mori (2006) with BMTx’d ApcMin/+ mouse pathology 
  
 
Polyps in the SI (a,b), occasional microadenomas in the colon (c,d), and large 
colonic adenomas (e,f) were observed in ApcMin/+ mice reviewed by Yamada et 
al., (2006) [a,c,e] in ApcMin/+ mice at 1 month post BMTx from this study (b,d,f).  
(a,c,e) Images taken from [183]; no magnifications were provided; b: x10; b, f; 
x1. 
Author’s note:  Images from the original Moser et al., (1990) publication were 








Figure 3.2:  Comparison of Apc1322T mouse GI pathology described by Pollard 
et al., (2009) with BMTx’d Apc1322T mouse pathology 
 
  
Occasional adenomas in the pyloric antrum (a,b), small polyps in the SI (c,d), 
and large adenomas in the SI (e,f) were observed in Apc1322T mice described by 
Pollard et al., (2009) [a,c,e] and Apc1322T mice transplanted with Apc1322T mouse 
bone marrow at 1 month post BMTx from this study (b,d,f).  (a,c) Images taken 
from [55]; no magnifications were provided; b,d: x10;  (e) Image kindly provided 





Figure 3.3:  Comparison of Il10-/- mouse pathology described by Berg et al., 
(1996) with BMTx’d Il10-/- mouse pathology 
 
  
Similar colitis-associated histological features such as crypt hyperplasia, 
inflammatory infiltrate (red arrows), and crypt abscesses (white circles) were 
observed in a Il10-/- mouse described by Berg et al., (1996) [a; 140x] with an 
Il10-/- mouse transplanted with Il10-/- mouse bone marrow at 5 months post 
BMTx from this study (b; x10) revealed.  However, we did not identify colonic 
adenocarcinoma (c; 50x) which has been described in certain strains of the Il10-







Figure 3.4:  Comparison of Tff1-/-  mouse pathology observed by Karam et al., 




(continued on the next page) 
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Figure 3.4:  Comparison of Tff1-/-  mouse pathology observed by Karam et al., 
(2008) and Soutto et al., (2011) with BMTx’d Tff1-/-  mouse pathology [continued] 
  
High-grade dysplasia in the antrum was observed in a 6 month old Tff1-/- mouse 
by Soutto et al., (2011) (a; x4) and a Tff1-/- mouse transplanted with Tff1-/- 
mouse BM 6 months post BMTx (8 months of age) in this study (b; x4). Antral 
pyloric adenomas were observed in untransplanted Tff1-/- mice at 12 months of 
age (c; no magnification,d; x4) and in a Tff1-/- mouse transplanted with Tff1-/-  
mouse BM 12 months post BMTx (14 months of age) in this study (e; x1). 
Adenocarcinoma in an untransplanted Tff1-/- mouse reported by Soutto et al., 
(2011) [g; no magnification given].  Intramucosal carcinoma in a Tff1-/- mouse 
transplanted with Tff1-/- mouse BM at 16 months post BMTx (f; x40). Mitotic 
cells are indicated by green arrows.  Apoptotic cells are indicated by yellow 
arrows. (a,d) Images kindly provided by Wael El-Rifai. (f) Image taken from [33]. 

















Figure 3.5:  Comparison of histology in a BMTx’d Tff1-/- mouse adenoma with 
invasive adenocarcinoma described by Karam et al., 2008 
 
Herniation of adenomatous cells into the submucosa is observed in an antral 
adenoma of a Tff1-/- mouse transplanted with Tff1-/- mouse BM at 12 months 
post BMTx (boxed in a; x1).  Magnification reveals that neoplastic cells (black 
arrows) and normal (white arrows) epithelial cells are surrounded by muscle (b; 
x10). There is an absence of stromal and inflammatory reaction. (c) Similar 
pathology was reported as invasive adenocarcinoma in a 12 month old Tff1-/- 










Parietal cells (black arrows) are observed in a WT mouse transplanted with WT 
mouse BM (WT→WT) at 6 months post BMTx whereas parietal cell loss 
occurred in a WT mouse transplanted with Tff1-/- mouse BM (Tff1-/-→WT) at 6 
months post BMTx (H&E images, x4 with x40 insets).  H+/K+ ATPase IHC 
identifies parietal cells in the WT→WT mouse (brown staining).  In areas of 
parietal cell loss in the Tff1-/-→WT mouse, H+/K+ ATPase is only expressed by 
remaining parietal cells. Similarly, IHC for pepsinogen demonstrated chief cells 
at the base of fundic glands (brown staining) in the WT→WT mouse but no 
expression in the base of fundic glands affected by parietal cell loss was 
observed in the Tff1-/-→WT mouse.  Magnification of H+/K+ ATPase and 















Figure 3.6b: Comparison of fundic pathology in WT mouse groups at 6 months 
post BMTx (continued) 
 
Isotopic ISH for Tff2 mRNA demonstrated expression in the mucous neck 
region of the fundus of the WT→WT mouse.  In the Tff1-/-→WT mouse an 
abnormal expansion of Tff2 mRNA expression confirmed SPEM.  Comparison 
of cell proliferation revealed rare BrdU+ (brown staining) cells in the region of 
SPEM of the Tff1-/-→WT mouse (BrdU images; x10). There were no BrdU+, Tff2 
mRNA expressing cells in regions of SPEM.  Analysis of ABdPAS staining 
demonstrated that the mucous neck region does not stain with either Alcian 
blue or PAS (magenta) in normal fundus, whereas Alcian blue positive mucous 
secreting cells (aqua staining in inset) were observed in areas of parietal cell 
loss in a WT mouse transplanted with Tff1-/- mouse BM (Tff1-/-→WT) at 6 
months post BMTx (ABdPAS images, x4 with x40 insets). GKN2 (pink staining) 
protein are strongly expressed by foveolar cells in the fundus of the WT→WT 
mouse but decreased in the Tff1-/-→WT mouse.  Tff2 mRNA expression 
appears as black grains in bright field images (BF) and white grains in dark field 
















Author’s  note  regarding  ApcMin/+  mouse  crossover  study  tissues  
Analysis   of   BMD-­‐‑myofibroblast   engraftment   in  ApcMin/+  tissues  was   limited   by  
the  following  factors:    
• Paraffin-­‐‑embedded   tissues   from   5  mice  were  missing   from   the  ApcMin/+  
mouse  BM  transplanted  into  ApcMin/+  mice  group  at  2  months  post  BMTx  
and  the  paraffin-­‐‑embedded  tissues  from  1  mouse  was  missing  from  the  
WT  mouse  BM  into  WT  mice  group  at   the  same  time  point.     Therefore,  
we   were   unable   to   carry   out   a   statistically   valid   comparison   of  
engraftment  at  1  and  2  months  post  BMTx.  
• For  each  mouse,  a  single  longitudinal  section  of  SI  and  colonic  tissue  was  
available.      Perhaps   as   result,   very   few   microadenomas,   polyps,   or  
adenomas  were  available  to  analyse.      
Based   on   these   considerations,   we   did   not   attempt   to   draw   any   conclusions  
regarding   BMD-­‐‑myofibroblast   contribution   in   ApcMin/+   mouse   adenomas   (see  
Figure  3.16  in  Section  3.4.3),  as  there  were  only  3  adenomas  available  from  the  
entire  cross  over  study  to  analyse  and  therefore  would  not  make  a  statistically  
valid  observation.    Instead,  we  focused  on  screening  all  available  ApcMin/+  mouse  
crossover   study   tissue   samples   for   putative   BMD-­‐‑epithelial   cells,   as   well   as  





3.2   Contribution  of  BMDCs  in  neoplastic  and  inflamed  epithelium    
This  study  analysed  over  105  crypts,  villi  and  gastric  glands  and  their  associated  
202   adenomas.      There  was   not   a   single   instance   of   the   Y-­‐‑chromosome   signal  
occurring   in   either   a   dividing   cell   or   a   putative   stem   cell   position   in   either  
glands   or   crypts,   nor   were   there   any   doublets   or   clusters   of   Y+   cells   in   the  
epithelium   which   would   indicate   clonal   expansion   from   an   engrafted   cell.    
Instead,   putative   BMD-­‐‑epithelial   cells   were   identified   as   rare   events,   whose  
frequencies  were  unaffected  by  the  presence  of  inflammation  or  adenomas.  
  
3.2.1   Putative  BMD-­‐‑epithelial  cells  were  rare,  random  events  
Putative  BMD-­‐‑epithelial  cells  were  identified  in  the  epithelial  layer  as  immune  
cell   marker-­‐‑negative   (e.g.   lacking   dark   pink   staining)   with   a   dark   brown  
nuclear   dot   representing   the   Y-­‐‑chromosome.   Putative   BMD-­‐‑epithelial   cells  
appeared   as   single   random   events   (Figure   3.7).      Quantification   of   putative  
BMD-­‐‑epithelial   cells  was   carried   out   in   adenomas   of   Tff1-­‐‑/-­‐‑  mice   transplanted  
with  Tff1-­‐‑/-­‐‑  mouse   BM,  Apc1322T  mouse   SI   and   Il10-­‐‑/-­‐‑  mouse   colon   following   the  
methods  described  in  Section  2.4.5.     The  frequency  of  putative  BMD-­‐‑epithelial  
cells  averaged  ≤  1.0%  in  a  150,000µm2  area  of  epithelium  (Figure  3.8).        
The  presence  of  adenomas  in  the  Apc1322T  mouse  SI  or  areas  of   inflammation  in  
Il10-­‐‑/-­‐‑  mouse  intestines  did  not  significantly  increase  the  percentage  of  putative  
epithelial   cells   derived   from   BM   compared   to   nearby   normal   epithelium   in  
these  mice.      
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Demonstration of a putative BMD-epithelial cell via immune cell marker IHC/Y-
chromosome ISH.  Negative and positive control splenic (a,b; x4) and colonic tissue 
(c,d: x4) for immune cell marker IHC. Positivity is shown through dark pink staining. 
Negative and positive control splenic tissue for Y-chromosome ISH (e,f; x20).  Y-
chromosome positivity is show by a dark brown nuclear spot. Immune cell IHC/Y-
chromosome ISH carried out on inflamed colonic tissue of an Il10-/- mouse transplanted 
with Il10-/- mouse BM at 5 months post BMTx (g; x60) demonstrates a rare putative 
BMD-epithelial cell (black arrow) as shown by an absence of immune cell marker 
staining and Y-chromosome positivity. Blue arrows point to donor-derived immune 
cells.   
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The percentage of putative epithelial cells from BM in 150,000 µm2 was 
analysed in normal and inflamed colonic mucosa of Il10-/- mice transplanted with 
Il10-/- mouse BM at 3 and 5 months post BMTx (data for the two time points 
combined), normal and adenomatous SI of Apc1322T mice transplanted with 
Apc1322T mouse BM at 1 month post BMTx, and the gastric adenomas of Tff1-/- 
mice transplanted with Tff1-/- mouse BM at 12 months post BMTx.  Mean±SEM.  





3.3   Analysis   of   Lgr5   mRNA   expression   in   neoplastic   and   inflamed  
epithelium    
We   examined   the   role   of   altered   Wnt   signalling   in   tumourigenesis   and  
inflammation   by  performing  Lgr5  mRNA   isotopic   ISH  on  Apc1322T  mice,  Tff1-­‐‑/-­‐‑,  
mouse   crossover   experimental   groups,   and   Il10-­‐‑/-­‐‑   mouse   tissues.      We   were  
unable  to  carry  out  analysis  on  ApcMin/+  mouse  crossover  study  tissues  due  to  the  
isotopic   ISH  service   closing  down.     Nevertheless,  we  observed   increased  Lgr5  
mRNA   expression   in   adenomas   of   Apc1322T  mice   as   previously   described   by  
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Lewis  et  al.,  (2010)  [57].    In  comparison,  Lgr5  mRNA  expression  in  Tff1-­‐‑/-­‐‑  mouse  
adenomas  (either  transplanted  with  WT  or  Tff1-­‐‑/-­‐‑  mouse  BM)  was  not  dissimilar  
to   expression   in   WT   antrum,   indicating   that   any   stem   cell   activity   in   Tff1-­‐‑/-­‐‑  
mouse   adenomas   was   unlikely   to   be   maintained   by   Lgr5-­‐‑associated   Wnt  
signalling.      In   addition,   Lgr5  mRNA   expression   was   not   observed   in   SPEM  
tissues,  suggesting  that  SPEM  lineages  are  also  not  maintained  by  aberrant  Wnt  
signalling.        
In  Il10-­‐‑/-­‐‑  mouse  tissues,  we  were  unable  to  detect  Lgr5  mRNA  expression.  This  
was   unlikely   to   be   a   reflection   of   experimental   error,   mRNA   degradation   or  
poor  tissue  quality,  as  the  Actb  mRNA  control  was  positive  and  other  isotopic  
ISH  assays  worked  on  these  tissues.  Therefore,  one  possibility   is   that,  as  Lgr5-­‐‑
expressing  cells  have  been  rarely  observed  at  the  base  of  colonic  crypts  in  Lgr5  
cell  lineage  tracing  experiments  [184],  the  mRNA  signal  from  a  few  cells  in  Il10-­‐‑/-­‐‑  
mouse   colonic   crypts   (which   are  devoid  of   an  Apc  mutation   that  would  have  
caused  increased  Lgr5  expression)  may  have  been  too  feint  to  be  detected.  
  
3.3.1   Lgr5  mRNA  was  strongly  expressed  in  adenomatous  SI  of  Apc1322T  mice  
Lgr5  mRNA  expression  was  observed  at  the  crypt  base  in  normal  SI  of  Apc1322T  
mice.    Strong  Lgr5  mRNA  expression  occurred  in  adenomatous  SI  as  previously  
described  by  Lewis  et  al.,  2010  [57]  (Figure  3.9).    We  were  unable  to  analyse  Lgr5  
mRNA  in  Apc1322T  mouse  colons  due  to  time  constraints.  
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Figure 3.9:  Lgr5 mRNA expression in Apc1322T mouse SI 
 
Lgr5 mRNA was strongly expressed in small (a,b; x4) and large SI adenomas 
(c,d; x4) and bottom) in  Apc1322T mouse transplanted with Apc1322T mouse BM 
at 1 month post BMTx.  Strong Lgr5 mRNA expression in large SI adenomas 
was also reported by Lewis et al., 2010 [57] (e; no magnification given).  In 
normal SI expression occurred along crypt bases (white arrows). Lgr5 mRNA 
expression appears as black grains in bright field images (a,c,e) and white 
grains in dark field images (b,d).  Magnification: x4. 
  
3.3.2   Upregulated  Lgr5  mRNA  expression  was  not  observed  in  Tff1-­‐‑/-­‐‑  mouse  
adenomas   
Compared   to  WT  mouse  group   tissues,  Tff1-­‐‑/-­‐‑  mouse  group  adenomas  had  an  
increase   in   BrdU+   cells   suggesting   increased   cell   proliferation.      In   addition,  
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ABdPAS  staining  demonstrated  that  Tff1-­‐‑/-­‐‑  mouse  adenomas  were  composed  of  
a  heterogeneous  mucin  cell  population  (Figure  3.10).    In  addition,  an  expansion  
of   Tff2  mRNA   (Figure   3.10)   further   demonstrated   the   heterogeneity   of   Tff1-­‐‑/-­‐‑  
mouse   adenoma   cell   population.      These   findings   supported   Karam   and  
colleagues   (2008)  observation  of  a  highly  proliferative  cell  population   in  Tff1-­‐‑/-­‐‑  
mouse  adenomas   that  expressed  all   cell   lineages   [28].     However,   ISH   for  Lgr5  
mRNA   (Figure   3.11)   demonstrated   that   expression  was   limited   to   the   base   of  
the  adenomatous  pyloric  glands,   similar   to  basal   expression   in  non-­‐‑neoplastic  
pyloric   glands.      Collectively   these   findings   suggest   that   whilst   Tff1-­‐‑/-­‐‑   mouse  
adenomas   have   highly   proliferative,   heterogeneous   cell   populations  
cell  populations,  these  cells  do  not  have  upregulated  Lgr5  mRNA  expression.    
  
3.3.3   Upregulated  Lgr5  mRNA  expression  was  not  observed  in  SPEM  tissues  
We  investigated  whether  Lgr5  expression  is  altered  during  SPEM  by  analyzing  
Lgr5   mRNA   expression   via   isotopic   ISH.      As   with   normal   fundic   glands   we  
were  unable   to  detect  Lgr5  mRNA   in   SPEM   (data  not   shown).      This   suggests  
that   upregulation   of   Lgr5   gene   expression   (and   therefore   Wnt   signaling)   is  
unlikely  in  SPEM.    However,  this  observation  does  not  rule  out  the  possibility  
SPEM  cell   lineages  originating  from  the  Lgr5+  stem  cells  at   the  base  of  oxyntic  




Figure 3.11: Comparison of Lgr5 mRNA expression in WT mouse antrum and 
Tff1-/- mouse antral adenomas 
 
  
In both WT mouse antrum (a,b; x10) and Tff1-/- mouse adenomas (c,d; x10), 
Lgr5 mRNA expression was limited to the base of antral glands (shown in white 
arrows) [a,c: bright field images; b,d: dark field images].    
  
3.4   Contribution  of  BMD-­‐‑myofibroblasts  to  tumour  stroma  
BMD-­‐‑immune   cells   and  myofibroblasts  were  observed   in   the   tissue   stroma  of  
all  mouse  models.      In  contrast,  BMD-­‐‑pericytes  and  endothelial  cells  were  rare  
and,   most   often   the   case,   not   observed   at   all.      Therefore,   only   BMD-­‐‑
myofibroblasts  were  quantified  in  the  stroma.  
BMD-­‐‑myofibroblasts   were   identified   in   the   stroma   by   dark   pink   α–SMA  
cytoplasmic   staining  encircling  a  nucleus  with  a  dark  brown  dot   representing  
the   Y-­‐‑chromosome   (Y+).      BMD-­‐‑myofibroblasts   were   quantified   using   the  
methods  described  in  Section  2.4.5.      In  brief,   the  number  of  α-­‐‑SMA+  cells  with  
and  without  a  Y  chromosome  signal  was  counted  within  a  150,000µm2  area  of  
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lamina  propria   beneath   the   epithelium.      Then   the   number   of  Y+/α-­‐‑SMA+   cells  
was   divided   by   the   total   number   α-­‐‑SMA+   cells   and   multiplied   by   100   to  
calculate   the   percentage   of   donor-­‐‑derived  myofibroblasts.     We   demonstrated  
that  fibrosis  and  tumour  burden  correlated  with  a  significant  increase  in  BMD-­‐‑
myofibroblasts  in  Tff1-­‐‑/-­‐‑  and  Apc1322T  mouse  tissues.    
  
3.4.1   BMD-­‐‑myofibroblasts  contributed  to  the  desmoplastic  response  in  Tff1-­‐‑
/-­‐‑  mouse  antral  pyloric  adenomas  
For  simplicity,  Tff1-­‐‑/-­‐‑  mouse  crossover  study  experimental  groups  are  referred  to  
by  shorthand  symbols  detailed  in  Table  3.1  in  this  section.  
  
  
Tff1-­‐‑/-­‐‑   mouse   groups   (e.g.   Tff1-­‐‑/-­‐‑→Tff1-­‐‑/-­‐‑   and   WT→Tff1-­‐‑/-­‐‑)   exhibited   antral  
dysplasia  at  6  month  post  BMTx  which  progressed  to  adenomas  observed  at  the  
12  month  and  16  month  post  BMTx  time  points.    Desmoplasia  was  observed  in  
Tff1-­‐‑/-­‐‑  mouse  adenomas  at  12  and  16  months  post  BMTx.    This  was  identified  by  
increased   α-­‐‑SMA   IHC   staining,   BMD-­‐‑myofibroblasts,   and   an   increased  
Table 3.1:  Details of shorthand symbols used for Tff1-/- mouse crossover study 




Code Details of BMTx experiment 
Tff1-/- mouse 
groups 
Tff1-/-→Tff1-/- Tff1-/- mouse BM transplanted into Tff1-/- mice 
WT→Tff1-/- WT mouse BM transplanted into Tff1-/- mice 
WT mouse 
groups 
WT→WT WT mouse BM transplanted into WT mice 
Tff1-/-→WT Tff1-/- mouse BM transplanted into WT mice 
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presence  of  BMD   inflammatory   cells   compared   to   the   stroma  of  dysplastic   or  
normal   pyloric   antrum   of  Tff1-­‐‑/-­‐‑  mice   at   6  months   post   BMTx   (Figure   3.12).   It  
was  noted  that  normal  or  SPEM  WT  mice  from  the  WT  groups  (e.g.  WT→WT  
and  Tff1-­‐‑/-­‐‑→WT)  did  not  develop  desmoplasia.      
Consistently  observed  was   increased  desmoplasia  at   the   top   (e.g.   towards   the  
lumen)   of   adenomas.      One-­‐‑way   ANOVA   demonstrated   that   the   number   of  
Y+/α-­‐‑SMA+   cells   and   the   percentage   of   gastric   SEMFs   derived   from   BM  
significantly  increased  at  the  tops  of  adenomas  compared  to  the  middle  or  base  
(Figure  3.13).     However,   the   total  number  of  α-­‐‑SMA+  cells   in  each   region  was  
not  significantly  different.     Following  the  observation  of  geographical   location  
changes   in  BMD-­‐‑gastric   SEMF  numbers,   quantification   in  Tff1-­‐‑/-­‐‑  mouse  gastric  
adenomas  involved  counting  a  50,000  µm2  area  at   the  base,  middle  and  top  of  
the  adenomatous  stroma  (totalling  150,000  µm2)  to  get  an  overall  assessment  of  
BMD-­‐‑myofibroblast  engraftment  in  Tff1-­‐‑/-­‐‑  mouse  adenomas.      
Based  on  this,  BM  contributed,  on  average,  11%  of  the  total  number  of  SEMFs  in  
a  150,000  µm2  area  of  adenomatous  stroma  in  the  Tff1-­‐‑/-­‐‑  mouse  groups  at  12  and  
16  months   post   BMTx.      In   comparison,   BM   contribution   averaged   4%   of   the  
total   number   of   SEMFs   in   the   same   area   of   normal   stroma   in   the  WT  mouse  
groups  at  any  time  point  post  BMTx  (e.g.  6,  12,  or  16  months).    Engraftment  of  
BMD-­‐‑myofibroblasts   with   time   after   BMTx   was   analysed   using   one-­‐‑way  
ANOVA  with  a  Bonferroni  multiple  comparison   test.     There  was  a  significant  
increase   both   in   the   percentage   of   gastric   SEMFs   derived   from   BM   and   the  
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number  of  Y+/α-­‐‑SMA+  cells  in  the  adenomas  of  Tff1-­‐‑/-­‐‑  mouse  groups  at  12  and  16  
months  post  BMTx  compared  to  normal  antral  tissue  near  dysplastic  antrum  of  
the  Tff1-­‐‑/-­‐‑    mouse  groups  at  6  months  post  BMTx  (Figure  3.14).    
However,  there  was  no  significant  difference  in  the  percentage  of  gastric  SEMFs  
derived   from   BM   or   the   number   of   Y+/α-­‐‑SMA+   cells   in   Tff1-­‐‑/-­‐‑   mouse   group  
adenomas  between  12  and  16  months  post  BMTx.    These  observations  suggest  a  
plateau   in   BMD-­‐‑myofibroblast   engraftment,   reminiscent   of   the   shorter-­‐‑term  
experimental  data  of  Lee  et  al.,  (2011)  in  the  GI  tract  of  RAG2  colitic  mice  [155].    
This  could  be  a  consequence  of  Tff1-­‐‑/-­‐‑  mouse  adenomas  remaining  relatively  the  
same   size   at   16  months  post  BMTx  as   at   the   12  month  post  BMTx   time  point  
(see   Figure   3.24a   and   Figure   3.24b   in   Section   3.5.1).      There   is   evidence   that  
engrafted   BMD-­‐‑myofibroblasts   can   proliferate   in   situ.   Brittan   and   colleagues  
(2005)  demonstrated  that  BMD-­‐‑keratinocytes  are  able  to  proliferate   in  vivo  and  
in   vitro   [185],   however   the   plateauing   of   BMD-­‐‑myofibroblast   numbers   in  my  
experiments  suggest  their  proliferation  is  not  a  significant  factor.    
Analysis   of   the   total   number   of   α-­‐‑SMA+   cells   using   a   Bonferroni   multiple  
comparison   test   revealed   that   overall   there   was   no   significant   difference  
between  experimental  groups  or  with  time  (Figure  3.15).      However,  there  was  a  
single   instance  where   a   significant   difference  was   observed   (Figure   3.15).      In  
context  with  the  other  groups  and  time  points  however,  there  appears  to  be  no  
biological   significance   to   this   difference,   as   the   levels   of   engraftment   were  
broadly  constant  across  groups  and  time.  
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3.4.1.1  Allogeneic   BMTx   had   no   observable   effect   on   BMD-­‐‑myofibroblast  
engraftment  in  WT  and  Tff1-­‐‑/-­‐‑  mouse  groups  
Comparison  of  the  allogeneic  and  syngeneic  BMTx’d  groups  using  a  Bonferroni  
multiple   comparison   test,   revealed   that   there  was   no   significant   difference   in  
the  percentage  of  BMD-­‐‑  gastric   SEMFs,   the  number  of  Y+/α-­‐‑SMA+  or   the   total  





Figure 3.12:  Development of desmoplasia and presence of BMD-
myofibroblasts in antral pyloric adenomas in BMTx’d Tff1-/- mice (continued) 
 
(a-d) Controls for α-SMA IHC/ Y-chromosome ISH. (a,b; x4) Gastric 
adenomatous tissue with α-SMA antibody omitted (a; x1) and with (pink 
staining, b; x1). (c,d; x40) Male spleen control without Y-chromosome probe (c; 
x40) and with (d; x40). Y-chromosome positivity is indicated with a dark brown 
nuclear spot. (e-g) α-SMA IHC/ Y-chromosome ISH carried out on normal (e; 
x10) and dysplastic (f; x10) pyloric antrum at 6 months post BMTx and an antral 
pyloric adenoma (g) at 12 months post BMTx in Tff1-/- mouse group mice.  (h-j) 
Higher magnification images of boxed images in g.  BMD-myofibroblasts (black 
arrows) are identified by α-SMA+ cells with Y-chromosome positivity.  Y-
chromosome negative myofibroblasts are indicated with a white arrow. Within 
the antral adenoma a rare BMD-blood vessel smooth muscle cell was observed 
(green arrow). Inflammatory infiltrate is observed in h with inflammatory cells  




































Figure 3.13:  Comparison of BMD-myofibroblast engraftment in different 




α-SMA+ cells were quantified in 150,000 µm2 areas at the base, middle and top 
of pedunculated gastric adenomas of the Tff1-/-→Tff1-/- group at 12 months post 
BMTx (a; x1).  One-way ANOVA was performed to analyse whether there was a 
significant difference in percentage of gastric SEMFs derived from BM or the 
number of Y+/α-SMA+ or α-SMA+ cells in each region. There was a significant 
increase in the percentage of gastric SEMFs derived from BM in the top of 
adenomas versus the base (P<0.01) and middle of adenomas versus the base 
(P<0.05) (b).  On the other hand, there was no significant increase in the 
number of α-SMA+ cells in these regions (c), but there was a significant 
increase in the number of Y+/α-SMA+ cells in the top of adenomas versus the 








One-way ANOVA with a Bonferroni multiple comparison test was performed to analyse 
whether there was a significant difference in the percentage of gastric SEMFs derived 
from BM (a) or the number of Y+/α-SMA+ cells (b) with time in the Tff1-/- mouse 
crossover study.   
 
(a) Only the Tff1-/-→Tff1-/- group demonstrated a significant increase in the percentage 
of gastric SEMFs derived from BM from normal antrum surrounding dysplastic antrum 
(ND) into dysplastic antrum (DYS) at 6 months post BMTx (P<0.05, red line). There 
was a significant increase in the percentage of gastric SEMFs derived from BM from 
ND at 6 months post BMTx to adenomatous antrum at 12 months post (Tff1-/-→Tff1-/- 
[P<0.01] WT→Tff1-/- [P<0.001, blue line]).  However, there was no significant increase 
from 12 to 16 months post BMTX in these groups.  A single decrease in the percentage 
of gastric SEMFs derived from BM in normal antrum was observed from 6 to 16 
months in the WT→WT group (P<0.05, green line). 
 
(b) There was no significant increase in the number of Y+/α-SMA+ cells into dysplastic 
antrum at 6 months post BMTx or adenomatous antrum at 12 months post BMTx from 
ND at 6 months in the Tff1-/-→Tff1-/- group.  A significant increase was observed from 
ND at 6 months post BMTx to adenomatous antrum at 12 months post BMTx in the 
WT→Tff1-/- group [P<0.01].  However, there was no further significant increase from 12 




Figure 3.15:  Number of α-SMA+ cells in the pyloric antrum with time in the Tff1-




Cells With Time 







































One-way ANOVA with a Bonferroni multiple comparison test demonstrated that in 
the Tff1-/-→Tff1-/- group there was a significant increase in the number of α-
SMA+ cells in adenomatous antrum at 16 months post BMTx compared to 
dysplastic antrum at 6 months post BMTx (P<0.05). Mean±SEM; *P<0.05. 
 
 
3.4.2   BMD-­‐‑myofibroblasts   were   observed   in   non-­‐‑fibrotic   ApcMin/+   mouse  
tumours  
BMDCs  frequently  contributed  to  normal  and  adenomatous  SI  in  ApcMin/+  mice.    
A  build-­‐‑up  of  tumour  stroma  was  not  a  feature  of  ApcMin/+  mouse  adenomas  as  
demonstrated   by   little   α-­‐‑SMA   immunoreactivity.      Despite   this,   BMD-­‐‑
myofibroblasts  were   observed   in   the   tumour   stroma   (Figure   3.16).     However,  
 
Figure 3.14:  BMD-myofibroblast engraftment with time in the Tff1-/- mouse 
crossover study (continued) 
 
There was no significant difference in the percentage of gastric SEMFs derived from 
BM or the number of Y+/α-SMA+ cells from 6-16 months post BMTX in the Tff1-/-→WT 
mouse group (orange line). 
 
To account for the smaller sample number in the WT→Tff1-/- group at 16 months (n=4) 
a non-parametric Kruskal-Wallis test was additionally performed yielding the same 
results. N normal; ND normal antrum near dysplastic antrum; DYS dysplasia.    
Mean±SEM; *P<0.05, **P<0.01, *** P<0.001. 
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quantification  of  BMD-­‐‑myofibroblasts   in  these  tissues  was  not  carried  out  due  
to   only   3   adenomas   being   available   for   analysis   that   would   not   allow   for  
statistically  valid  comparisons.  
 
 
Figure 3.16:  Micrograph of BMDCs in the stroma of normal and adenomatous 
ApcMin/+ mouse SI  
 
 
α-SMA IHC (pink staining) of normal SI (a; x10) and a small intestinal adenoma (b; x1 
c magnification of boxed image in b; x40) in an ApcMin/+ mouse transplanted with 
ApcMin/+ mouse BM at 1 month post BMTx.  Within the adenoma, numerous BMD-
myofibroblasts (black arrows) were identified as well as rare BMD-cells in the epithelial 
layer (grey arrow).  BMD-myofibroblasts are identified by α-SMA+ cells with a dark 
brown nuclear spot indicating Y-chromosome positivity. 
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3.4.3   BMD-­‐‑myofibroblast  engraftment  increased  with  tumour  burden  in  
Apc1322T  mice 
BMDCs   frequently   contributed   to   the   normal   and   adenomatous   SI   of  Apc1322T  
mice   (Figure   3.17).   As   with   ApcMin/+   adenomas,   desmoplasia   did   not   occur.    
Quantification   of   BMD-­‐‑SI   SEMF   engraftment   in   small   intestinal   stroma  
demonstrated   a   significantly   increased   percentage   of   SI   SEMFs   derived   from  
BM  in  small  and   large  SI  adenomas  compared  to  normal  SI   (Figure  3.18).     On  
the  other  hand,  analysis  of   the  number  of  Y+/α-­‐‑SMA+  cells   in   these   tissues  did  
not  demonstrate  a  significant  increase  into  adenomas,  though  there  was  a  trend  
which  paralleled  that  of  the  percentage.    However,  inspection  of  Figure  3.18  is  
an  example  of  this  increasing  trend  into  large  adenomas.      
Analysis   of   the   number   α-­‐‑SMA+   in   normal   SI   and   small   and   large   small  




















Figure 3.17:  Micrograph of BMDCs in the stroma of normal and adenomatous 
Apc1322T mouse SI 
 
α-SMA IHC (pink staining) of normal SI (a; x20), a small adenoma (b; x20) and a large 
adenoma (c: left; x4, right; x40) in an Apc1332T mouse at 1 month post BMTx.  Within the 
adenoma, numerous BMD-myofibroblasts (black arrows) were identified.  BMD-
myofibroblasts are identified as α-SMA+ cells with a dark brown nuclear spot indicating 
Y-chromosome positivity.  
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Figure 3.18:  BMD-myofibroblast engraftment in the SI in Apc1322T mice 





































































































































One-way ANOVA with a Bonferroni multiple comparison test was performed to 
determine whether there was a significant difference in the percentage of gastric 
SEMFs derived from BM or the number of Y+/α-SMA+ cells in normal and adenomatous 
SI in in Apc1322T mice transplanted with Apc1322T mouse BM at 1 month post BMTX.  (a) 
The percentage of small intestinal (SI) SEMFs from BM was significantly increased in 
large adenomas compared to normal SI (P<0.001) and small adenomas (P<0.01) in 
Apc1322T mice.  (b) There was no significant increase in the number of Y+/α-SMA+ cells 
into small or large small intestinal adenomas compared to normal SI. Mean±SEM; ** 
P<0.01; *** P<0.001; n=4. 
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There was no significant difference in the number of α-SMA+ cells in normal SI 




3.4.4   Engraftment   of   BMD-­‐‑colonic   SEMFs   did   not   increase   in   areas   of  
inflammation  in  colitic  Il10-­‐‑/-­‐‑  mice    
The  Il10-­‐‑/-­‐‑  mouse  model  exhibited  the  most  inflammation  compared  to  all  of  the  
other   mouse   models   used   in   this   study.      An   abundance   of   inflammatory  
infiltrate   was   observed   in   the   villi   and   crypt   stroma   of   these   mice   in   H&E  
stained  sections  and  confirmed  by  immune  cell  IHC.    Fibrosis  was  not  a  feature  
of   pathology   in   these  mice.      In   fact,   very   little  α-­‐‑SMA   immunoreactivity  was  
observed  in  the  stroma.    
As   Bamba   and   colleagues   (2006)   demonstrated   an   increase   in   BMD-­‐‑colonic  
SEMFs  in  inflamed  mucosa  compared  to  non-­‐‑inflamed  mucosa  in  Il10-­‐‑/-­‐‑  mice  on  
a  C57/BL10  background  [78],  this  led  us  to  suspect  that,  despite  the  more  severe  
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colitis  developed   in   Il10-­‐‑/-­‐‑  mice  on  a  BALB/c  background,  BALB/c  background  
mice  do  not  develop  fibrosis  as  a  consequence.    Indeed,  comparison  of  α-­‐‑SMA  
IHC/Y-­‐‑chromosome   ISH   in   colonic   mucosa   of   C57/BL10   and   BALB/c  
background   Il10-­‐‑/-­‐‑  mice  shows  distinct  α-­‐‑SMA  staining  patterns   (Figure  3.20a).  
Moreover,   immune   cell   IHC/Y-­‐‑chromosome   ISH   demonstrated   the  
predominance  of  immune  cells  in  the  stroma  (Figure  3.20b).  
In  some  Il10-­‐‑/-­‐‑  mice  of  this  study,  such  as  the  one  illustrated  in  Figure  3.20a  and  
Figure   3.20b,   there   were   very   few   myofibroblasts   present   in   the   inflamed  
stroma.      In   this   mouse,   31%   of   colonic   SEMFs   were   derived   from   BM   of  
inflamed  colonic  stroma.    However,  this  percentage  was  derived  from  counting  
a  total  of  49  myofibroblasts  in  a  150,000m2  area  of  stroma,  15  of  which  were  Y-­‐‑
positive.     With   this   is   mind,   whilst   an   increasing   trend   in   the   percentage   of  
colonic   SEMFs   was   observed   both   in   inflamed   mucosa   compared   to   non-­‐‑
inflamed  mucosa  and  with  the  duration  of  colitis  (Figure  3.21),  the  number  of  α-­‐‑
SMA+   cells   in   these   areas   decreased   (Figure   3.21).      This   could   be   because   the  














Figure 3.20a:  Comparison of BMD-colonic SEMF engraftment and the presence of 
immune cells in Il10-/- mice on a C57BL/10 and a BALB/c genetic background 
 
 
Bamba and colleagues (2006) demonstrated substantial α-SMA immunostaining (a) 
frequently observed BMD-colonic SEMFs (b,c) in an Il10-/- mouse on a C57BL/10 
genetic background.  In comparison, little α-SMA staining was observed in the inflamed 
colonic mucosa of an Il10-/- mouse on a BALB/c genetic background from this study (d).  
α-SMA is shown as pink staining and a brown dot indicates Y-chromosome positivity.  
Bar = 0.1mm; a-c taken from [78]. (d) Left hand image: x4; x20 magnification of boxed 
area is shown in the right hand image. 
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Figure 3.20b:  Comparison of BMD-colonic SEMF engraftment and the  
presence of immune cells in Il10-/- colonic mucosa of mice described by Bamba 




Immune cell IHC/Y-chromosome ISH on another tissue section from the Il10-/- 
mouse in d in Figure 3.22a.   Here, immune cell marker positivity is shown 
through pink staining and once again Y-chromosome positivity is indicated by 
dark brown nuclear dots. Left hand image: x4, x20 magnifications of boxed area 



















Figure 3.21:  Comparison of BMD-myofibroblast engraftment at 3 months 



































































































































Two-way ANOVA of normal versus inflamed colonic mucosa at 3 versus 5 
months post BMTx in Il10-/- mice transplanted with Il10-/-  mouse BM was carried 
out for the percentage of colonic SEMFs derived from BM (a), the number of 
Y+/α-SMA+ (b), and the number of SMA+ cells (c).  A decreasing trend in the 
number of SMA+ cells in inflamed areas from 3 months post BMTx to 5 months 
post BMTx is suggested.  Mean±SEM, n=6. 
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3.4.5  Engraftment  of  BMD-­‐‑gastric  SEMFs  is  not  observed  in  areas  of  SPEM  in  
WT  mice  
BMD-­‐‑inflammatory   cells   in   the   mucosa   and   submucosa   were   frequently  
observed   in   SPEM   tissues   at   6,   12,   and   16   months   post   BMTx.      However,  
inflammatory   fibrosis  was   not   observed   as   a   part   of   SPEM   pathology   at   any  
time   point.      Moreover,   little   α-­‐‑SMA   immunoreactivity   and   very   few   BMD-­‐‑
gastric   SEMFs  were   observed   (Figure   3.22).     We   attempted   to   quantify  BMD-­‐‑
SEMF   contribution   in   these   areas   but   found   there   was   insufficient   stroma   in  














Figure 3.22: BMDCs in normal and SPEM fundic tissue in WT mice 
  
In normal fundic tissue very little stroma (lamina propria) was observed as 
demonstrated by ∝-SMA IHC (a; x10).  Similarly, despite the presence of 
hyperplasia and inflammation in SPEM, fibrosis was not observed (b; x10).  
Few gastric SEMFs (grey arrows) and BMD-gastric SEMFs (black arrows) were 
observed in the stroma (c; x40).  Instead, an inflammatory infiltrate in the 




3.5   Summary   of   the   contribution   of   putative   BMD-­‐‑epithelial   cells   and  
BMD-­‐‑myofibroblasts  in  four  mouse  models  
Tables  3.2-­‐‑3.6  summarise  the  contribution  of  putative  BMD-­‐‑epithelial  cells  and  
BMD-­‐‑myofibroblasts   according   to   pathology   in   the   Tff1-­‐‑/-­‐‑   mouse   crossover  





























3.6   Mechanisms   of   BMD-­‐‑myofibroblast   recruitment   in   tumourigenesis  
and  inflammation  in  all  mouse  models 
To  better  understand  the  mechanisms  of  BMD-­‐‑myofibroblast  recruitment,  Opn  
mRNA   isotopic   ISH  was   employed   in   all   mouse   models   of   this   study.      Our  
findings  suggest  that  Opn  mRNA  at  desmoplastic  reaction  sites  at  the  edges  of  
Tff1-­‐‑/-­‐‑   mouse   adenomas   was   associated   with   increased   BMD-­‐‑myofibroblast  
engraftment.      In   contrast,  Opn   mRNA   expression   in  ApcMin/+  and  Apc1322T  mice  
tumours   was   diffuse   and   did   not   correlate   with   increased   α-­‐‑SMA  
immunoreactivity  or  an  increased  presence  of  BMD-­‐‑SEMFS.    In  Il10-­‐‑/-­‐‑  and  SPEM  
mouse   tissues,  Opn  mRNA  expression  varied  and  did  not   increase   in  areas  of  
increased  inflammation.      Moreover,  Opn  mRNA  expression  in  did  not  correlate  
with   increased   α-­‐‑SMA   immunoreactivity   or   an   increased   presence   of   BMD-­‐‑
SEMFS.  
  
3.6.1   Opn  mRNA  expression   in  desmoplastic   reaction   sites   in  Tff1-­‐‑/-­‐‑  mouse  
adenomas  correlated  with  an  increased  frequency  of  BMD-­‐‑myofibroblasts    
Opn  mRNA  expression  was   analysed   in  normal,   dysplastic   and   adenomatous  
gastric  mucosa  in  the  Tff1-­‐‑/-­‐‑  mouse  crossover  study    (summarised  in  Table  3.7).    
Opn   mRNA   expression   was   predominantly   epithelial   but   occasional   stromal  
expression   was   also   observed.   In   normal   pylorus   and   dysplastic   pyloric  
antrum,  Opn  mRNA  was  expressed  along  the  base  of  glands  (Figure  3.23).      In  
antral   pyloric   adenomas,   strong  Opn   mRNA   expression   occurred   throughout  
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adenomas  with  increased  expression  occurring  towards  the  lumen  of  adenomas  
at   desmoplastic   reaction   sites   (Figure   3.24a   and   Figure   3.24b).   Increased  Opn  
mRNA   expression   at   the   top   of   adenomas   was   consistent   with   an   increased  
number   of   BMD-­‐‑SEMFs.      Figure   3.25   demonstrates   an   area   of   increased  Opn  
mRNA   expression   correlating   with   the   increased   presence   of   myofibroblasts  
and  BMD-­‐‑myofibroblasts.    Visual  comparison  of  Opn  mRNA  expression  in  Tff1-­‐‑
/-­‐‑  mouse  adenomas  at  12  months  versus  16  months  post  BMTx  suggested  a  slight  
decrease  in  Opn  mRNA  expression  in  adenomas  at  16  months  post  BMTx.      
There  was  no  observable  difference  in  Opn  mRNA  expression  in  any  mice  that  





Table 3.7:  Summary of Opn mRNA expression in normal, dysplastic, and 




Opn mRNA expression Actb  
Normal pylorus 
(n=15) 
+      (3.5)     




+      (2.6) 
Focal expression restricted to the lower 2/3 of the 
gland.  Epithelial expression. 




+     (2.3) 






++   (4.3) 
Strong basal and focal expression (particularly 
towards the lumen) in adenomas. Mainly epithelial 
and occasional stromal expression.  
+++        
Symbol scores were allocated according to mean derived numeric scores (bracketed) 
for each group using the scoring schemes detailed in Table 2.16 in Chapter 2.  Actb= 




Figure 3.23:  Opn mRNA expression in normal and dysplastic pyloric antrum 
 
 
Opn mRNA was expressed throughout the base of normal antral glands of a 
WT mouse transplanted with WT BM at 6 months post BMTx (a; x4) and 
dysplastic antrum of a Tff1-/- mouse transplanted with WT mouse BM at six 
months post BMTx (b; x10).  Opn mRNA expression appeared as black grains 

























Figure 3.24b:  Opn mRNA expression in gastric adenomas of Tff1-/- mice 
 
 
Micrographs of Opn mRNA expression in two gastric adenomas of Tff1-/-  mice 
that had been transplanted with Tff1-/-  mouse BM at 16 months post BMTx. 
Moderate and strong epithelial (and occasional stromal) expression was 
observed predominantly towards the lumen.  Opn mRNA expression appears 





Figure 3.25:  Opn mRNA expression and BMD-myofibroblast engraftment in a 
Tff1-/- mouse gastric adenoma 
 
 
A patch of strong epithelial Opn mRNA expression in a gastric adenoma of a 
Tff1-/- mouse transplanted with Tff1-/- mouse BM at 16 months post BMTx (black 
grains in a; x4) corresponds to an area with increased α-SMA immunostaining 
(boxed in b; x4). A larger magnification of this area (c; x40) shows a 
concentration of BMD myofibroblasts (pink staining surrounding cells with a 





3.6.2   Opn  mRNA  expression  in  ApcMin/+  and  Apc1322T  mouse  adenomas  did  not  
correlate  with  the  increased  frequency  of  BMD-­‐‑myofibroblasts  
In  contrast  to  Tff1-­‐‑/-­‐‑  mouse  tissues,  Opn  mRNA  expression  in  ApcMin/+  and  Apc1322t  
mouse  tissues  was  frequently  both  epithelial  and  stromal.    Expression  between  
ApcMin/+  and  Apc1322T  mice   differed,  with  Opn  mRNA   expression   undetected   in  
normal   small   intestinal   or   colonic   mucosa   of   ApcMin/+   mice,   but   occasionally  
detected   in   the   SI   and   rarely   observed   in   the   colonic  mucosa   of  Apc1322T  mice  
(summarised   in   Table   3.8).      Opn   mRNA   was   also   observed   in   the   colonic  
muscularis  propria  consistent  with  reported  expression  in  ganglion  cells  in  the  
myenteric  plexus  [186].    However,  Opn  mRNA  expression  was  not  observed  in  
the  muscularis  mucosa  of  the  SI  or  stomach  in  ApcMin/+  and  Apc1322T  mice,  or  Tff1-­‐‑/-­‐‑  
or  Il10-­‐‑/-­‐‑  mice  for  that  matter.    
Increased,   diffuse  Opn   mRNA   expression   in   epithelial   and   stromal   cells   was  
demonstrated   in   ApcMin/+   and   Apc1322T   mouse   adenomas   compared   to   normal  
tissues   (Figure   3.26   and   Figure   3.27).      In   Apc1322T   mice   there   appeared   to   be  
increased  expression  in  large  adenomas  compared  to  small  adenomas  in  the  SI.    
However,   we   could   not   convincingly   demonstrate   that   the   Opn   mRNA  
expression   in  ApcMin/+   and  Apc1322T  mouse  adenomas   correlated  with   increased  
α–SMA   immunoreactivity   or   increased   engraftment   of   BMD-­‐‑myofibroblasts  





Table 3.8:  Summary of Opn mRNA expression in ApcMin/+ and Apc1322T mouse 
intestinal tissue 
 
Region of Intestine Opn mRNA expression βAC  
Normal ApcMin/+ mouse SI - +++  
Normal Apc1322T mouse SI 
+  (2.0) 
Occasional focal expression. 




of the Apc1322T mouse SI 
+      (2.8)                         
Epithelial and stromal 
expression 
+++        
Large adenomas  
of the Apc1322T mouse SI 
++    (4.0) 




Normal ApcMin/+ mouse colon* - +++        
Normal Apc1322T mouse colon 
+ (2.0) 
Very rare focal expression.  
Both epithelial and stromal. 
+++ 
ApcMin/+ mouse colonic adenoma 
(n=1) 
+ (4.0) 
Patchy, more often stromal +++  
 
Symbol scores were allocated according to mean derived numeric scores 
(bracketed) for each group using the scoring schemes detailed in Table 2.16 in 
Section 2.5 of Chapter 2.  * strong focal expression occasionally appeared in 





















Analysis of Opn mRNA expression in an ApcMin/+ mouse transplanted with 
ApcMin/+ mouse BM at 1 month post BMTx.  No Opn mRNA expression was 
observed in normal SI (a) and colonic (b) epithelium. Strong focal expression 
was observed in the colonic muscularis mucosa and adjacent submucosa (c). 
Opn mRNA expression appears as black grains in bright field images (left) and 








Figure  3.27:  Opn mRNA expression in the normal and adenomatous Apc1322T 
mouse intestine 
 
Opn mRNA was occasionally expressed in normal SI (a) and rarely expressed in the 
colon (b) in Apc1322T mice transplanted with Apc1322T mouse BM at 1 month post BMTx.  
Increased epithelial and stromal Opn mRNA expression was observed in small (c) and 
large (d) adenomas in the SI.  Opn expression appears as black grains in bright field 
images (left) and white grains in dark field images (right).  Magnification of all images: 
x20. 
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Figure 3.28:  Opn mRNA expression and BMD-myofibroblast engraftment in an 
ApcMin/+ mouse colonic adenoma  
 
 
Opn mRNA was expressed by epithelial and stromal cells at the base of a colonic 
adenoma of an ApcMin/+ mouse transplanted with ApcMin/+ mouse BM at 1 month post 
BMTx (boxed; a).  This corresponded to a nearby area with enhanced α-SMA 
immunoreactivity (d; x4, e; x20).  However, a higher magnification of this area (f; x40) 
revealed few BMD myofibroblasts (pink staining surrounding cells with a brown nuclear 
dot).  Opn mRNA expression appears as black grains in bright field images (a; x4 b; 
x20) and white grains in dark field images (c; x20).  
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3.6.3   Opn   mRNA   expression   in   Il10-­‐‑/-­‐‑   and   SPEM   mouse   tissues   did   not  
correlate  with  increased  inflammation   
In   the   inflamed  mucosa  of   Il10-­‐‑/-­‐‑  and  SPEM  mice,  Opn  mRNA  expression  was  
focal   and  predominantly   epithelial   (Figure  3.30  and  Figure  3.31).        Occasional  
stromal   expression   was   also   observed   and   rare   expression   in   the   muscularis  
propria   was   also   observed.      Opn   mRNA   expression   did   not   increase   with  
disease  severity  or  disease  duration  in  either  Il10-­‐‑/-­‐‑  or  SPEM  mouse  tissues.    As  
mentioned  in  Section  3.3.4  and  3.3.5,  fibrosis  or  an  increased  presence  of  BMD-­‐‑



















Opn mRNA was expressed in epithelial cells (a) and stromal cells (b) in the 
colonic mucosa of an Il10-/- mice transplanted with Il10-/- mouse BM at 5 months 
post BMTx. There was with no increase in Opn mRNA expression when normal 
mucosa (a) was compared to inflamed mucosa (b).  Expression occurred mainly 
in the mucosa, however expression in the muscularis propria was also 
observed (c).  Opn mRNA expression appears as black grains in bright field 




Figure 3.31:  Opn mRNA expression in SPEM mouse tissues 
 
Epithelial Opn mRNA was focally expressed in regions of SPEM in a WT mouse 
transplanted with Tff1-/- mouse BM at 6 months post BMTx (a; x10, b; x20 
images) and WT mice transplanted with WT BM at 12 (c; x10, d; x20 images) 
and at 16 months (e; x10, f; x20 images) post BMTx.  Opn mRNA expression 
appears as black grains in bright field images (left hand images in b,d,f) and 




























Summary  discussion  and  future  directions  
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Since  the  demonstration  of  BMD-­‐‑neoplastic  gastric  glands  by  Houghton  et  al.,  in  
2004  [39],  only  recently  have  Varon  et  al.,  (2011)  been  able  to  reproduce  similar  
findings.      Amid   these   two   studies   has   been   a   seven-­‐‑year   endeavour   with  
conflicting   reports  on   the   contribution  of  BMDCs   to   the   intestinal   epithelium.    
Clarifying  whether  GI  tumours  are  derived  from  BM  is  important  as  it  presents  
an   alternative   route   to   neoplasia   that   can   be   exploited   therapeutically   by  
inhibiting  chemotaxis  of  BMDCs  into  intestinal/tumour  epithelium.    
In   this   study,   BMD   glands,   crypts,   or   their   respective   tumours   were   not  
identified   in   four   short   and   long-­‐‑term   mouse   models   of   gastrointestinal  
tumourigenesis.   The   percentage   of   putative   epithelial   cells   derived   from   BM  
quantified  was  ≤1%,   concurring  with   the   low   frequencies   reported   in   clinical  
and   experimental  BMTx   studies   [82,   156,   187,   188].     We  also  demonstrated   in  
the  inflamed  mucosa  of  Il10-­‐‑/-­‐‑  and  Tff1-­‐‑/-­‐‑  mice  that   inflammation  alone  does  not  
drive  BMD-­‐‑epithelial  engraftment  as  had  been  proposed  [82].    This  led  us  back  
to   examining   the   Houghton   et   al.,   (2004)   and   Varon   et   al.,   (2011)   studies,   of  
which   a   unifying   factor   between   the   two   is   Helicobacter   infection.      The  
mechanisms  of  BMD-­‐‑  mesenchymal  stem  cell  repopulation  of  gastric  epithelium  
during  Helicobacter  infection  are  beginning  to  be  uncovered.    One  clue  lies  in  the  
elevated   IFN-­‐‑γ   in   response   to   infection   [189,   190].      This   has   been   recently  
demonstrated  in  vivo,  where  IFN-­‐‑γ  induced  the  proliferation  and  recruitment  of  
MSCs   to   the   stomach   via   Shh   secretion   and   signaling   [191].      A   paradigm   of  
BMD-­‐‑MSC  re-­‐‑population  has  also  been  proposed  by  Houghton  et  al.,   (2005)  in  
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which  ablation  of  the  gastric  stem  cell  niche  via  Helicobacter   infection  results  in  
engraftment  of  BMDCs   in   the   stem  cell   niche   conferring   stemness   and  giving  
rise  to  gastric  cell  lineages  [40].    We  propose  that  future  research  could  test  this  
theory   through   targeted   ablation   of   the   gastrointestinal   stem   cell   niche   in  
BMTx’d  mice.      Additional   experiments   could   also   investigate  whether   BMD-­‐‑
tumours  are  exclusive  to  pathogen-­‐‑induced  carcinogenesis  by  BM  transplanting  
mouse  models  of  HPV-­‐‑induced  cervical  neoplasia  or  hepatitis  B   induced   liver  
tumourigenesis   prior   to   infection   and   analysing   the   BMDC   contribution  
throughout  the  development  of  neoplasia.    
We   then   turned  our  attention   to  examining  altered  stem  cell  dynamics  within  
the  different  mouse  models  using  Lgr5  mRNA  ISH  to  analyse  Wnt  signalling  in  
the   epithelium.   As   previously   demonstrated,   Lgr5   mRNA   was   strongly  
expressed   in  normal  and  adenomatous   intestinal   tissue  of  ApcMin/+   and  Apc1322T  
mice   [57].      However   in   Tff1-­‐‑/-­‐‑   and   Il10-­‐‑/-­‐‑   mice,   which   do   not   harbour   Apc  
mutations,  Lgr5  mRNA  was  either  weakly  expressed  by  epithelial  cells  or,  in  the  
case  of  Il10-­‐‑/-­‐‑  colonic  mucosa,  undetected.    A  possible  explanation  for  this  is  that  
weak  mRNA  expression   from  slowly  cycling  Lgr5+   cells   in   these   tissues   could  
not  be  detected  by  the  isotopic  ISH  technique.    
Of   particular   interest   was   investigating   whether   premalignant   or   malignant  
gastric  lesions  would  have  altered  Lgr5  mRNA  expression,  possibly  associated  
with  stem  cell  activity.    For  example,  a  long-­‐‑held  theory  was  that  SPEM  resulted  
from  the  expansion  of   the  stem  cell  zone   in   the  mucous  neck  region  of   fundic  
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glands.    However,  as  in  normal  fundic  glands,  we  could  not  detect  Lgr5  mRNA  
in  SPEM.    As  with  previous  Lgr5  gene  expression  studies  in  human  and  mouse  
tissues,   we   could   not   demonstrate   upregulated   Lgr5   expression   in   gastric  
metaplasia  [192,  193].    In  addition,  during  this  study  Nam  and  colleagues  (2011)  
demonstrated   through   cell   lineage   tracing   experiments   that   Lgr5+   cells   at   the  
base   of   fundic   glands   do   not   give   rise   to   SPEM   lineages   [194].      Moreover,  
another  study   from  the  same  group  has  suggested   that  SPEM  originates   from  
the  transdifferentiation  of  mature  Mist1  expressing  chief  cells  [182].  
Similarly,  to  the  findings  in  SPEM  mouse  tissues,  whilst  Tff1-­‐‑/-­‐‑  mouse  adenomas  
exhibited  cell  heterogeneity  and  increased  proliferation  as  previously  described  
[28],  Lgr5  mRNA  expression  did  not  differ  from  normal  antrum.    The  absence  of  
Lgr5  mRNA   expression   in   premalignant   and  malignant   gastric   lesions   in   this  
study   may   simply   be   a   reflection   of   how   Wnt   pathway   mutations,   or  
indications   of   aberrant  Wnt   signalling,   are   rarely   observed   in   human   gastric  
cancers  [195].    Therefore,  we  propose  that  future  experiments  could  investigate  
the   possibility   of   inflammation-­‐‑based   gastric   tumours   being   derived   from   a  
stem   cell   population   at   the   base   of   antral   glands   that   express  Villin-­‐‑promoter  
(Villin-­‐‑promoter+).      This   is   because,   the   normally   quiescent   Villin-­‐‑promoter+  
stem  cells  have  been  demonstrated  to  become  highly  proliferative  and  generate  
all  cell   lineages  in  response  to  IFN-­‐‑γ   [196].     Analysis   in  Tff1-­‐‑/-­‐‑  mouse  adenomas  
could  be  a  good  starting  point  to  test  this  hypothesis,  as  Tff1-­‐‑/-­‐‑  mouse  adenomas  
develop  in  an  inflammatory  context  as  a  consequence  of  absent  TFF1  regulation  
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of   the  NF-­‐‑ΚB   signalling  pathway   [33].     Therefore,  we  envision  an   experiment  
with  two  aims.    The  first  to  compare  IFN-­‐‑γ  secretion  in  Tff1-­‐‑/-­‐‑  mouse  adenomas  
compared  to  normal  antrum  and  the  second  to  examine  Villin-­‐‑promoter  mRNA  
expression  in  these  tissues.    Our  hypothesis  would  be  that  Tff1-­‐‑/-­‐‑  mouse  antrum  
has  an  elevated  level  of  IFN-­‐‑γ  as  a  consequence  of  chronic  inflammation  which  
induces  the  proliferation  of  Villin-­‐‑promoter+  stem  cells  that  give  rise  all  antral  
cell   lineages   that  make   up   the   heterogeneous   cell   population   of  Tff1-­‐‑/-­‐‑   mouse  
adenomas.    
Outside  of  the  tumour  epithelium,  we  demonstrated  a  significant  contribution  
of  BMD-­‐‑myofibroblasts   to   the   tumour   stroma,   as   in  previous   studies   [37,   92].    
We  demonstrated  that  tumour  burden  was  a  driver  of  BMD-­‐‑SEMF  recruitment  
in   Apc1322T   small   intestinal   adenomas,   with   increased   recruitment   into   larger  
adenomas  compared  to  smaller  ones.     The  presence  of  desmoplasia  or  fibrosis  
also  appeared   to  be  a  driving   factor   in  BMD-­‐‑myofibroblast  engraftment.        For  
example,   the   presence   of   BMD-­‐‑SEMFs   increased   with   the   presence   of  
desmoplasia  in  Tff1-­‐‑/-­‐‑  mouse  antral  pyloric  adenomas.    In  contrast,  we  could  not  
demonstrate  a  significant  increase  in  Tff1-­‐‑/-­‐‑  mouse  dysplastic  lesions.        We  also  
examined  whether  chronic  inflammation,  which  was  also  a  feature  of  Tff1-­‐‑/-­‐‑,  Il10-­‐‑
/-­‐‑,   and  SPEM  mouse  pathology,  was  on   its  own  a  contributing   factor   to  BMD-­‐‑
SEMF  recruitment.     Whilst,   increased  engraftment  of   colonic  SEMFS  has  been  
demonstrated   in   areas   of   inflammation   in   colitic   Il10-­‐‑/-­‐‑   by   Bamba   et   al.,  
(2006)[78],  we  did  not  observe  a  significant  contribution  of  BMD-­‐‑SEMFS  in  the  
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inflamed   tissues   of   Il10-­‐‑/-­‐‑  and   SPEM  mice.        A   clear  distinction   between   these  
tissues  and  the   inflamed  colonic  mucosa  observed  by  Bamba  et  al.,   (2006)  was  
the   absence   of   fibrosis   (as   demonstrated   by  α-­‐‑SMA   immunoreactivity)   in   the  
former.    The  same  can  be  said  for  comparison  with  Tff1-­‐‑/-­‐‑  mouse  adenomas.  This  
led  us  to  conclude  that  inflammation  without  fibrosis  was  insufficient  to  drive  
BMD-­‐‑myofibroblast  recruitment.    
To  investigate  the  mechanism  of  BMD-­‐‑myofibroblast  recruitment  in  neoplastic  
and  inflamed  tissues  we  utilised  isotopic  ISH  to  analyse  Opn  mRNA  expression.    
Opn  was   selected   from   the   literature   due   to   its   upregulation   in   inflammation  
[197]   and   malignancies   [125].      Furthermore,   OPN   protein   secreted   from  
tumours  has  been  shown  to  correlate  with  BMDC  engraftment  in  vivo  [80,  136].    
Opn  mRNA  expression  differed  between  tumours  with  predominantly  stromal  
expression   observed   in   Apc1322T   and   ApcMin/+   mouse   adenomas   and   epithelial  
expression   observed   in  Tff1-­‐‑/-­‐‑  mouse   adenomas.        We   observed   increased  Opn  
mRNA   expression   with   tumour   burden   in   Apc1322T   and   ApcMin/+   mouse  
adenomas.    However  it  was  only  its  expression  in  desmoplastic  reaction  sites  in  
Tff1-­‐‑/-­‐‑   mouse   adenomas   that   coincided   with   increased   BMD-­‐‑myofibroblast  
engraftment.   This   particular   finding   suggests   an   epithelial-­‐‑stromal   interplay,  
where   OPN   secreted   from   Tff1-­‐‑/-­‐‑   mouse   tumour   epithelial   cells   can  
chemotactically  recruit  BMD-­‐‑myofibroblasts  to  meet  the  biological  demands  of  
the  tumour  stroma.    Uncovering  the  mechanisms  of  this  interplay  is  worthwhile  
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as   it   presents   an   opportunity   for   therapeutic   treatment   in   cancers   where  
desmoplasia  is  a  feature  of  pathology.  
In   WT   mice   with   SPEM   or   colitic   Il10-­‐‑/-­‐‑   mice,   Opn   mRNA   expression   was  
unaffected  by  increased  inflammation.    This  may  be  a  reflection  of  a  decreased  
demand  for  BMD-­‐‑myofibroblasts  in  these  tissues  as  Opn  expression  in  tissues  is  
strongly   associated   with   inflammatory-­‐‑associated   fibrosis   in   vivo   [198].    
However,  Opn  mRNA  expression  in  Il10-­‐‑/-­‐‑  colonic  mucosa  was  more  frequently  
observed  compared  to  expression  in  ApcMin/+  and  Apc1322T  mouse  colonic  mucosa.    
This   suggests   a   global   upregulation   of   Opn   in   Il10-­‐‑/-­‐‑  mouse   colonic   mucosa  
where   increased   secreted   OPN   protein   may   play   additional   roles   in  
immunoregulation   and   mucosal   protection,   as   has   been   demonstrated   in  
Crohn’s  disease  patients  [128,  129].    
A  surprising   finding  of   this  study  was   the  development  of  SPEM  in  WT  mice  
without  Helicobacter  infection  or  chemical  induction.    We  demonstrated  through  
IHC  and   ISH   that   the  pathological   features  of   SPEM  developed   in   these  mice  
was  consistent  with  previous  experimental  observations.    However,  the  reason  
as   to  why   these  mice  developed  SPEM   is  unknown  as  microbiological   testing  
excluded   the   possibility   of  Helicobacter   infection.      Therefore,  without   a   repeat  
study  with  further  experiments,  the  reason  as  to  why  some  of  the  WT  mice  of  
this   study   developed   SPEM   can   only   be   speculated.      A   possibility   is   that  
damage  occurred   to   the  parietal   cells  of   some  mice  via   ionising   radiation   that  
may   have   caused   the   trans-­‐‑differentiation   of   mature   chief   cells   into   TFF2-­‐‑
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expressing  cells.  For  example,  DNA  damage  within  parietal  cells  may  have  lead  
to   the   expression   of   splice   variant   isoforms   of   CD44   (CD44v).      CD44v  
expression   has   been   demonstrated   to   occur   as   a   result   of   SPEM   and   is  
associated   with   the   proliferation   of   metaplastic   cells   in   experimental   SPEM  
models   [199].      The   latter   has   been   the   proposed  mechanism  behind   chief   cell  
transdifferentiation   via   CD44v   interaction   with   xCT   (a   subunit   of   cysteine  
transporter   xc),   which   promotes   cysteine   uptake   for   glutathione   synthesis,  
which  in  turn  promotes  cell  proliferation  [199].     Therefore,   future  experiments  
could   investigate   CD44v   and   Mist1   expression,   as   well   as   investigating  
signalling   pathways   implicated   in   SPEM   such   as   EGFR   signalling   [200]   and  
PGE2  signaling  [201].  
An   interesting   observation   in   SPEM  mouse   tissues  was   the   earlier   onset   and  
greater  disease  severity  was  observed   in  WT  mice   that  had  been   transplanted  
with  Tff1-­‐‑/-­‐‑  mouse  BM.    The  Tff1-­‐‑/-­‐‑→Tff1-­‐‑/-­‐‑  and  WT→Tff1-­‐‑/-­‐‑  mouse  groups  did  not  
develop   SPEM   most   likely   because   they   do   not   express   TFF2   in   the   fundus  
[202].     So  could  the  absence  of  TFF1  in  BMTx’d  immune  cells  played  a  role   in  
accelerating  SPEM  in  WT  mice?     The  loss  of  TFF1  has  been  shown  to  result   in  
the   activation   of  NF-­‐‑κB  pathway   that  TFF1   suppresses   [33].      This   can   lead   to  
chronic   inflammation   caused   by   the   overproduction   of   pro-­‐‑inflammatory  
cytokines   and   chemokines   [203].      The   stimulation   of   inflammation   by   Tff1-­‐‑
deficient   BMD   immune   cells   may   have   played   a   role   in   accelerating   and  
worsening   SPEM   in   the   Tff1-­‐‑/-­‐‑→WT   mouse   group.   For   now,   we   can   only  
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speculate   that   SPEM   could   have   arisen   from   radiation   induced   parietal   cell  
damage  or  DNA  damage  that  may  have  set  off  a  molecular  chain  of  events  that  
led  to  the  transdifferentiation  of  mature  chief  cells.     Adding  to  this,  we  cannot  
fully   exclude   the   possibility   of   infection   with   a   new   and/or   undetected  
pathogen.    
In   conclusion   the   data   presented   in   this   study   taken   together   with   previous  
studies   strongly   suggest   that   BMD-­‐‑epithelial   cells   do   not   generate   tumours  
beyond   Helicobacter   infection,   and   that   indeed   this   is   an   exceedingly   rare  
phenomenon.      More   commonplace   was   the   contribution   of   BMD-­‐‑SEMFs   to  
tumour   stroma.      Our   findings   suggest   that   the   biological   demand   from  
increased  tumour  burden  and  desmoplasia  drives  engraftment.      In   the  case  of  
desmoplasia,   our   observation   of   increased   Opn   mRNA   expression   in   Tff1-­‐‑/-­‐‑  
desmoplastic  reaction  sites  coinciding  with  increased  BMD-­‐‑SEMFs  suggest  that  
OPN   plays   an   important   role   in   recruitment   of   BMD-­‐‑myofibroblasts   into  
desmoplastic  reaction  sites.    Our  observations  in  Il10-­‐‑/-­‐‑  and  SPEM  mouse  tissues  
also   indicate   that   inflammation  without   fibrosis   is   insufficient   to   drive  OPN-­‐‑
mediated   chemotaxis   of   BMD-­‐‑myofibroblasts.   Some   minor   findings   of   this  
study  were   the  demonstration  of  unaffected  Lgr5  mRNA  expression   in   SPEM  
and  Tff1-­‐‑/-­‐‑  mouse  adenomas  and  the  development  of  SPEM  without  Helicobacter  
or  chemical  induction.    
A  table  comparing  the  hypotheses  generated  before  and  during  this  study  with  
their  experimental  findings  can  be  found  in  Table  4.1  and  Table  4.2.  
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Table 4.1:  A comparison of hypotheses formed at the commencement of this 
study and the conclusions derived from the present studies 
 
Hypothesis at the 
commencement of this study 
  
Experimental conclusions  
BMD-glands, crypts, and tumours 
would occur in absence of 
Helicobacter infection as a result 
of inflammation or increased 
tumour burden. 
 
BMD-glands, crypts, and tumours were not 
observed in any of the mouse models. 
BMDCs could contribute to both 
benign and malignant epithelial 
cells. 
Both benign and malignant epithelial cells 
were observed (albeit inconclusively 
identified).  However, these were rare 
events making up ≤ 1.0% of cells in a 
150,000µm2 area of epithelium. 
 
Engraftment of BMD-epithelial 
cells would be driven by either 
inflammation or tumour burden. 
 
Neither inflammation or tumour burden 
affected BMD-epithelial engraftment. 
BMD-myofibroblasts would home 
into areas of increased tumour 
burden. 
In Apc1322T tissues, the percentage of 
SEMFs derived from BM increased in larger 
adenomas compared to smaller adenomas.  
This suggests that BMD-myofibroblasts 
recruitment is determined by tumour burden 
in some cases. 
 
Opn mRNA expression in 
tumours would correlate with 
increased BMD-myofibroblast 
engraftment. 
Increased Opn mRNA expression was 
observed in Tff1-/-, ApcMin/+, and Apc1322T 
mouse adenomas.  However, whether this 
correlated with BMD-myofibroblast 
engraftment was only suggested in Tff1-/- 
mouse adenomas, where Opn mRNA 
expression occurred at desmoplastic 
reaction sites, which had an increased 
presence of BMD-myofibroblasts. 
 
Aberrant Opn mRNA expression 
in inflamed tissues would 
correlate with increased BMD-
myofibroblast engraftment. 
Increased Opn mRNA expression was not 
observed in areas of increased 
inflammation or disease severity in Il10-/- or 
SPEM tissues.  Moreover, an increase of 
BMD-myofibroblasts was not observed in 







Table 4.1:  A comparison of hypotheses formed at the commencement of this 
study and the conclusions derived from the present studies (continued) 
  
Tff1-/- mouse adenomas would 
have upregulated Lgr5 mRNA 
expression as a result of aberrant 
Wnt signalling promoting a stem 
cell phenotype.  
Whilst an increased cell proliferation and a 
heterogeneous cell population were 
observed in Tff1-/- mouse adenomas, 
isotopic ISH demonstrated that Lgr5 mRNA 
expression was limited to the base of 
adenomatous pyloric glands.  This finding 
suggests two possibilities.  The first is that 
adenomatous cells originating from the 
stem cell niche at the base of antral glands 
differentiated and ceased expressing Lgr5.  
The second possibility is that any stem-cell 
activity in Tff1-/-  mouse adenomas is the 
result of the increased proliferation of Villin-
promoter+ stem cells in the isthmus in 
response to increased IFN-γ due to the 







Figure 4.2:  A comparison of hypotheses formed during this study and the 
conclusions derived from the present studies 
 
Hypothesis formed during this 
study 
Experimental conclusions 
Lgr5 mRNA expression would 
increase in SPEM mouse tissues 
compared to normal fundic tissue 
in mice.  
Lgr5 mRNA expression could not be 
detected in SPEM fundic glands.   
BMD-gastric SEMF engraftment 
would increase in SPEM due to 
the inflammation present.  
Very little lamina propria was observed in 
SPEM tissues indicating that fibrosis was 
not a part of the disease pathology.  Very 
few BMD-myofibroblasts were observed. 
Opn mRNA expression would 
increase in SPEM tissues due to 
the inflammation present. 
Opn mRNA expression in SPEM tissues 
was unaffected by inflammation severity or 


























A.1   Method  development:  fluorescent  in  situ  hybridisation  to  demonstrate  
cell  fusion  
We  attempted   to   investigate  whether   cell   fusion-­‐‑mediated  BM  engraftment  of  
cells  occurs  in  our  mouse  models  using  fluorescent  in  situ  hybridisation  (FISH).    
Various   mouse   chromosome   probes   and   pancentromere   probes   were   tested  
using  FISH  with   the  aim   that  one  of   these  probes  could  be  combined  with  Y-­‐‑
chromosome  FISH  to  demonstrate  polyploidy  (Table  A.2).  The  standard  in  situ  
hybridisation  protocol  (described  in  Section  2.4.4)  was  used  with  the  following  
changes:  
• A  pepsin  digestion   time   trial  was   carried  out   for   each   tissue  block  and  
for   each   probe   tested.   This   would   entail   pepsin   digestion   of   different  
sections  of  the  same  tissue  blocks  at  various  time  points  (for  example,  5,  
10,  and  15  minutes).  
• Sections  were  denatured  at  80°C  for  pancentromeric  probes.  
• Mounted  slides  were  kept  refrigerated  at  4°C  in   the  dark  until  viewing  
with  fluorescent  microscopy.  
  
The   author   and   other   collaborators   were   unable   to   demonstrate   that   X-­‐‑
chromosome,   various   chromosomes,   or   the   use   panentromeric   probes   as  
reliable   methods   of   demonstrating   cell   fusion.      Figure   A.3   demonstrates   the  
inconsistent  results  of  X  and  Y-­‐‑chromosome  FISH  carried  out  by  the  author  and  
Rosemary   Jeffrey.   However,   considering   the   reliability   of   the   mouse   Y-­‐‑
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chromosome   probe,   future   experiments   to   analyse   cell   fusion   using   sex  
mismatched  BMTX  may  be  facilitated  by  engineering  the  expression  of  GFP  or  
beta  galactosidase   in  host  cells.  Fused  cells   therefore  would   then  express  both  
the  Y-­‐‑chromosome  and  the  host  cell  marker.    
  
Table A.1:  Details of FISH DNA probes tested as cell fusion markers 
 
Probe Supplier Conclusions Tester 
Chromosome 1 Cambio Unreliable.  Chromosome signal 
often bulky and difficult to interpret. 
RJ 
Chromosome 3 Cambio RJ 
Chromosome 17 Cambio RJ 
X-chromosome 
Cambio Inconsistent, unreliable ALB, 
CYL, RJ  
ID labs ALB, RJ 
Y-chromosome  
FITC labelled 





ID labs To be used only for fluorescence.  
Cannot be used in place of Cambio 
FITC-labelled Y chromosome for 
combined immunohistochemistry/Y-
chromosome in situ hybridisation. 
ALB, RJ 




 Pancentromeres  ID labs 









Figure A.1:  Testing of X and Y-chromosome FISH 
 
 
X/Y-chromosome FISH carried out by the author (a, b) and Rosemary Jeffrey 
(c).  (a,b) X/Y-chromosome FISH on small intestinal tissue of a male stock WT 
mouse.  In one assay (a; x10) X and Y-chromosomes are easily identified (red 
and green dots, respectively), whereas in another (b; x40) very few cells contain 
cells with both X and Y (white arrow) and the majority of cells contain only the 
Y-chromosome (yellow arrow). (c; x10)  Combined X/Y-chromosome FISH on 
spleen of female mouse transplanted with male BM.  Y-chromosome is 
observed throughout, whereas cells containing X-chromosome occurs only 








A.2   GKN2   protein   expression   is   gradually   lost   with   the   progression   of  
dysplasia  to  adenomas  in  Tff1-­‐‑/-­‐‑  mice  
Analysis  of  GKN2  protein,  which  exists  as  a  heterodimer  with  TFF1  protein  in  
gastric  secretions,  revealed  a  gradual  loss  of  GKN2  from  6  months  post  BMTx  



















Figure A.2:  GKN2 protein expression in the gastric mucosa of  BMTx’d WT 
and Tff1-/- mice 
 
In a WT mouse transplanted with WT mouse BM at 6 months post BMTx, 
GKN2 protein (pink staining) is expressed by foveolar cells along the fundus 
(a) pylorus (d).  A slight decrease in GKN2 expression was observed in the 
fundus of a Tff1-/- mice mouse transplanted with Tff1-/- mouse BM at 6 months 
(b) and 12 months (c) post BMTx.  The decrease in GKN2 expression is more 
pronounced in the antrum, where there is significant decrease in normal (e) 
and dyplastic (f) antrum in a Tff1-/-mouse transplanted with Tff1-/- mouse BM 6 
months post BMTx. In an antral pyloric adenoma of a Tff1-/- mouse 
transplanted with Tff1-/- mouse BM at 12 months post BMTx (g), GKN2 is 






A.2.1   Discussion  and  conclusions    
A  minor   finding  of   this  study  was   the  observation  of  a  significant  decrease   in  
GKN2   protein   expression   in   the   fundus   and   normal   antrum   of   Tff1-­‐‑/-­‐‑  mouse  
groups.   As   dysplastic   lesions   progressed   into   adenomas   in   Tff1-­‐‑/-­‐‑   mice   a  
successive   loss   of   GKN2   protein   was   observed.      One   explanation   for   this  
finding  is  that  as  TFF1  and  GKN2  are  co-­‐‑secreted  as  a  heterodimer,  the  decrease  
of   GKN2   in   absence   of   TFF1  may   be   due   to   destabilisation   of   the   protein   or  
decreased  resistance  against  proteolysis  or  gastric  acid.      To  our  knowledge  the  
loss   of   GKN2   has   not   been   reported   in   Tff1-­‐‑/-­‐‑   mice   to   date.      However,   our  
findings  support  observations  from   in  vivo  and  human  gastric  tumour  studies.    
For   example,   a   significant   decrease   in  Gkn2   mRNA   expression   has   also   been  
observed   in   the   antral   tumours   of   the   Gp130F/F   mouse   model   of   gastric  
tumourigenesis   [181].   In  human  gastric   adenocarcinoma,  GKN2  and  TFF1  are  
downregulated  with  decreased  GKN2  observed  in  very  early  tumours  [34,  35].    
Moreover,   expression   of   TFF1   in   gastric   tumours   in   the   absence   of   GKN2   is  
associated  with   lymph  node  metastasis  and  poor  clinical  outcome  [34].  To   the  
point,   overexpression   of   TFF1   has   been   frequently   observed   in   tumour   cells  
[204].   It   has   been   suggested   the   pro-­‐‑migratory   and   anti-­‐‑apoptotic   effects  
conferred   by   TFF1   that   are   necessary   for   mucosal   restitution   under   normal  
conditions   are   responsible   for   the   migration   of   tumour   cells   when   TFF1   is  
aberrantly   expressed.     These   studies   suggest   that   the   formation  of   the  GKN2-­‐‑
TFF1   heterodimer   is   necessary   for   the   tumour   suppressor   activity   of   TFF1   or  
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that  GKN2  itself  acts  as  a  gastric   tumour  suppressor.         If   the   latter   is   the  case,  
then  the  decrease  in  GKN2  resulting  from  TFF1  deficiency  in  Tff1-­‐‑/-­‐‑  mice  may  be  
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